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Lay Abstract  
As climate change and the protection of the environment are high on the global agenda, the 
chemical industry is adapting to this paradigm shift. Specifically, there is a necessity to find 
methodologies that avoid the creation of toxic waste and pollutants and the use of harsh conditions 
(high pressures or extreme temperatures). A fast-developing branch of chemistry, called green 
chemistry, supports the development of more environmentally-benign processes. An important 
aspect of green chemistry is biocatalysis. This consists in using biological systems, either whole cells 
or enzymes, for the production of industrially-relevant compounds. Indeed, biological systems, 
produce naturally a wide range of very complex chemical compounds under mild conditions (room 
temperature or 37°C in most cases, and atmospheric pressure), are very efficient and, in most cases, 
do not generate any toxic, unwanted side products. Moreover, enzymes are organic compounds, 
which means that they themselves can be recycled and do not contain any expensive and polluting 
heavy metals.  
However, very often, enzymes will only be effective for their natural substrates, which are rarely 
interesting from a commercial point of view. To make them fit to produce other, more marketable 
products, they require to be further optimised and engineered. A suite of techniques and tools, called 
directed evolution, pioneered by 2018 Chemistry Nobel Prize winner, Prof. Frances Arnold (California 
Institute of Technology), has dramatically reduced the time and cost required to engineer enzymes. 
However, these methods require a basic understanding of their mechanism. 
This work will focus on understanding the mechanism of two different transformations carried by 
specific enzymes. The first one, the Morita-Baylis-Hillman reaction, is a widely used reaction which 
makes it possible to couple together two molecules which have specific features, to create one larger, 
more complex compound. In the second one, the mechanism of a small family of enzymes called nitrile 
synthetases will be investigated, with the aim of engineering them to make amides, one of the most 
important type of molecules in the pharmaceutical industry as they represent more than 25% of all 






In recent years, enzymes, and their uses as biocatalysts for synthetic organic chemistry, have been 
positively disrupting the pharmaceutical and chemical industries. With the development of the third 
wave of biocatalysis and directed evolution, enzyme engineering has become easier, cheaper and 
quicker. However, while random enzyme evolution is possible in the absence of structural data, the 
development of efficient biocatalysts is accelerated when 3D structures and mechanistic information 
of the target are available. In this work, two enzymes, each catalysing different chemical 
transformations will be studied, with the aim of gaining structural and mechanistic data which shall 
be used to guide future engineering strategies.  
The first enzyme studied is the pimeloyl-ACP methyl ester esterase, BioH, from E. coli (EcBioH). 
Previously it was found that EcBioH is able to catalyse the Morita-Baylis-Hillman (MBH) coupling of 4-
nitrobenzaldehyde (4-NBA) and methyl vinyl ketone (MVK), with less than 50% conversion. The MBH 
reaction forms a C-C bond by coupling an aldehyde and an electron-poor alkene, and leads to the 
formation of a chiral alcohol. However, the mechanism of the enzyme-catalysed biotransformation is 
unclear. Specifically the identities of the active residues involved in substrate binding and catalysis are 
not known. Here we describe the characterisation of recombinant EcBioH and study its role in 
catalysing the MBH reaction. We used site directed mutagenesis to probe the role of a proposed 
catalytic triad of conserved residues (Ser-Asp-His) in the mechanism. We also investigate the 
involvement of a cysteine residue by covalent modification and mass spectrometry. Since none of 
these residues were found to be essential for MBH catalysis, this suggested that the protein 
hexahistidine (also known as 6His) affinity tag used to purify the enzyme displays inherent MBH 
activity. This hypothesis was confirmed by screening other hexahistidine tagged proteins available in 
the laboratory and discovering that they also displayed MBH activity. Furthermore, an engineered 
EcBioH “double-tagged” at both the N- and C- termini displayed the highest MBH activity. No enzyme 
displayed enantioselectivity in the MBH product distribution. These results provide strong evidence 
that this commonly-used tag plays an important role in MBH biocatalysis. These observations 
suggested that the intrinsic MBH activity of the tag arises from a synergistic acid/base relationship 
between the histidine residues and oxo-anion intermediates. 
In a second, independent project, a small family of enzymes, the nitrile synthetases (NS) was 
investigated. Interestingly, members of this family catalyse the conversion of a carboxylic acid to a 




formation of an amide intermediate, and the second step results in amide to nitrile conversion. There 
is still a lack of clarity of the mechanistic role of ATP in the two steps catalysed by NS. Most notably, 
no attempts at separating/decoupling the two steps catalysed by the NSs have been successful so far. 
In this work, two members of the NS family, QueC from Bacillus subtilis (BsQueC) and ToyM from 
Streptomyces rimosus (SrToyM) were purified from E. coli and characterised. Both NSs were assayed 
for their natural reaction, the transformation of 7-carboxydeazaguanine (CDG) into 7-
cyanodeazaguanine (PreQ0), via the corresponding primary amide (ADG). Their substrate scope was 
assessed and it was found that both enzymes had a very restricted acid substrate selectivity but were 
able to form a small range of secondary and tertiary amides with primary and secondary amines. 
Crystal trials resulted in the preparation of diffraction-quality crystals and the determination of the X-
ray structure of the BsQueC:ADP complex at a resolution of 2.1 Å. This structure, was combined with 
the structure of a previously published BsQueC:phosphate complex and a sequence alignment of 
various members of the NS family. This analysis located well conserved residues and guided rational 
engineering of BsQueC. Well-conserved hydrophilic residues in close proximity to the phosphate 
moiety of the ADP molecule identified three residues for mutagenesis. A large decrease of the amide 
to nitrile conversion activity was observed for two of the single-point mutants generated (BsQueC 
K163A and BsQueC R204A). Importantly, a double-mutant enzyme which combines both these 
mutations (BsQueC K163A R204A) was not able to catalyse nitrile formation. However, this rationally-
designed biocatalyst displayed bone-fide amide synthetase activity and allowed kinetic parameters for 
the CDG substrate to be determined for the first time. Finally, the first large scale biocatalysed 
transformation of CDG to ADG was carried out and the amide product was isolated with >95% purity. 
These studies provide the necessary insight and strategy required to carry out further directed 
evolution of the NS family to expand their substrate scope and allow synthesis of commercially-
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Chapter 1 Introduction 
1.1 Background to biocatalysis 
1.1.1 Biocatalysis in a nut shell 
The world’s oldest brewery was found in a prehistoric burial site in Haifa, Israel1. There, traces of 
beer dating from 11 000 BC were found1. Knowing that yeast is required for the alcoholic fermentation 
of cereals and that agriculture was only developed around 10 000 BC2, one may say that humanity was 
able to domesticate microorganisms and enzymes before plants or animals. Today, humans are able 
to harness the huge potential that enzymes offer to carry out a wide range of chemistries and produce 
a large array of complex compounds3-6.  
The study, engineering and optimisation of enzymes for applications in industrial synthetic 
chemistry defines the field of biocatalysis. This field has considerably developed, especially over the 
last few decades, culminating in the award of the 2018 Nobel Prize in Chemistry to Frances Arnold 
(Caltech), one of the pioneers of the field7. According to Uwe Bornscheuer and colleagues, this 
development can be divided in three parts, named the “three waves of biocatalysis”8. In the first wave, 
which started in the beginning of the 20th century, it was recognised that some components the living 
cells of animals, plants or microorganisms could be useful to promote useful chemical transformations 
such as the hydroxylation of steroids9. In the second wave of biocatalysis, which started in the 1980s 
with the advances of structural biology and the successful determination of high resolution protein 
structures, initial protein engineering approaches were introduced. These advances allowed the 
manufacture of pharmaceutical intermediates and fine chemicals, such as the calcium channel blocker 
diltiazem10. Finally, in the third wave of biocatalysis, which is still currently running, advances in 
molecular biology and bioinformatics enable the “directed evolution” of enzymes. This process moves 
the Darwinian process of evolution and natural selection into the laboratory as it consists of subjecting 
a gene to iterative rounds of mutagenesis, screening and selection to identify the variants which 
exhibit an improvement compared to the parent.  
Biocatalysis is developing fast because it is a viable response to the global challenges attached to 
the high economic and environmental costs of chemical manufacture. Specifically, while homo- and 
heterogeneous catalysis often rely on energy-intensive processes and on the use of expansive second 
and third row transition metals, enzymes are biodegradable and require mild reaction conditions. 
Enzyme reactions are typically carried at temperatures ranging from room temperature (RT) to 50°C, 




diastero- and enantioselectivities which shall reduce the number of synthetic steps required to 
generate a given product and the need of protection/deprotection steps. Paul Anastas and John 
Warner have developed “The 12 principles of Green Chemistry”11. Table 1.1 displays these principles, 





No Principle Biocatalysis solution 
1 Waste prevention 
It is better to prevent waste than to treat or clean up waste 
after it has been created. 
 
2 Atom economy 
Synthetic methods should be designed to maximize 
incorporation of all materials used in the process into the final 
product. 
 
3 Less hazardous chemical syntheses: 
Wherever practicable, synthetic methods should be designed 
to use and generate substances that possess little or no 
toxicity to human health and the environment       
Unlike most chemical catalysts, enzymes are 
biocompatible and do not exhibit any toxicity for humans 
or the environment. In addition, biocatalysis can enable 
the use of alternative starting materials and reagents 
with lower toxicity 
4 Designing safer chemicals 
Chemical products should be designed to preserve efficacy 
of function while reducing toxicity. 
 
5 Safer solvents and auxiliaries 
The use of auxiliary substances (e.g., solvents, separation 
agents, etc.) should be made unnecessary wherever possible 
and, innocuous when used. 
While a small percentage of organic solvents might be 
needed to put the reagents in solution, enzymes are 
active in water 
6 Design for energy efficiency 
Energy requirements should be recognized for their 
environmental and economic impacts and should be 
minimized. Synthetic methods should be conducted at 
ambient temperature and pressure. 
Enzyme reactions are typically carried at temperatures 
ranging from RT to 50°C and at atmospheric pressure. 
In addition, unlike most traditional catalysts, most 
enzymes are not air- or water-sensitive and do not 
require air or water elimination systems. Hence, 
enzymatic processes are typically highly energy efficient 
7 Use of renewable feedstocks 
A raw material or feedstock should be renewable rather than 
depleting whenever technically and economically practicable. 
Biocatalysts are fully biodegradable 
8 Reduce derivatives 
Unnecessary derivatization (use of blocking groups, 
protection/deprotection, temporary modification of 
physical/chemical processes) should be minimized or avoided 
if possible, because such steps require additional reagents 
and can generate waste. 
Enzymes commonly exhibit desirable regio-, diastero- 
and enantioselectivities which shall reduce the number 
of synthetic steps required to generate a given product 
and the need of protection/deprotection steps 
9 Catalysis 
Catalytic reagents (as selective as possible) are superior to 
stoichiometric reagents. 
Enzymes are catalysts. 
10 Design for degradation 
Chemical products should be designed so that at the end of 
their function they break down into innocuous degradation 
products and do not persist in the environment. 
As for Principle 7 
11 Real-time analysis for pollution prevention 
Analytical methodologies need to be further developed to 
allow for real-time, in-process monitoring and control prior to 
the formation of hazardous substances. 
 
12 Inherently safer chemistry for accident prevention 
Substances and the form of a substance used in a chemical 
process should be chosen to minimize the potential for 
chemical accidents, including releases, explosions, and fires. 
As for Principles 3, 5 and 6, enzymes commonly require 
mild conditions and non-toxic solvents, reducing the 
risks of chemical accidents  
Table 1.1: Solutions for the “12 principles of Green Chemistry” provided by biocatalysis. The 








1.1.2 Limitations of Biocatalysis 
Despite its previously discussed advantages, several drawbacks are associated with biocatalysis. 
The first one is the limited stability of typical biocatalysts which restrict the range of conditions 
(temperature, solvent, concentration of reagents…) that most biocatalysts can be used in and the 
possibilities of coupling chemical and biocatalytic processes. In addition, while biocatalysts can exhibit 
desirable regioselectivity, an associated downside is that most enzymes exhibit poor substrate scopes. 
For this reason, there is a very limited number of commercial, ready-to-use efficient enzymes, such as 
lipases. In the vast majority of cases, enzymes which carry the desired transformation will need to be 
screened for the given substrate and hits will necessitate further optimisation to have activities that 
are comparable with chemical catalysts. Currently, an increasing number of industrial biotechnology 
companies (Codexis, Prozomix, Biocatalysts, Johnson Matthey, Almac…) supply enzyme screening kits 
to assist users in finding enzymes that display activity to their specific substrate. In addition, as 
biocatalysis is poised to play an ever-increasing role in industrial chemistry, substantial research 
efforts are dedicated to developing tools to ease the development of novel biocatalysts. Especially, 
the development of novel bioinformatic tools should become increasingly efficient at predicting hot 
spots for mutations, which shall reduce the time required to develop novel biocatalysts. 
1.1.3 “Biocatalomics”: the economic aspects of biocatalysis 
Unsurprisingly, biocatalysis is an expanding market. While the global enzyme market value was 
estimated to be $7 billion, it is estimated to reach $10 billion by 2024, with an impressive compound 
annual growth rate (CAGR) of 7.4%13. Biocatalysts have applications in a wide range of sectors, such 
as food processing, textile, pharma or biofuels and both for bulk and fine chemicals. While examples 
of fine chemicals produced partially or wholly using enzymes will be further discussed in the next 
section, an example of bulk chemical enzymatically produced is acrylamide. Acrylamide is produced 
by Nitto Chemical Company at a scale of 10 000+ tonnes per year using a nitrile hydratase enzyme, as 
shown in Figure 1.1, completely supplanting the previously used chemical approach that required a 
copper catalyst14. 
 





 Examples of 20 compounds manufactured by biotransformation at scales higher than 100 




Product Application(s) Enzyme type 
1000000+ High corn syrup Food & beverage Glucose isomerase 
100000+ Lactose-free milk Food & beverage Lactase 
10000+ Acrylamide Biotechnology; contact 
lenses 
Nitrile hydratase 
 Cocoa butter Food & beverage; 
cosmetics 
Lipase 
1000+ Nicotinamide Dietary supplement Itrilase 
 D-pantothenic acid Dietary supplement Aldonolactonase 
 (S)-chloropropinoic acid Chemical building block lipase 
 6-aminopenillanic acid Pharmaceutical    
(precursor) 
Penicillin amidase 
 Aspartame Food & beverage Thermolysin 
 L-aspartate Pharmaceutical; dietary 
supplement 
Aspartase 
 D-phenylglycine Pharmaceutical    
(precursor) 
Hydantoinase 
 4-hydroxy-D-phenylglycine Pharmaceutical    
(precursor) 
Hydantoinase 
100+ Ampicillin Pharmaceutical Penicillin amidase 
 L-methionine, L-valine Dietary supplement; 
chemical building block 
Aminoacylase 
 L-carnitine Dietary supplement Dehydratase/hydroxylase 
 L-DOPA Pharmaceutical B-tyrosinase 
 L-malic acid Food & beverage; chemical 
building block 
Fumarase 
 (S)-methoxyisopropylamine Chemistry Lipase 
 (R)-mandelic acid Pharmaceutical    
(precursor) 
Nitrilase 
 L-alanine Food & beverage; chemical 
building block 
L-Asp-β-decarboxylase 






Table 1.2 highlights the wide range of industrial applications of biocatalysis and the large array of 
enzyme types that are used in industry. Majorly, biocatalysis has positively disrupted the industrial 
production of fine chemicals and some examples of this will be discussed in the next section. 
1.1.4 Biocatalysis in the industrial production of fine chemicals 
Many examples of enzymes are currently used in the pharmaceutical and fine chemical 
industries16. In this part, a few key examples will be cited. The use of a ketoreductase to induce chirality 
in the synthesis of Lipitor17,  a statin drug which was the second most prescribed drug in the United 
States in 201717. Ketoreductases are, by far, the most used enzyme family in industry since, already in 
2012, this family of enzymes was used to generate chiral alcohols in the route of 17 prescribed drugs8. 
Another enzyme family which has a high industrial potential is the transminases, which generate chiral 
amines. Notably, a highly engineered transaminase, which underwent 27 rounds of mutations to 
increase its activity and stability, was found to generate sitagliptin (Januvia)18. Another example of 
enzyme used in industry is a penicillin G acylase to produce amoxicillin19. Pathway engineering can 
also be achieved to “program” whole cells biosynthesis of active pharmaceutical ingredients. For 
example, Sanofi was able to engineer a yeast to produce the anti-malarial drug, Artemisinin20. Last but 
not least, an enzymatic cascade can be engineered to produce key molecules such as Islatravir21. The 














Company Molecule Enzyme 
family 
Transformation Revenues 




























Table 1.3: Examples of biocatalytic strategies used in the fine chemical industry. 
 
1.2  Examples of organic reactions in biocatalysis 
Name reactions are a set of chemical transformations which carry significant importance in 
organic synthesis. Many of these reactions have been observed in nature, in the biosyntheses of 
natural products and substantial research in the biocatalysis field have been dedicated at 
understanding the mechanisms of these enzymes and how they compare with chemical methods. 
Enzymes catalysing most classes of reactions such as condensation, rearrangement, oxidation and, 
even, halogenation were characterised26. Two examples of Name condensation reactions which were 
found to occur in biological systems, the Stetter reaction and the Rauhut-Currier reaction will be 
briefly discussed. Two other reactions where biocatalysis could potentially play a major role, the MBH 
reaction and the amide coupling reaction will also be discussed in this part. 
1.2.1 Stetter reaction 
The Stetter reaction is a condensation reaction between an α-β unsaturated ketone and an 
aldehyde, to form a dicarbonyl product, as shown on Figure 1.2. This reaction is traditionally catalysed 
by a cyanide ion. However, in nature, cofactor thiamine pyrophosphate (TPP) is used by enzymes to 
carry this transformation. For example, MenD, an enzyme in the biosynthetic pathway of 




isochorismate, to form a 1,4-dicarbonyl27. The proposed mechanism of this reaction, shown in Figure 
1.2, is thought to consist of two steps: in a first step, 2-ketoglutarate is decarboxylated to form a 
succinic semialdehyde-TPP anion. This anion will then carry nucleophilic attack on isochorismate, to 
form the product and regenerate the TPP cofactor. 
 
Figure 1.2: Biocatalysed MenD Stetter reaction scheme and mechanism: the reaction proceeds in 
two steps: first, 2-ketogluterate, bound to TTP, is decarboxylated to form an zwitterionic derivative 
which will carry nucleophilic attack on isochorismate. The adduct will then break down, generating 
the product. 
 
Another example of biological Stetter reaction is catalysed by PigD from Serratia marcescens and 
involves the decarboxylative condensation of (2E)-octenal with pyruvate in the antiobiotic prodigiosin 
biosynthetic pathway, as shown in Figure 1.328. 
 









1.2.2 Rauhut-Currier reaction 
The Rauhut-Currier (RC) reaction is C-C bond-forming coupling twos electron-deficient alkenes. 
This reaction, shown in Figure 1.4, is often associated to the Morita-Baylis-Hillman (MBH) reaction, 
which will be extensively discussed in this work, in the sense that the RC reaction is thought to proceed 
via a similar mechanism. The main difference between the MBH and RC reactions is that, while the 
MBH reaction is the coupling of an electron-deficient alkene to an aldehyde, the RC reaction is the 
coupling of any two electron-withdrawing alkene29. Because of this difference, the RC reaction is often 
referred as a “vinylogous MBH” reaction. Interestingly, as it will be developed during this work, no 
enzyme catalysing a natural MBH reaction have been characterised. However, a few enzymes 
catalysing the RC reaction were found. An example of such enzymes is SpnL from Saccharopolyspora 
spinosa, an enzyme involved in the biosyntheses of spinosyns, a class of polyketide insecticides30. SpnL 
catalyses an intramolecular RC cyclisation. One of SpnL nucleophilic residues will undertake a 
nucleophilic attack on the substrate30. Interestingly, the identity of the nucleophile is unknown30.  This 
will increase the nucleophilicity of the alkene and trigger the formation of a novel C-C bond. 
Rearrangement and regeneration of the catalyst will then afford the product. Its mechanism is shown 






Figure 1.4: SpnL-catalysed RC reaction: the nucleophilic catalyst undertake Micheal addition on 
the substrate, generating a novel nucleophilic site which will form an intramolecular C-C bond, 
hence forming a novel 5-membered ring. Rearrangement and regeneration of the catalyst will 
afford the product.    
 
1.2.3 Morita-Baylis-Hillman (MBH) reaction 
 As previously introduced, the MBH reaction is a more general variant of the RC reaction and 
represents the base-catalysed coupling of an electron-deficient alkene to an aldehyde. This reaction 
was extensively studied, as it will be discussed later in this work, and many organocatalysts have been 
developed31. However, no example of a natural “MBHase” enzyme have been reported in the 
literature and attempts at producing novel biocatalysts were based on exploiting the synthetic 
promiscuity of enzymes catalysing other reactions, such as esterases32, lipases33, halogenases34 or 
racemases34. Amongst these attempts at finding a potent MBH biocatalyst, the pimeloyl-ACP methyl 
ester esterase BioH from E. coli, an esterase involved in the biotin biosynthetic pathway in numerous 
species was found to catalyse the coupling of 4-nitrobenzaldehyde and methyl vinyl ketone with a 46% 





Figure 1.5: Scheme of the E.coli BioH-catalysed MBH reaction between 4-nitrobenzaldehyde and 
methyl vinyl ketone. 
 
This represented a good starting point in the research of a potent MBH biocatalyst. As no 
mechanistic data was available, one of the aim of this work is to gain an understanding of the 
mechanism of this biocatalysed reaction through investigating the involvement of some features that 
could play a role in the reaction. 
1.2.4 Amide coupling 
By many metrics, the coupling of a carboxylic acid with an amine to generate an amide is amongst 
the most important reactions in synthetic organic chemistry. Chemically, this transformation requires 
the use of stoichiometric amounts of coupling reagents. For this reason, this reaction is considered 
atom inefficient and biocatalysis is thought to be a potential solution. Indeed, in nature many enzymes 
catalysing this reaction have been characterised. A comprehensive review of these will be carried later. 
Amongst these enzymes, an interesting small family of ATP-dependent enzymes have been described 
recently: the nitrile synthetases. These enzymes are capable of carrying the standard coupling of a 
carboxylic acid, 7-carboxydeazaguanine (CDG) and ammonium sulfate to generate the corresponding 
primary amide (7-amidodeazaguanine, ADG). However, the singularity of this enzyme family resides 
in that the amide is then further transformed into the corresponding nitrile (PreQ0) as shown on Figure 
1.636. 
 
Figure 1.6: Nitrile synthetase (NS) reaction scheme. CDG is first transformed into ADG, using one 
equivalent of MgATP and then into PreQ0 using a second equivalent of MgATP. 
 
As the mechanism of these enzymes is not known, another aim of this work will be to gain insights 
on the residues involved in the transformations and engineer an amide synthetase from the NS: an 
engineered biocatalyst fit to carry the transformation of the carboxylic acid into an amide but not into 
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Chapter 2 Towards a biocatalytic approach for 
the Morita-Baylis-Hillman Reaction  
2.1 Introduction 
2.1.1 The Morita-Baylis-Hillman (MBH) reaction 
The Morita-Baylis-Hillman (MBH) reaction is a widely used C-C bond-forming reaction in organic 
synthesis. It involves the base-catalysed coupling of an aldehyde and an electron-withdrawing (EW) 
alkene. This reaction was first developed by Ken-ichi Morita and colleagues in 1968,1 when 
tricyclohexylphosphine was originally used as the catalyst. Nevertheless, this catalytic system 
displayed limited efficiency as the reaction afforded low yields (<25%) and had to be carried out under 
harsh conditions. However, in 1973, Melville Hillman and Anthony Baylis significantly improved the 
versatility of the Morita reaction2 (Figure 2.1). They found that using nucleophilic nitrogen-containing 
bases such as 1,4-diazabicyclo[2.2.2]octane (DABCO) dramatically improved the yield (>80%). The 
scope of the reaction was expanded to any electron-withdrawing alkenes and high temperatures were 
no longer required. DABCO is still widely used today as a MBH reaction organocatalyst, although it is 
not stereoselective 
 
Figure: 2.1: General scheme of the MBH reaction along with the structure of the catalysts used by 
Morita and by Baylis and Hillman. This reaction couples an aldehyde with an electrophilic alkene 
to form an alcohol. 
 
The proposed mechanism of the MBH reaction, shown in Figure 2.2, is thought to consist of three 
steps3.   The first step is the Michael addition of the nucleophilic catalyst on the alkene double bond 
(I) to form an extremely reactive zwitterionic adduct (II). This adduct will attack the electrophilic 
aldehyde, forming a new carbon-carbon bond. Then a product-catalysed proton transfer, thought to 






Figure 2.2: MBH reaction proposed mechanism for a vinyl ketone, an example of an electron-
withdrawing alkene. The nucleophilic catalyst undergoes Micheal addition on the alkene, forming 
an extremely nucleophilic zwitterion which will attack the electrophilic aldehyde. A product-
catalysed proton transfer and elimination of the catalyst afford the product. 
 
As this reaction creates a chiral centre, a lot of research effort has been dedicated to control the 
stereochemistry of the product. The early work done in this area was concentrated on the use of 
unmodified chiral nitrogen bases such as brucine, quinidine or nicotine but none produced any 
significant stereocontrol of the reaction (<20% enantiomeric excess (ee))4-5. Chiral auxiliaries such as 
Oppolzer’s sultams-(α-β) unsaturated ketone derivatives were also used, generating the 
corresponding 1,3-dioxan-4-one which is subsequently converted to the MBH product by 
transesterification with good overall yields (55-80%) and excellent ee (>99%) but vastly reduced the 
substrate scope, as showed in Figure 2.36.  
 
Figure 2.3: Use of Oppolzer’s sultams-(α-β) unsaturated ketone as chiral auxiliaries for 
enantioselective MBH reaction. 
 
The first work which reported moderate enantioselectivity (45%) for a chiral base-catalysed MBH 
reaction was carried by Hayase and colleagues, who used the phosphine catalyst (S)-(−)-(1,1-
Binaphthalene-2,2-diyl)bis(diphenylphosphine) ((S)-BINAP) shown in Figure 2.4, but with poor yields 
(8-26%). 





Figure 2.4: (S)-BINAP-catalysed reaction scheme and structure of the catalyst. 
 In 1999, however, a significant breakthrough occurred as Iwabuchi, Hatakeyama and co-
workers reported a novel catalyst, thereafter called Hatakeyama catalyst, which resulted in medium 
to good yields (55-65%) and excellent ee (>90%) as shown in Figure 2.58. The innovation in this chiral 
catalyst lies in the fact that, besides the Lewis basic site common to all MBH catalysts, this catalyst 
also features a Bronsted acidic site, which shall stabilise the enolate, direct its attack on the aldehyde 
and catalyse the rate-limiting proton transfer, favouring one enantiomer over the other. The weakness 
of this catalytic system is the formation of a few by-products (11-25%) 
 
Figure 2.5: Hatakeyama-catalysed MBH reaction scheme and structure of Hatakeyama catalyst8. 
The structure of the chirality-inducing transition state is shown: one enantiomer is favoured over 
the other as the proton from the Bronsted acidic site of the catalyst undergoes H-bonding to the 
anionic alkoxyde. 
 
The concept of complementing a Lewis basic site with a Bronsted acidic site or hydrogen bond 
donor to control the stereochemistry gained significant interest over the years3. As such, the preferred 




with a chiral co-catalyst, which stabilise the enolate. Examples include the use of 4-dimethyl 
aminopyridine (DMAP) and thiourea derivatives9 (yield: >50%, ee: >70%), or triethyl phosphine with 
(R)-binaphthol-derived Bronsted acids (yield:  >40%, ee: >70%)10. This strategy was also adopted with 
amino acids, using proline as a Lewis base and a synthetic 7-mer peptide as co-catalyst with moderate 
to good yield and ee (yield: <40%, ee: 40-80%)11.  
Most recent research still relies vastly on the chiral chemical catalysts presented before and many 
reports have expanded their substrate scope. For example, the Hatakeyama catalyst was successfully 
used for the enantioselective reaction of maleimidines with 7-azaisatine derivatives to afford chiral 3-
hydroxy-7-aza-2-oxindoles (yield: >40%, ee: >60%)12 and to convert furfural and a hexafluoroisopropyl 
acrylate analogues for the total synthesis of the naturally-occurring antibiotic (-)-tirandamycin B (yield: 
70%, ee: 99%)13. Binaphtalene derivatives optimised for specific substrates, resembling those 
presented in Figures 5 and using the same catalytic machinery have also been described recently14-15. 
Hence, as such, this reaction has many strengths: 
• Unlike most carbon-carbon bond-forming reactions, which require organometallic catalysts, 
the use of an organocatalytic system makes this reaction cheap and environmentally benign. 
• The starting materials, being an aldehyde and an alkene are usually easily accessible. 
• This reaction introduces a stereogenic centre, therefore the MBH reaction can be used in a 
synthetic route to generate enantiopure molecules 
However, this reaction has also some drawbacks:  
• Even though this reaction proceeds readily with electron-withdrawing substituents, MBH 
reaction on electron-donating substituent is complicated as the first step, the Micheal 
addition of the catalyst on the alkene is not favoured. 
• Although great progress was made in making the MBH reaction enantioselective, chiral 
control still require non-commercially available catalysts which necessitate a multistep 
synthesis. 
• Finally, this reaction often requires very long reaction times (up to 7 days) 
This aim of this workis to explore the use of biocatalysis to overcome the limitations of the 





2.1.2 Literature review of biocatalysed MBH reactions 
The most popular approach in the development of a MBH biocatalyst is to couple a nucleophilic 
site, which will easily attack the alkene derivative in the first step of the reaction, and a hydrogen-
bond donor, which will stabilise the alkoxide intermediates, on an enzyme template. The first trial of 
a biocatalysed MBH reaction was published in 2007 by Manfred Reetz and co-workers, where serum 
albumin proteins from various species as well as some lipase enzymes were screened for MBH activity 
16. The best conversion was observed after 48h with bovine serum albumin (conversion = 35%, ee = 
9%) while the best ee (conversion 15%, ee = 19%) was observed with bovine serum albumin (fraction 
V). as showed in Figure 2.6. 
 
Figure 2.6: First published attempt at a biocatalysed MBH reaction by Reetz et al.16. 
 
 Reetz & colleagues proposed a mechanism for the biocatalysed reaction: it involves a nucleophilic 
residue such as lysine, cysteine or histidine undergoing a Micheal addition on the alkene while the 
alkoxide negative charge of the subsequent intermediate is stabilised by H-bond interactions with the 
protein residues, in an oxyanionic hole as shown on Figure 2.7.  
 
Figure 2.7: Interaction of the substrate with the protein oxyanionic hole. The substrate is stabilised 
by H-bond donating interactions from the protein. 
 
 In contrast, David Baker and colleagues used quantitative modelling and molecular dynamics 
approaches to design enone-binding biocatalysts for the MBH reaction17. Substantially agreeing with 
Reetz about the importance of H-bond donors to stabilise the oxyanionic transition states, they 
postulated that an efficient biocatalyst should also feature a hydrophobic and/or aromatic binding site 
to add subsequent favourable protein-substrate interactions. They screened 48 proteins and found 
two with increased activity for MBH reaction: an alanine racemase from Geobacillus 




methods, various point mutants were made and they performed saturation mutagenesis at selected 
positions near the active site on these two proteins.  A single mutant (haloacid dehalogenase N14I), 
which was 2.4-fold more active than the wild-type, displayed 24% conversion after 18h, at very high 
protein concentration (38 mol%), with no reported ee. Notably, they were also able to observe a 
protein-cyclohexenone covalent adduct by mass spectrometry, providing further evidence that a 
nucleophilic residue attacks the electrophile. 
In addition, Joshi et al. have screened enzymes containing a histidine and arginine pair18. They 
postulated that the histidine will act as a nucleophile while the arginine will act as a hydrogen bond 
donor (HBD) and stabilise the oxyanionic intermediates. Although they were able to obtain promising 
conversion (up to 72%) with lysozyme C from hen egg-white, they were using an extremely high 
catalyst loading (10 mol%).  
Another approach first studied by Jiang et al. is to use enzymes containing a α/β-hydrolase fold 
(ABHF) such as lipases and hydrolases19. Through screening AHBF-containing enzymes, Jiang showed 
that pimeloyl-acyl carrier protein (ACP) methyl ester esterase (BioH) from E. coli (EcBioH) displayed 
best activity for the MBH reaction between 4-nitrobenzaldehyde (4-NBA) and methyl vinyl ketone 
(MVK) as 46% conversion was obtained. Considering this higher efficiency, EcBioH appears to be a 
promising platform to exploit to gain insights on the biocatalysed MBH reaction.  
The same team have also published the EcBioH-catalysed aldol and Knoevenagel reactions and 
obtained up to 91% conversion for the aldol reaction and 55% for the Knoevenagel reaction which 
suggests an interesting synthetic promiscuity for EcBioH20.   
2.1.3 Alpha-beta hydrolase fold, an interesting structural motif 
The highly conserved ABHF structural motif is characterised by 6 to 9 parallel β-sheets, which are 
flanked by α-helices21. The active site is composed of a serine protease catalytic triad made of Ser, Asp 
and His located on the loops that separate the helices and sheets. The function of such catalytic triad 
is to deprotonate the Ser to drastically increase its nucleophilicity. The pKa of serine being 15.9, non-
catalytic Ser will be protonated. However, interactions with the Asp and His residues will trigger Ser 
deprotonation. The deprotonated Asp residue of the triad (pKa = 2.90) will give electron density 
through a hydrogen bond to the nearby histidine. The electron-rich histidine will, in turn, be able to 














Figure 2.8: ABHF-containing enzymes catalytic triad: The nucleophilicity of the histidine is 
increased by the electron density given out by the deprotonated aspartic acid. This allows this 
histidine to abstract a proton from serine, dramatically increasing its nucleophilicity. 
 
As such, a catalytic Ser could act as the nucleophilic activator in the MBH reaction. Furthermore, 
the ABHF structural motif also features an oxyanionic hole, which could stabilise anionic intermediates 
as shown previously on Figure 2.7, making the ABHF a promising structural scaffold for MBH catalysis. 







The proposed mechanism of the ABHF-biocatalysed MBH reaction is that the Ser in the catalytic site 
would attack the electrophilic alkene (I) while a hydrogen bond donor (HBD) located in the oxyanionic 
hole will stabilise the oxyanionic intermediate. The first intermediate, being nucleophilic will attack 
the aldehyde (II) and this oxyanionic intermediate will also be stabilised by the oxyanionic hole which 
will promote the proton transfer which will trigger the elimination of the catalyst (III), forming the 
product (IV) as shown on Figure 2.10. 
 






Figure 2.10: Proposed mechanism of the ABHF-catalysed MBH reaction. 
2.1.4 EcBioH, a promiscuous esterase 
Pimeloyl-ACP methyl ester esterase is, as its name suggests, an esterase that catalyses the 
hydrolysis of pimeloyl-ACP methyl ester into pimeloyl-ACP in the biotin biosynthetic pathway. In E. 
coli, it is a 29.5 kDa protein that can be found both as a monomer and as a dimer. EcBioH was first 
purified and characterised in the Campopiano group22. In E. coli, from malonyl-ACP methyl ester 
undergoes two cycles of fatty acid synthase to elongate its alkyl chain, forming pimeloyl-ACP methyl 
ester26. Then follows the BioH-catalysed hydrolysis of the pimeloyl-ACP methyl ester into pimeloyl-
ACP. In effect, the BioC/BioH couple “hijacks” the fatty acid pathway. However, although most steps 
in this biosynthetic pathway are conserved across species, this step is catalysed by multiple enzymes, 
depending on the species. For most Gram-negative bacteria such as E. coli or M.flagellatum, this 
reaction is catalysed by BioH, which will be further discussed later27. However, it was shown that BioG 
could catalyse this reaction in Haemophilus influenzae, BioK in cyanobacteria, BioV in Helicobacter, 
BioJ in Francisella or BtsA in Moraxella bacteria28. Although all these proteins catalyse the same 
reaction, they share very low sequence identity (Figure 2.14), have different transcriptional 
regulations and belong to different subclades of the ABHF superfamily29. BioF then converts the 
pimeloyl-ACP into 8-amino-7-oxononanoic acid, with the substitution of the ACP by ethylamine33. 





Figure 2.11: Biotin biosynthetic pathway from malonyl ACP methyl ester.  
ACP: Acyl carrier protein; FAS: Fatty acid synthase  
Hence, BioH role in the biotin biosynthetic pathway has been discussed. As this enzyme catalyses 
ester hydrolysis, it is a esterase enzyme. As discussed earlier, BioH carries a catalytic triad with a 
nucleophilic serine. This serine will be able to attack the substrate to catalyse the hydrolysis reaction. 
The methanol by-product and the substrate are then liberated, hence regenerating the biocatalyst. 











Figure 2.12: Mechanism of the BioH-catalysed hydrolysis of pimeloyl-ACP methyl ester: The 
catalytic serine undergo nucleophilic substitution, liberating methanol and activating the pimeloyl-





BioH sequence is mostly conserved across species as displayed in Figure 2.13. However, as shown 
on Figure 2.14, sequence homology of EcBioH with other pimeloyl-ACP methyl ester esterases, BioG, 
BioV, BioJ, BioK and BtsA is very low.  It was found that serine residues that are part of a conserved 
GXSXG sequence motif are likely to be involved in an esterase catalytic triad32. As expected, Ser82, the 
catalytic serine is part of a GXSXG sequence motif that is very well conserved across species. Other 
residues of the catalytic triad are also well conserved across species. However, interestingly, EcBioH 
possess a second GXSXG motif in residues 51 to 55. While this second GXSXG sequence motif is well 
conserved across all BioH species, it is not observed any other pimeloyl-ACP methyl ester esterases. 
 
Figure 2.13: Sequence alignment between ECBioH (UniProt : P13001), Salmonella enterica BioH 
(A0A1R2SY91), Klebsiella pneumonia BioH (A6TF35), Shigella flexneri BioH (Q83PWO), 
Neisseria meningitis BioH (A0A1B1ZBF7) and P.atrosepticum (Q6CZL9) obtained from CLUSTAL 
omega. White over red residues are conserved across all species, red on white are conserved 
across most while black on white are variable across species. The yellow rectangle shows the 
GXSXG sequence motif thought to be part of the main catalytic site while the green rectangle 
shows the GXSXG sequence motif thought to be part of the cryptic catalytic site. As shown, 






Figure 2.14 : Sequence alignment between ECBioH (UniProt : P13001), Helicobacter BioV 
(A0A553V3R2), H.influenzae BioG (P44251),  Francisella tularensis BioJ (A0Q641), 
Prochlorococcus marinus BioK (A0A0A2C7Y6) and Moraxella catarrhalis BtsA (A0A3A9P6D5) 
obtained from CLUSTAL omega. White over red residues are conserved across all species, red 












The structure of EcBioH was successfully determined in 2003 and is shown on Figure 2.1530. EcBioH 
was shown to have a structure typical of ABHF-containing enzymes. It presents 6 parallel -sheets 
flanked by -helices on either sides. It also displays a capping domain made of four -helices (K121 to 
T185). These motifs are separated by large, flexible loops. As expected, its catalytic triad displays an 
arrangement which makes it extremely fit for catalysis, with His235 being within H-bond distance of 
both Ser82 and Asp 207. As discussed, BioH enzymes feature a second GXSXG sequence motif, 




















Figure 2.15 A) EcBioH WT crystal structure (PDB ID: 1M33). The ABHF motif is shown in red.  
B) EcBioH crystal structure zoomed on the main catalytic triad. The distance between Ser82 and 
His235 is 2.1Å and the distance between His235 and Asp207 is 2.2Å.  
C) Structure of the EcBioH potential cryptic catalytic site (PDB ID: 1M33). The distance between 


















This cryptic site appears much less fit to catalyse the hydrolysis reaction as the intermolecular 
distances between Ser53/His20/Asp46 are far greater than for the Ser82/Asp207/His235 triad, 
reducing their ability to undergo hydrogen-bonding interaction. However, as these residues are 
located on loops, significant flexibility shall be expected, and they may interact together to 
deprotonate Ser53 and, as a result, be involved in catalysis. Other structures of BioH, from different 
organisms, have also been determined and are available on the PDB. It was found that they all display 
similar properties. These structures are summarised in Table 2.1: 
PDB ID Organism Phenotype Ligand Reference 
1M33 E. coli Q100R, F136W 
(PCR errors) 
None 30 





WT None Deposited on the PBD but 
no reference publication 
6K5E Klebsiella 
pneumonia 
WT None 33 
Table 2.1: BioH crystal structures deposited to the PDB. 
 
Interestingly, Agarwal and co-workers were able to co-crystallise EcBioH with its ligand pimeloyl-ACP 
methyl ester31. However, they were not able to co-crystallise the wild-type enzyme but instead the 
catalytic serine knockout mutant (S82A). While this mutation might induce a different binding mode 
for pimeloyl-ACP, it nonetheless gives interesting insights on the structure of the enzyme-ligand 
complex. As expected, the distal part of the pimeloyl moiety binds the catalytic triad, for reaction 
(which is not occurring in this case due to the S82A mutation). The ACP displays four helices with a 





Figure 2.16: EcBioH S82A V243A co-crystal structure with a pimeloyl-ACP methyl ester (PDB: 
4ETW).  
A) Full structure. EcBioH is shown in green. Pimeloyl-ACP is shown in yellow.  
B) Zoomed on the catalytic triad. EcBioH is showed in green, pimeloyl-ACP methyl ester is showed 
in yellow. The residues of EcBioH catalytic triad and the pimeloyl methyl ester moiety and the ACP 
phosphopantetheine arm are shown as sticks.  
 
 In addition to BioH, the crystallographic structures other pimeloyl-ACP methyl ester esterases 
were determined. BioG from H.influenzae structure was determined by the group of John Cronan in 
201634 (PDB ID: 5GNG) and BioJ structure was determined in 2019, although the structure has still not 
been made available on the PDB (PDB ID: 6K1T)27. All the published structures of BioH enzymes were 
overlapped as well as the structure of EcBioH with H.influenzae BioG, as shown on Figure 2.17.  








Figure 2.17: A) Overlay of BioH structures: E. coli BioH: PDB ID: 1M33 (blue) and PDB ID: 4ETW 
(green); Salmonella enterica PDB ID: 4NMW (magenta) and K.pneumonia PDB ID: 6K5E (orange). 
 B) Overlap of EcBioH structure PDB ID 1M33 (blue) with H.influenzae BioG PDB ID: 5GNG (black). 
 
From Figure 2.18, it was observed that BioH displays a very high degree of structural similarity 
across species. In contrast, BioG is structurally more different and displays an atypical ABHF. While on 
BioH, the parallel β-sheets are flanked by α-helices on both sides, in BioG, large loops replace four of 
six of these α-helices. The parallel β-sheets core is, however, very similar in BioH and BioG. 
To obtain detailed insights into the biocatalysed MBH reaction mechanism, the role of all the 
features discussed will be explored. In first instance, EcBioH catalytic triad will be deactivated. This 
would determine whether the catalytic triad is involved in MBH catalysis. Thus, if a normal or slightly 
reduced activity is observed when the catalytic triad is inactivated, it will be possible to conclude that 
another feature of the enzyme plays a predominant role in the reaction. Such features will be 
investigated. 
2.1.5 Aims 
The general objective of this part is to gain mechanistic insight into the biocatalysed MBH reaction. 
As such, the aims of this project are:  
• To clone, express, purify and characterise EcBioH. 
• To design a suitable assay to monitor efficiently and precisely the MBH reaction. 
• To optimise conditions for the biocatalytic MBH reaction. 







• To deactivate the conserved and cryptic catalytic triads by site-directed mutagenesis and to 
assess the role of the catalytic triads in the MBH reaction. 
• To gain mechanistic insights of the MBH reaction. 
• To screen other proteins and enzymes, which could catalyse the MBH reaction. 
2.2 Generation of the biocatalyst 
2.2.1: Cloning of E. coli BioH 
As discussed in the introduction, the starting point of this study is the esterase BioH from E. coli 
(EcBioH) as this enzyme was found by Jiang and co-workers to be able to catalyse the Morita-Baylis-
Hillman (MBH) coupling of 4-NBA and MVK with 46% conversion (Figure 2.1820).  
 
Figure 2.18: The EcBioH-catalysed MBH reaction scheme between 4-NBA and MVK. 
 
As a first step, the full-length BioH gene (E. coli strain K12, UNIPROT code: P13001) was cloned in 
different expression vectors and with or without the presence of a stop codon, in order to give two 
different recombinant forms of EcBioH: one with a non-cleavable N-terminal hexahistidine tag and 
one with a non-cleavable C-terminal hexahistidine tag. More specifically, the gene was cloned in 
pET22b and pET28a plasmids. Both plasmids possess two interesting features which make them 
particularly suitable for the overexpression of proteins: 
• An antibiotic resistance gene (kanamycin for pET28a and ampicillin for pET22b) which 
allows cells containing the plasmid to be resistant to a selected antibiotic, which will be 
added to the growth media to minimise the risk of contamination. 
• A lac1 operon, which allows the use of isopropyl-B-D-thiogalactopyranoside (IPTG) as an 
inducer for enzyme overexpression. IPTG will allosterically bind and inactivate the lac 
repressor, hence allowing RNA polymerase to initiate T7 transcription.  
All these variants were cloned with Nde1 and Xho1 restriction sites, allowing easy transfer in 





Entry name Position of the 
hexahistidine-tag 
Number of amino 
acids 
Vector Stop codon 
EcBioH-N N-terminal 276 pET28b Yes 
EcBioH-C C-terminal 264 pET22b No 
Table 2.2: Table showing the different recombinant forms of EcBioH cloned. 
* Molecular weights were calculated by ExPASy-ProtParam tool. Average mass is showed. 
 
EcBioH-C from Table 2.2 was cloned by Dr Menglu Wang while EcBioH-N was cloned at the 
commencement of this study. The vector maps for these two entries are shown in the appendix.  
2.2.2: Expression and purification of EcBioH. 
All variants of EcBioH were expressed in BL21 (DE3) E. coli strain after induction with 0.3 mM IPTG 
and incubation at 18ºC for 18 h, following the conditions presented by Agarwal and Cronan, which 
gave satisfactory results31. The enzyme was purified by immobilised Nickel affinity chromatography 
(IMAC) followed by size-exclusion chromatography (SEC). The hexahistidine-tagged EcBioH were 
purified with a gradient from 30 to 250 mM imidazole. Both EcBioH-N and EcBioH-C eluted at 75 mM 
imidazole. SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) analysis showed 
that the protein was recovered with a purity of 80+ %, with traces of a few higher molecular weight 
proteins as shown on Figure 2.4. The SEC step was initially carried on a Superdex S200 column (120 
mL). Interestingly, two large peaks were observed in every case: one with an elution volume of 76 mL 
and the second one with an elution volume of 84 mL. Analyses in denaturating conditions (SDS-PAGE 
and LC-MS-(ESI)) showed that the mass of the monomer in both cases was the same (approx. 30 kDa), 
suggesting that two different EcBioH quaternary structures were obtained. According to the Superdex 
S200 column calibration curve, the first peak corresponds to a mass close to the dimeric EcBioH 
(Determined Mwt of the complex from S200 calibration curve: 58 kDa; Expected Mwt of EcBioH dimer: 
59 kDa)  while the second peak should correspond to monomeric EcBioH (Determined Mwt of the 
complex from S200 calibration curve: 26 kDa; Expected Mwt of EcBioH monomer: 29 kDa). However, 
the separation of these peaks was not ideal. After investigating this issue, it was found that when using 
a Superdex S75 column two better resolved peaks were obtained with elution volumes of 54 mL and 
66 mL. In addition, one peak corresponding to higher molecular weight is observed, as shown in Figure 










Figure 2.19: Gel filtration chromatograms of purified EcBioH-C. 
A): Superdex S200 shows one small peak at 40 mL corresponding to high molecular weight 
aggregates, one peak at an elution volume of 76 mL corresponding to EcBioH-C dimer and one 
peak at an elution volume of 84 mL corresponding to EcBioH-C monomer.  
B): S75 chromatogram, showing one peak at 42 mL corresponding to high molecular weight 
EcBioH-C aggregates, one at 54 mL corresponding to the dimer and one at 66 mL which 
corresponds to EcBioH-C monomer. S75 purification affords the best resolution. 
 
It was investigated whether it is possible to control the yields of dimeric and monomeric 
versions of EcBioH. Indeed, while it was found that these quaternary structures display similar 
activities on the various assays carried, it was thought to be important to have a single quaternary 
structure for structural studies. While changing the buffer didn’t significantly affect the distribution, it 
was found that lowering the flow rate from 1 mL/min to 0.6 mL/min favours the isolation of the 
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Figure 2.20: Superdex S75  chromatograms of EcBioH-C.  
A): flow rate = 1 mL/min 
B): flow rate = 0.6 mL/min. The peak at 65 mL was found to be much larger upon lowering the flow 
rate, suggesting increased purification of EcBioH-C monomer. 
 
While baseline resolution of the monomer and the dimer was not obtained, the monomer was 
recovered with high purity when the flow rate was reduced, with the dimer present as a small impurity. 
The impact of the size-exclusion chromatography flow rate on protein behaviour was already 
described by Harrowing and Chaudhuri on the size-exclusion refolding of β-lactamase35. 
From SDS-PAGE analysis, it was found that after size-exclusion chromatography, the enzyme 















Figure 2.21: 12% SDS-PAGE gel of EcBioH-C purification steps 
L: Low molecular weight ladder; P: Cell pellets; Ni: After immobilised nickel affinity chromatography; 
D: Fractions corresponding to the dimer after size-exclusion chromatography; M: Fractions 
corresponding to the monomer after size-exclusion chromatography.  
     L       P    Ni         D                      M 












































































Yields of 10-15 mg/L of culture of pure EcBioH were routinely obtained. The constructs were 
characterised by electrospray ionisation mass spectrometry (ESI-MS). A routine MS spectrum for 
EcBioH is showed in Figure 2.22. Low levels of impurity which could be the oxidised protein were 
observed. The theoretical and measured masses for the different EcBioH are shown in Table 2.3:  
 
 
Figure 2.22: ESI-MS spectrum for EcBioH-C. EcBioH-C deconvoluted mass spectrum is shown. 
 




Experimental molecular weight  
1 N-terminal 30668.34 Da 30536.51 ± 2.37 Da 
2 C-terminal 29570.13 Da 29569.61 ± 1.48 Da 
Table 2.3: MS data of the first EcBioH clones expressed. 
* Theoretical molecular weights were calculated by ExPASy-ProtParam tool. Average mass is 
showed. 
 
2.3 Development of robust assays 
Before optimising the biocatalysed MBH reaction, a method to efficiently monitor the reaction 
was required. The MBH product was obtained synthetically and fully characterised by nuclear 
magnetic resonance (NMR) spectroscopy and MS (See Methods). Hence standards for each reagent 
















29570 Da  




2.3.1 A robust, medium-throughput reverse phase HPLC MBH assay 
A useful tool to quantitatively assess the progress of a chemical reaction is high-performance 
liquid chromatography (HPLC). With this method, the components of a reaction mixture are separated 
on a column and subsequently detected by an ultraviolet (UV) detector. Quantitative data can easily 
be obtained as the area of the peak will depend on the extinction coefficient of the compound at that 
wavelength, and its concentration following the Beer-Lambert Law. Conditions which resulted in 
baseline resolution of the standard MBH reaction mixture were found to be an isocratic elution of 50% 
MeCN – 50% water at 1 mL.min-1 with UV detection at 254 nm. This wavelength was specifically chosen 
because it is the wavelength at which phenyl rings show maximum absorption36. In addition, methyl 
vinyl ketone does not absorb at this wavelength. Hence, what was eventually observed was the 
conversion of the 4-nitrobenzaldehyde into the MBH product. Consequently, methyl vinyl ketone was 
always used in excess.  The HPLC chromatogram obtained when mixing 4-NBA, MVK and the MBH 
product is shown in Figure 2.23 along with the standard reaction monitored in this study. Calibration 


























Figure 2.23: HPLC analysis of an equimolar mixture of 4-NBA, MVK and the corresponding MBH 
product. The peak with retention time (Rt) = 5.4 min corresponds to the MBH product while the 
peak with Rt = 6.8 min corresponds to 4-NBA. Methyl vinyl ketone does not absorbs at this 
wavelength. Calibration curves with 4-nitrobenzaldehyde and the MBH product were drawn 
(Appendix) and were used to determine the extinction coefficients of the two species: nitrobenzaldehyde 
= 7326 L/mol/cm and MBH product = 8126 L/mol/cm.  
Conditions: Luna 5μ C18 (2) RP-HPLC column (100Å, 250×4.60mm, Phenomenex) eluting at 1 







2.3.2 Chiral HPLC MBH assay 
As the MBH reaction induces chirality, a way to distinguish and quantify both enantiomers of the MBH 
product was investigated. A chiral HPLC method was therefore set up and optimised for high 
resolution separation of both enantiomers. Stationary and mobile phases were therefore screened. It 
was found that the method which led to the best enantiomeric resolution was an isocratic elution of 
8% isopropanol in hexane using a ChiralPak IC column. This column uses cellulose tris(3,5-
dichlorophenylcarbamate) as a chiral selector. Both enantiomers interact differently with this 
stationary phase, hence allowing chiral separation. As previously, the wavelength for detection was 



















Figure 2.24: Chiral HPLC chromatogram of a racemate of the MBH product at 254 nm. The 
retention times of the enantiomers were found to be 24.2 min and 26.4 min. The chirality of the 
species corresponding to each peak is unknown. 
Conditions: ChiralPak IC column eluting at 1 mL/min in 8% isopropanol in hexane 
  
Although this method had not been optimised as previously to quantify the conversion of 4-NBA 
into the MBH product, it was verified that the 4-NBA doesn’t co-elute with any of the enantiomers.  
2.3.2 Investigating alternative high throughput MBH assays 
Although an efficient HPLC methodology was set up, the required sample preparation and the 
lengthy analysis make it impractical for high-throughput (HTP) assay of the MBH reaction. Thus, a 



























reactions using a 96-wells plate reader. More precisely, an assay detecting either aldehydes or alcohols, 
but not ketones had to be developed. A Schiff reagent assay was therefore trialled. In this assay, it is 
expected that 4-NBA will react with a sulphurous fuschin derivative to form a purple product following 
the scheme shown in Figure 2.25. 
 
Figure 2.25: Schiff reagent assay scheme. 
 
Hence, the Schiff reagent will selectively react with aldehydes to form an adduct which displays 
high UV absorbance at 540 nm, as shown in Figure 2.26. 
 
Figure 2.26: UV-Vis spectrum of Schiff reagent in mixture with 4-NBA, methyl vinyl ketone (MVK), 
cyclohexenone, the MBH product and the buffer between 450 and 700 nm after one minute 
incubation. A significant absorbance at 540 nm is observed for 4-nitrobenzaldehyde. 
 
Analysis by UV-Vis spectrometry shows that this assay is selective towards 4-NBA. 
Unsurprisingly, α-β unsaturated ketones such as methyl vinyl ketone and cyclohexenone also show 






















cross-reactivity was observed with Schiff reagent. However, the incubation time had to be closely 
monitored (maintained below one minute) as, after 30 minutes, all the reagents, the buffer alone or 
deionised water, incubated with Schiff reagent showed a deep purple colour and a large peak at 540 
nm on UV-Vis spectroscopy. This suggests that Schiff reagent is very reactive and that it would, 
therefore, be challenging to control background reactions. Besides, after multiple attempts in creating 
a calibration curve, no satisfactory linearity was achieved on the area under the curve (AUC) vs 
concentration graph. Reasons for this issue are still unclear as the mechanism of the reaction between 
the aldehyde and Schiff reagent is unclear. 
From these issues, it was concluded that the most effective way to monitor the conversion 
efficiently was the HPLC assay presented in part 2.3.1. 
2.3.4 Esterase reaction assay 
This project aims to take advantage of the EcBioH esterase promiscuity to generate biocatalysts 
which would work efficiently for the MBH reaction. However, the natural esterase activity of the 
enzyme should also be assayed as it would be interesting to compare how the esterase activity is 
affected by the enzyme engineering targeting the MBH catalytic activity. A substrate which undergoes 
a change in UV absorbance upon hydrolysis would be ideal for this as conversion could be easily 
monitored on a 96-well plate reader.  
p-nitrophenyl acetate (pNPA) was found to be interesting on that regard since its hydrolysis 
product, p-nitrophenol (pNP), absorbs at 410 nm when deprotonated. The scheme of that hydrolysis 




Figure: 2.27: p-nitrophenyl acetate assay reaction scheme. 
 
Hence, various concentrations of pNPA were reacted with EcBioH and formation of p-nitrophenol 
was monitored every 15 seconds for one hour. Figure 2.28 shows this conversion in the first 290 
seconds for EcBioH-C. 
410 nm 
             pNPA                                     pNP             Acetic acid                    








Figure 2.28: Formation of p-nitrophenol monitored over time (first 290s shown). Enzyme 
concentration: 67 nM 
 
The initial velocity of the enzyme at each concentration was then found by calculating the gradient for 
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Kinetics parameters were determined using OriginLab software. These kinetic parameters are 
shown in Table 2.4 along with those previously determined by Sanishvili and colleagues.30 
 
Parameter  Determined values Reported data (30) 
Michaelis constant KM 0.37 ± 0.08 mM  0.29 ± 0.04 mM 
Turnover number kcat 22.2 ± 2.13 s-1 18.5 ± 1.7 s-1 
Specificity constant kcat/KM 60.0 ± 14.2 mM-1.s-1 63.8 ± 10.6 mM-1.s-1 
Table 2.4: Kinetic parameters for EcBioH pNPA hydrolysis assay. 
 
The determined kinetic parameters were very similar to those previously determined, with 
the Michaelis constant and the specificity constant within the error margin, while the determined 
turnover number is slightly higher than the previously reported data while being of the same order of 
magnitude. Hence, this hydrolysis reaction data will be of significant use to compare biocatalysts 
esterase activity, to supplement the comparison of their MBH catalytic activities. 
2.4 Optimisation of the biocatalysed MBH reaction 
Before further investigating the origin of EcBioH MBH catalysis, optimised conditions had to be 
found. Previously, Jiang et al. had reported using 30 mg/mL of lyophilised lysate of E. coli 
overexpressing EcBioH to catalyse the coupling of 4-NBA with MVK with a 46% yield20. As the aim of 
this study was to use purified EcBioH to gain mechanistic insights on the biocatalysed MBH reaction, 
an initial conditions screen were carried. More specifically, three parameters were investigated: 
• Enzyme loading 
• Temperature  
• Concentration of reagents 
Similarly to the previous work, the conversion was measured after 96 hours. 
2.4.1 Enzyme loading 
The enzyme loading was the first parameter to be investigated. As Jiang’s work used an unpurified 
lyophilised lysate, it was difficult to quantify accurately the concentration of EcBioH that was present 
in their reactions. As such, a few concentrations of purified EcBioH-C were tried, and the conversion 











e.e.                                                                    
(%) 
16 542 28 Not measured 
8 271 20 Not measured 
4 136 13 0 
2 68 8 Not measured 
0 0 3 0 
Table 2.5: Conditions screen – Enzyme loading. 
Conditions: 4-NBA concentration: 4 mM; MVK concentration 8 mM; Temperature: 30ºC; Solvent: 
4% MeCN in 20 mM HEPES, 500 mM NaCl, 10% glycerol, pH 7.5. All reactions were run in 
duplicates. The conversion and e.e. were measured after 96 hours. ee was measured only for the 
best conditions. 
 
Hence, from the results above, the chosen optimal purified EcBioH-C loading was 4 mg/mL, as it 
provides a good balance between measurable conversion and low enzyme loading. It was also found 
that the wild-type enzyme does not provide any enantioselectivity as shown on Figure 2.30. 
 
 
Figure 2.30: Chiral HPLC chromatogram of the biocatalysed MBH reaction. The chirality of the 
species corresponding to each peak is unknown. 
Conditions: EcBioH-C loading: 4 mg/mL, 4-NBA concentration: 4 mM; MVK concentration 8 mM; 
Temperature: 30C; Solvent: 4% MeCN in 20 mM HEPES, 500 mM NaCl, 10% glycerol, pH 7.5.  
 
22.6  





Using 4 mg/mL EcBioH-C, the temperature was then investigated as a parameter to maximise the 
biocatalytic conversion. Four temperatures were investigated as showed in Table 2.6. 








Table 2.6: Conditions screen – Temperature. 
Conditions: 4-nitrobenzaldehyde concentration: 4 mM; methyl vinyl ketone concentration 8 mM; 
EcBioH-C loading: 4 mg/mL; Solvent: 4% MeCN in 20 mM HEPES, 500 mM NaCl, 10% glycerol, 
pH 7.5. All reactions were run in duplicates. The conversion was measured after 96 hours. 
 
Interestingly, it was found that although at 23ºC, very low conversion was observed, the 
conversion was similar at 30ºC, 37ºC and 44ºC. This suggests that this biotransformation can be 
carried in a wide range of conditions and that EcBioH-C is fairly thermostable. As such, the lowest 
temperature where significant conversion is observed, 30ºC, was chosen in the optimised conditions. 
2.4.3 Concentration of reagents 
The final parameter to be optimised was the concentration of reagents. First, the 
concentration of the limiting reagent was investigated while using one equivalent of 4-NBA and two 






protein     (%) 
Conversion without 
protein (%) 
2 4 12 2 
4 8 13 2 
8 16 17 3 
16 32 16 4 
Table 2.7: Conditions screen – limiting reagent concentration. 
Conditions: EcBioH-C loading: 4 mg/mL; Temperature: 30ºC; Solvent: 4% MeCN in 20 mM HEPES, 
500 mM NaCl, 10% glycerol, pH 7.5. All reactions were ran in duplicates. Conversion was 





As shown in Table 2.5, the concentration of the limiting reagent, 4-NBA does not affect the 
conversion dramatically. However, precipitation of the starting material was observed when using       
16 mM of 4-NBA. As such, 8 mM of 4-NBA were used in this study. Then the number of equivalents of 
MVK was optimised as shown in Table 2.8. HPLC chromatograms for the EcBioH-C-catalysed reactions 
with each number of equivalents are shown on Figure 2.31. 





protein  (%) 
Conversion without 
protein (%) 
1 8 4 1 
2 16 17 3 
4 32 37 5 
8 64 55 9 
16 128 62 16 
Table 2.8: Condition screen – number of equivalents of methyl vinyl ketone. 
Conditions: 4-NBA concentration: 8 mM; EcBioH-C loading: 4 mg/mL; Temperature: 30C; Solvent: 
4% MeCN in 20 mM HEPES, 500 mM NaCl, 10% glycerol, pH 7.5. All reactions were run in 
duplicates. The conversion was measured after 96 hours. 
 
Changing the number of equivalents of MVK has a significant effect on the conversion. It was 
found that increasing the number of equivalents from 2 to 8, leads an increase in the conversion from 
17% to 55%. This increase could be explained by the fact that adding more MVK should drive the 
reaction equilibrium towards the formation of the MBH product. However, it was found that 8 
equivalents of MVK were the optimal loading. Indeed, adding 16 equivalents of MVK only provides an 
improvement of the enzyme-free conversion. It was postulated that this was because, as MVK is very 
reactive, large concentrations of this compound would inhibit the reaction. This suggestion was 
strengthened by the fact that slow and partial precipitation of EcBioH-C was observed at all 



























Figure 2.31: HPLC chromatograms of the EcBioH-C reaction with 1, 2, 4, 8 and 16 equivalents of 
MVK after 96 hours. 
Conditions: 4-NBA concentration: 8 mM; EcBioH-C loading: 4 mg/mL; Temperature: 30C; Solvent: 
4% MeCN in 20 mM HEPES, 500 mM NaCl, 10% glycerol, pH 7.5.  


















































2.5 Investigating the involvement of the catalytic triad 
As the main aim of this work is to study the mechanism of the biocatalytic MBH reaction, a lot of 
effort was dedicated to the identification of the MBH catalytic active site. Indeed, as discussed in the 
introduction, there is a disagreement on the origin of the MBH catalytic activity and, more specifically, 
on the identity of the nucleophilic residue that undergoes the nucleophilic attack on the electron-
withdrawing alkene, in the first step (I) of the MBH mechanism shown on Figure 2.32. 
 
Figure 2.32: MBH reaction proposed mechanism for a vinyl ketone, an example of an electron-
withdrawing alkene. The nucleophilic catalyst undergoes Micheal addition on the alkene (I), 
forming an extremely nucleophilic zwitterion which will attack the electrophilic aldehyde (II). A 
product-catalysed proton transfer (III) and elimination (IV) of the catalyst afford the product. 
 
 Indeed, it has been postulated that this nucleophilic catalyst could be the side chain of a cysteine17, 
a histidine18, a lysine16 or a serine that is found in a catalytic triad16, while another hypothesis states 
that there is general protein catalysis where any histidine residue could trigger the reaction37. Hence 
some of these postulated hypotheses were tested to identify that nucleophilic residue. 
First, the serine that is part of the catalytic triad was investigated. As previously mentioned, EcBioH 
has two postulated catalytic triads, the “classic” one, composed of Ser82, Asp207 and His235, shown 
on Figure 1.15, is more likely to be of catalytic importance for the MBH reaction, since it was found 
that this deactivation of these residues lead to loss of esterase activity. The “cryptic” triad showed in 
Figure 1.16 is made of Ser53, Asp46 and His20. Upon inspecting the available BioH crystal structures, 
it seems that this triad is not involved in catalysis as the residues of this triad are not within H-bond 
distance from each other. However, as these residues are located on very flexible loops, the residues 
may swing to shorter distance and catalyse the reaction . This could be determined through structural 
studies of the protein-ligand complex. For completeness, both catalytic triads will be deactivated to 






2.5.1 Generation of the mutants 
The EcBioH-C mutants were generated using the overlapping primers site-directed mutagenesis 
technique developed by Liu and Naismith38. In this method, the pair of primers used to introduce the 
mutation are constituted of two parts: 
• A complementary region, where the forward and reverse primers are complementary to each 
other, which contains the desired mutation. 
• A non-overlapping region, significantly larger than the complementary region, which is 
complementary to the template DNA.  
All the mutations were introduced successfully and the mutated DNA was used to transform and 
express E. coli BL21 (DE3) cells and the mutant was purified similarly to the wild-type enzyme. Mutants 
containing S82A, H235A and S55A mutations gave similar yields to the wild-type enzyme (10+ mg/L of 
culture). However, the D207A mutant resulted in very poor yields (approx. 0.8 mg/L of culture).  
SDS-PAGE analysis (Figure 2.33) demonstrated that the poor yield results from the fact that this 
mutation leads to the insolubility of the protein. Indeed, substantial changes in protein solubility due 
to the addition or removal of an aspartic acid were already described in the literature39. Aspartic acid 
is very hydrophilic because the free carboxylic acid on its side chain will be deprotonated at biological 
pH as its pKa is 2.6840. Hence, the aspartic acid will be a potent H-bond acceptor both useful as part of 
the catalytic triad, as developed earlier, but also valuable for creating key interactions with water 
molecules to solubilize the protein. 
Because of this poor solubility, the EcBioH-C D207A mutant was only purified by nickel affinity 
chromatography as it was found by SDS-PAGE that this purification step was sufficient to obtain the 
pure protein. The protein was then buffer exchanged into the MBH reaction (gel filtration) buffer by 
diafiltration using a 10 kDa spin column. Furthermore, because of these solubility issues, the full 






















Figure 2.33: 12% SDS-PAGE gels of a hexahistidine-tagged EcBioH-C D207A purification.  
L: Low molecular weight ladder; I: Insoluble fraction (cell pellets); S: Soluble fraction (cell pellets); 
Ni: After immobilised nickel affinity chromatography; 
A large band at EcBioH-C expected mass (26 kDa) is observed in the insoluble fraction. 
 
All the purified mutants (S82A; S82A D207A; S82A H235A; S55A) were characterised by ESI-MS. 
The results are shown in Table 2.9 




S82A 29554.13 29553.20 ± 1.01  
S82A D207A 29510.12 29514.17 ± 0.59 
S82A H235A 29488.07 29487.88 ± 0.68 
S53A 29554.13 29553.43 ± 0.76 
 
Table 2.9: MS data of the EcBioH-C mutants. 
* Theoretical molecular weights were calculated by ExPASy-ProtParam tool. Average mass is 
shown. 
 
2.5.2 Assaying the mutants 
The generated mutants were assayed for their MBH and esterase activities. The MBH activity was 
determined from the HPLC assay presented in Section 2.2.1 while the esterase activity was measured 




       L        I        S                  Ni 
                  
 
























WT 55 ± 2 1.000 22.2 ± 2.13  1.000 
S82A 58 ± 3 1.054 0.38 ± 0.02 0.017 
S82A D207A 53 ± 2 0.963 0.42 ± 0.04 0.019 
S82A H235A 57 ± 3 1.036 0.13 ± 0.01 0.006 
S53A 55 ± 3 1.000 15.8 ± 2.58 0.712 
Table 2.10:  MBH and esterase assay results for EcBioH-C WT and a range of EcBioH-C mutants 
with deactivated catalytic triads residues. 
Conditions: 4-NBA concentration: 8 mM; MVK loading: 64 mM; EcBioH-C loading: 4 mg/mL; 
Temperature: 30C; Solvent: 4% MeCN in 20 mM HEPES, 500 mM NaCl, 10% glycerol, pH 7.5.  
 
Hence, while the esterase catalytic efficiency drops significantly for all the main catalytic triad 
knockout mutants with an almost 100-fold decrease in activity, it was interesting to observe that the 
MBH conversion remains similar for all these mutants. Indeed, all the results are contained within the 
wild-type error. This suggests that the main catalytic triad does not have an effect in MBH biocatalysis. 
Similarly, no change in MBH activity was observed when deactivating the second cryptic catalytic 
triad (S53A mutant). This suggests that this catalytic triad is not involved in MBH catalysis, hence not 
supporting the hypothesis that a serine part of a catalytic triad is responsible for MBH catalysis. 
Interestingly, however, a significant decrease in esterase activity was observed upon deactivating the 
auxiliary catalytic triad. While, at first, this could suggest that about 30% of the esterase activity 
originates from this auxiliary triad, this hypothesis is not supported by the fact that upon deactivating 
the main catalytic triad, a 98-99.5% loss of activity is observed. This would mean that the auxiliary 
triad contributes to up to 0.5% of the esterase activity. However, it is postulated that deactivating the 
auxiliary catalytic triad might disrupt the folding of the enzyme, resulting in a less efficient 
arrangement of the catalytic triad or a less easily accessible active site which could explain the 
observed 30% loss in activity. 
2.5.3 Mass spectrometry analysis of the EcBioH covalent product 
To further confirm the non-involvement of the catalytic triad, mass spectrometry experiments 
were also performed. The aim of these experiments was to verify that, when the catalytic serine is 
modified, the first step of the MBH reaction (the Micheal addition of the biocatalyst, Figure 2.34) still 





Figure 2.34: The proposed first step of the biocatalysed MBH reaction is the Micheal addition of a 
nucleophilic residue on cyclohexanone. 
 
Cyclohexenone (96 Da) was used for this study instead of MVK (70 Da) as it provides a larger, more 
pronounced mass difference. The MBH coupling of 4-nitrobenzaldehyde with cyclohexenone was 
found to be almost as efficient as MVK with a conversion of 10% after 96 hours, using non-optimised 
conditions, which resulted in 13% conversion for the coupling of 4-NBA and MVK. Hence, EcBioH-C WT 
and EcBioH-C S82A were incubated with phenylmethylsulfonyl fluoride (PMSF) (1 mM). This reagent, 
which serves as a serine protease inhibitor41, binds covalently modifies the catalytic serine and 
deactivates it. This reaction is a simple nucleophilic substitution where PMSF’s fluorine atom is 
substituted by the catalytic serine, forming a protein-phenylmethylsulfonyl (PMS) covalent adduct. 
The mechanism is shown in Figure 2.35.  
 
Figure 2.35: Mechanism of the PMSF deactivation of the catalytic serine.  
 
After one hour incubation, the deactivation of the EcBioH-C WT catalytic serine by PMSF was 
observed by ESI-MS. In contrast, the  EcBioH-C S82A mutant, where the catalytic serine was mutated, 
did not react with PMSF. Cyclohexenone (1 mM) was subsequently added and the reaction was 
incubated for one more hour as shown on Figure 2.36.  
 
Figure 2.36: ESI-MS experiment scheme. Both PMSF and cyclohexanone were added to EcBioH-
C, leading to an increase in mass which was monitored by LC-ESI-MS. 
 
Δ 156 Da 




As expected, the complex EcBioH-C WT + PMS + cyclohexanone (+252 Da) was observed by ESI-
MS (Figure 2.37),  providing further support of the non-involvement of the catalytic triad in the MBH 
reaction catalysis. 
Bottom-up proteomics was attempted and the sample was digested using trypsin to generate 
protein fragments which were analysed by Fourier-transform ion cyclotron resonance mass 
spectrometry (FTICR-MS). However, these analyses were unsuccessful due to poor coverage. Hence 










       
 
 
   
   
 
 
         
 
  
Figure 2.37: 1: Deconvoluted MS(ESI) spectrum for: 1: BioH only – only one peak is observed at 29569 Da.  
2: BioH + PMSF – 2 peaks are observed: one small corresponding to unbound BioH and one large peak at +126 Da 
corresponding to BioH + PMS.  
3: BioH + cyclohexenone – 2 peaks are observed: one corresponding to unbound BioH and one smaller one at +96 Da 
corresponding to the BioH + cyclohexanone complex.  
4: BioH + PMSF + cyclohexenone – 3 peaks are observed: one corresponding to BioH only, one at +126 Da corresponding 




2.6 Investigating the involvement of cysteine 
2.6.1 Cysteine, another potent nucleophile 
Another potential nucleophile which could trigger the first Michael addition in the MBH reaction 
is cysteine (pKa = 8.3)40. At the reaction pH (7.5) the thiol should be reduced, unless the 
microenvironment of the active site sufficiently alters the pKa of the cysteine residue to allow it to be 
oxidised42. Indeed, while being one of the least abundant amino acids, an analysis of the distribution 
of conservation levels of residues within enzymes showed that cysteine is one of the most conserved 
residues, with a conservation degree of 90+%43. Examples of the nucleophilicity of cysteines include 
the whole class of cysteine protease enzymes. These enzymes share a common mechanism which 
involves a nucleophilic cysteine close to a basic residue such as a histidine in a catalytic dyad. These 
enzymes degrade proteins through cleaving their peptide bonds and are commonly encountered in 
fruits such as fig or pineapple44. Their proposed mechanism of action is shown in Figure 2.3845. 
 
Figure 2.38 Cysteine protease reaction mechanism: Upon deprotonation by histidine, cysteine will 
undergo nucleophilic substitution on the peptide to be cleaved. The amine (C-ter end of the peptide) 
will be released first. Then an hydrolysis reaction will occur to free the acid (N-ter end of the 
peptide). 
 
2.6.2 Cysteine alkylation experiments 
To investigate the involvement of the free thiol contained in cysteine residues, reactive cysteines 
should be alkylated to examine if the MBH reaction still occurs. It was found that iodoacetamide (IAA) 
is a useful reagent since it undergoes selective alkylation of reactive cysteine residue(s)41. The cysteine 




adduct53. The protein was then assayed for the MBH reaction. The mechanism of this alkylation is 
shown in Figure 2.39 and the results of this assay are shown on Table 2.11. 
 
Figure 2.39: Mechanism for the active cysteine alkylation by iodoacetamide. 
 
Reactive cysteine residue(s) MBH conversion (%) 
Not alkylated (Control) 55 ± 2 
Alkylated (with iodoacetamide) 56 ± 4 
Table 2.11: Results of the MBH assay with and without alkylating the reactive cysteine(s).  
Conditions: 4-NBA concentration: 8 mM; MVK loading: 64 mM; EcBioH-C loading: 4 mg/mL; 
Temperature: 30C; Solvent: 4% MeCN in 20 mM HEPES, 500 mM NaCl, 10% glycerol, pH 7.5.  
 
Following this assay, it was demonstrated that alkylating cysteine residues does not affect the 
MBH conversion, suggesting that cysteine does not act as a nucleophilic activator for the biocatalysed 
MBH reaction. Alkylation of the cysteine was proven by LC-MS (ESi). To give further evidence of the 
non-involvement of this cysteine, MS-adducts experiments were undergone, similarly to Part 2.5.3 
using IAA to alkylate any reactive cysteine residues. Hence, at first EcBioH-C WT (0.1 mM) was 
incubated for one hour with IAA (1 mM). Full alkylation of one cysteine was observed by LC-MS(ESI) 
as one single peak corresponding to the mass of EcBioH-C + one acetamide was observed. This 
suggests that, out of the three cysteine residues contained in EcBioH protein sequence, only one is 
accessible. Then the alkylated EcBioH-C was incubated for one hour with cyclohexenone (1 mM) and 
the EcBioH-C WT + acetamide + cyclohexenone was detected by LC-MS(ESI). The reaction scheme is 
shown on Figure 2.40 and the MS spectra obtained are shown on Figure 2.41. The fact that 
cyclohexenone binds EcBioH-C when the reactive cysteine is alkylated provides further evidence on 
the non-involvement of a reactive cysteine residue in MBH catalysis. 
 
Figure 2.40: ESI-MS experiment scheme. Both PMSF and cyclohexanone were added to EcBioH-
C, leading to an increase in mass which was monitored by LC-ESI-MS. 
Δ 57 Da 














   
     
      
  
  
      
      
     
  





    29722 
57 
96 
     3 
57    96 
Figure 2.41: 1: Deconvoluted MS(ESI) spectrum for: 1: BioH only – one peak is observed at 29569 Da.  
2: BioH + IAA – One peak at +57 Da corresponding to BioH + acetamide.  
3: BioH + cyclohexenone – 2 peaks are observed: one corresponding to unbound BioH and one smaller one at +96 Da 
corresponding to the BioH + cyclohexanone complex.  
4: BioH + IAA + cyclohexenone – 2 peaks are observed: one at BioH + 57 Da corresponding to BioH + acetamide and 




Bottom-up proteomics was attempted and the sample was digested using trypsin to generate 
protein fragments which were also analysed by FTICR-MS. However, these analyses were unsuccessful 
due to poor coverage. Hence this technique could not provide insights on which cysteine is targeted 
by IAA. 
2.7.1 Investigating another pimeloyl-ACP methyl ester esterase 
The involvement of the ABHF and its role in the BioH-catalysed MBH reaction was then 
investigated. The rationale behind this is, while the approach explored so far was that the first step of 
the catalysis was the activation of the electrophile by a highly nucleophilic residue, another effect to 
consider is the stabilization of the oxyanions intermediates by the oxyanionic hole of the enzyme. Such 





Figure 2.42: Second proposed MBH biocatalysed reaction mechanism: As the partial positive 
charge of the vinylic carbon will be increased because of the carbonyl H-bond interaction, weaker 
nucleophiles might be able to undergo Micheal addition. 
 
Carbonyl activation through H-bonding interaction is a well-documented mechanism triggering 
various reactions, including the Diels-Alder46-47 reaction and the aldol reaction48.  
2.7.2 BioG, an atypically folded enzyme  
Hence, to assess the involvement of the enzyme fold, another pimeloyl-ACP methyl ester esterase, 
BioG from H.influenzae (HiBioG) was used. As discussed in section 2.1.4, the structure of HiBioG, which 
has 25% identity to EcBioH was determined in 2016 by the group of John Cronan. It revealed that 
HiBioG possesses an atypical α/β-hydrolase fold34. While on BioH, and typical ABHF enzymes, the 
parallel β-sheets are circled by α-helices on both sides, large loops replace four α-helices in HiBioG. 




enzyme might display more promiscuity34. The structure of HiBioG, showing that loops have replaced 













Figure 2.43: HiBioG crystallographic structure highlighting the atypical α/β hydrolase structure 
(PDB ID: 5GNG34). The six parallel -sheets are shown in magenta. In blue are shown BioG 
atypical loops to which are superimposed in orange the EcBioH (PDB ID: 1M33) α-helices 
expected to be observed on an α/β hydrolase fold.  
 
HiBioG pET28 plasmid was obtained from Prof John Cronan’s lab (University of Illinois Urbana-
Champaign). The N-terminal histagged enzyme was expressed and purified following the published 
procedure34. Yields of 12 mg/L of culture, comparable to the ones obtained for EcBioH, were obtained. 














Figure 2.44: A) 12% SDS-PAGE gel for the purification of HiBioG. L: Low molecular weight ladder; 
Ni: Sample post-Ni affinity chromatography; SEC: Sample post-size-exclusion chromatography. 
B) LC-ESI-MS spectrum of HiBioG. Theoretical molecular weight: 26266.73 Da, Experimental 
molecular weight: 26267.37 ± 1.17 Da.  
 
2.7.3 Assaying HiBioG 
HiBioG was assayed both for their pNPA esterase and MBH activities. The Michealis-Menten plot 
for HiBioG pNPA esterase activity is shown on Figure 2.45 and the results of the pNPA esterase and 
the MBH assays are shown on Table 2.12.  




















Figure 2.45: Michaelis-Menten plot for the HiBioG pNPA hydrolysis assay. 
 
Parameter  HiBioG values EcBioH values 
Michaelis constant KM 0.59 ± 0.06 mM  0.37 ± 0.08 mM  
Turnover number kcat 2.25 ± 0.12 s-1 22.2 ± 2.13 s-1 
Specificity constant kcat/KM 5.51 ± 0.60 mM-1.s-1 60.0 ± 14.2 mM-1.s-1 
 
MBH activity  55 ± 2 58 ± 3 
Table 2.12:  pNPA esterase and MBH assay results for and HiBioG WT and EcBioH-C WT. 
 
Hence, it was interesting to find that HiBioG also displays MBH activity and affords similar 
conversion to EcBioH for the MBH coupling of 4-NBA and MVK. These results suggest that ABHF 
structure does not affect the MBH reaction significantly. Interestingly, it was also found that, while 
HiBioG and EcBioH have similar Michealis constants, suggesting that pNPA have similar binding 
affinities for both enzymes, HiBioG turnover number is almost 10 times smaller than for EcBioH. It can 
therefore be concluded than HiBioG is much slower than EcBioH. This suggests that the increased 




2.8 Assaying the involvement of histidine in the EcBioH-
catalysed MBH reaction 
2.8.1 Histidine, a weak catalyst for the chemical MBH reaction 
 Previously, nucleophilic bases have been found by Morita, Baylis and Hillman to catalyse the 
C-C bond coupling of an aldehyde with an electron-poor alkene. While tricyclohexylphosphine and 
DABCO were first exemplified as suitable MBH reaction initiators, most research on the MBH reaction 
aimed at making enantioselective catalysts. However, simpler bases were also investigated by Luo et 
al. 49. They have found that the coupling of cyclopent-2-enone with 4-NBA could be “catalysed” by one 
equivalent of imidazole with a 92% yield as shown on Figure 2.4649. Imidazole appears to be a better 
base for this coupling than DABCO, which only produced a 32% yield49. This result was somewhat 
surprising as DABCO was found to be much more nucleophilic than imidazole50. The same group 
subsequently showed that one equivalent of L-histidine in a weakly basic aqueous solution (1M 
sodium bicarbonate) could also catalyse the coupling shown on Figure 2.46 with a 65% yield51. 
However, all these results were obtained using very high concentrations of imidazole/histidine (200-
250 mM).  
 
Figure 2.46: imidazole- and L-histidine-catalysed MBH reaction schemes  
Some attempts to understand the mechanism of the imidazole/histidine catalyzed MBH 
reaction were made. Interestingly, Pereira et al., in their work aiming at creating a MBH ionic liquid 
system, postulate that the histidine free amine (which would be part of the backbone in a protein 
scaffold) attacks the vinyl ketone derivative52. This hypothesis was formulated after they observed a 
slight increase of yield when they replaced imidazole by histidine and is hard to believe as this amine 
is protonated at pHs below 9.2 and that there is no mention of highly basic pH52 (the first intermediate 





Figure 2.47: Structure of the first MBH intermediate, as postulated by Pereira et al.52 
 
They postulated this after undertaking NMR and IR experiments which, unfortunately, were 
not discussed or included in the paper. Indeed, only MS experiments are presented in length, but 
these experiments are unable to determine which “part” of the histidine molecule attacks the 
electron-poor alkene.  
An alternative mechanism is the attack of the vinyl ketone derivative by the from the 
imidazole “end” of the molecule and the stabilisation of the oxyanionic intermediates thanks to an H-
bond between the oxyanion and a proton of the positively charged free amine, hence explaining the 
slight activity increase upon substituting imidazole with histidine as shown on Figure 2.48.  
 
 
Figure 2.48: Proposed structure of the first intermediate of the histidine-catalysed MBH reaction. 
The oxyanion in the first step is stabilised by an H-bond interaction with the protonated amine (vinyl 
ketone derivative showed in red, H-bond interaction in blue). 
 
As already mentioned, catalysts containing both a Lewis basic site which is able to attack the 
electron-poor alkene and also a Lewis acidic site which can stabilise the first and second oxyanions are 
very common for the MBH reaction. Raich et al. have described such catalyst where the Lewis basic 
site, which attacks the electron-poor alkene is an imidazole derivative53. Indeed, they have found that 
bicyclic imidazolyl alcohol (BIA) derivatives provide an improvement in activity compared to imidazole, 
while they have similar nucleophilicities53. Through computational approaches, they were able to 
show that, while a significant part of that improvement is due to the fact that they facilitate the proton 
transfer observed in the third step of the MBH reaction, part of this improvement is also caused by 
the fact that the oxyanionic intermediates will be stabilised by an H-bond network between the 













Figure 2.49: Proposed structures of the first oyxanionic intermediates in the cyclohexenone MBH 
reaction catalysed by imidazole (IMI - top) or by a bicyclic imidazolyl alcohol (BIA - bottom). An H-
bond network is stabilising the oxyanionic intermediate for the BIA-catalysed reaction. Adapted  
from 28. 
2.8.2 Proposed role of acid/base catalysis 
With a proposed role for imidazole, albeit at 200-250 mM concentrations, the role of the 
hexahistidine tag was to be explored. For this reason, it is important to control at this stage that the 
activity of the enzyme is not (solely) due to the basicity of histidine. There are 15 histidine residues in 
the wild type clone of EcBioH-C used so far for this study (9 in EcBioH sequence and 6 in the 
hexahistidine tag). EcBioH-C concentrations of 136 μM are used in this study. This means that the 
effective concentration of histidine residues is 15 x 136 = 2040 μM. As it is very unlikely that all of 
them are accessible, this should be an overestimation.  So the MBH reaction was set up using the same 
conditions than the biocatalysed one, except that, instead of using an EcBioH-C, 2000 μM L-histidine 
was used. The results are shown in Table 2.13: 
Reagent Concentration                      
(mM) 
Conversion after 96 hours                         
(%) 
L-histidine 2 16 ± 1 
EcBioH-C 0.13 55 ± 2 
Buffer only N/A 9 ± 2 




Hence, using concentrations of histidine which are in line with the anticipated concentrations in 
the biocatalytic assay results in much lower conversion than for the enzyme is observed. Hence it can 
be concluded that EcBioH-C activity doesn’t result solely from the basicity of the histidine residues. 
2.8.3 Investigating the involvement of the hexahistidine tag 
As described earlier, it was previously shown that the MBH reaction could be sharply improved if 
both a nucleophilic Lewis base and a Lewis acid, to stabilise the oxyanion, are present. It could be 
hypothesised that the hexahistidine tag which was used for this project for easy protein purification 
can be involved. It is thought that histidine can undergo the Micheal addition of the electron-
withdrawing alkene, as showed by Luo et al.24,26. Then, the formed oxyanion could be stabilised by a 
hydrogen-bond with neighbouring histidine of the tag, either directly or mediated by a water molecule 
as described by Raich and colleagues28. In turn, the neighbouring histidine will act as H-bond donor 
which will increase its nucleophilicity and favour its Micheal addition on another MVK molecule, as 




Figure 2.50: Proposed first step of the hexahistidine-tag catalysed MBH reaction. The oxyanion 
formed in the first step of the MBH reaction could be stabilised by a hydrogen-bond with 
neighbouring histidine of the tag 
 
To test this hypothesis, variants of EcBioH WT with different numbers of hexahistidine tags (0, 1 
and 2) will be produced and assayed. While both variants of EcBioH with one hexahistidine tag 




has been cloned already. Hence, at this point, only the version of EcBioH with two hexahistidine tags 
(EcBioH-NC) was to be produced. This was made by cutting the C-terminal hexahistidine tagged EcBioH 
gene, using Nde1 and Xho1 restriction enzymes, from a pET22a plasmid and ligating it to a pET28a 
plasmid. EcBioH-NC was purified following the same procedure than the one described in part 2.1.2. 
The only change observed is that the EcBioH-NC eluted later, at a concentration of 400 mM imidazole, 
in IMAC, as expected. After SEC, yields of 14 mg/L of culture of EcBioH-NC were obtained. The 







Figure 2.51: SDS-PAGE gel (12%) of EcBioH-C purification steps 
L: Low molecular weight ladder; Ni: Sample post-Ni affinity chromatography; SEC: Sample post-
size-exclusion chromatography. 
 
EcBioH-x was purified first by anion exchange chromatography, using a 0 to 1 M sodium 
chloride at pH 7.5 gradient and EcBioH-x eluted at 150 mM NaCl. SDS-PAGE analysis showed that the 
fractions containing the protein had a purity of 60+%. Notably, two proteins with molecular weights 
of 50 to 60 kDa were observed. Indeed, as EcBioH-x pI as calculated by the ExPASy-ProtParam tool is 
6.5, hence very close to biological pH, it was challenging to obtain a higher purity from the ion 
exchange step, thus enhancing the need of the purification by SEC. After SEC, some fractions still 
contained contaminant proteins but other fractions, which were used for further analysis, were >90% 
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Figure 2.52: SDS-PAGE (12%) gel of EcBioH-x purification steps 
L: Low molecular weight ladder; Ni: Sample post-Ni affinity chromatography; SEC: Sample post-
size-exclusion chromatography. 
 
Both forms were also characterised by LC-MS(ESI). The spectra and the results are showed in 
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Figure 2.53: ESI-MS spectra of the EcBioH clones expressed:  
A) EcBioH-x 
B) EcBioH-NC. A second set of peaks corresponding to the glycophosphorylated protein (m + 178 
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Determined molecular weight                                       
(Da) 
EcBioH-x 0 28505.01 28503.97 ± 2.87 
EcBioH-NC 2 31596.32 31597.02 ± 1.42 
Table 2.14: MS data of the EcBioH clones expressed. 
* Theoretical molecular weights were calculated by the ExPASy-ProtParam tool. The average 
mass is shown. 
 
2.8.5 Assaying EcBioH variants with different number of hexahistidine tags 

























It was observed that the presence of a hexahistidine-tag directly impacts the percentage 
conversion of the MBH reaction. Indeed, while after 24 hours, a conversion of 7% is observed for the 
EcBioH-x variant, a 2-fold conversion increase was observed for both EcBioH-N and EcBioH-C. 
Furthermore, a 5-fold conversion increase was noted for EcBioH-NC. In addition, EcBioH-N and EcBioH-
C display comparable results. This primary data is shown on Figure 2.55. This suggests an involvement 
of the hexahistidine tag in the EcBioH-catalysed MBH reaction and gives credit to the mechanism 


























































Figure 2.55: HPLC chromatograms of the MBH biocatalysed reaction with various numbers of 
hexahistidine tags after 96 hours.  
Conditions: 4-NBA concentration: 8 mM; MVK: 64 mM; EcBioH-C loading: 130 µM; 




2.8.6 Further investigation of the hexahistidine tag in the MBH reaction 
With this interesting observation in hand, the next step was to further establish the involvement 
of the hexahistidine tag through assessing the activity of other proteins both containing a 
hexahistidine tag or not. As such, various proteins used in the Campopiano lab, which will be briefly 
introduced next, were assayed for MBH activity.  
2.8.6.1 E. coli Acyl carrier protein (ACP) 
ACP is a well-known peptide carrier protein, involved in various biosyntheses, including fatty acids 
and polyketides18. This protein does not display any enzymatic activity. It is a flexible protein, 
containing only α-helices and large loops54. This protein is however very small, only containing 78 
residues for a molecular weight of 8.6kDa54. The ACP that was used in this study was from E. coli. Its 
crystal structure was first determined by Roujeinikova and co-workers and is showed in Figure 2.5654. 
 
Figure 2.56: Crystal structure of E. coli ACP (PDB ID: 1L0I). 
 
2.8.6.2 E. coli 8-amino-7-oxononanoate synthase (BioF) 
BioF is the enzyme directly succeeding BioH in the biotin biosynthetic pathway, as displayed in 
Figure 2.57, and catalyses the pyridoxal 5’-phosphate (PLP)-dependant decarboxylative Claisen-like 
condensation of pimeloyl-ACP and L-alanine to generate 8-amino-7-oxononanoate55.  
 




With a molecular weight of 41.6 kDa, E. coli BioF forms a homo-dimer. Its crystal structure, shown 
in Figure 2.58, was determined by Alexeev, Campopiano, Baxter and colleagues at the University of 
Edinburgh in 199856. It shows that, similarly to BioH, BioF contains an α/β-hydrolase fold as five β-
sheets are flanked by α-helices in one of the three domains of the enzyme.   
 
Figure 2.58: Crystal structure of E. coli BioF (PDB ID: 1BS0). 
 
2.8.6.3 E. coli 3-oxoacyl-ACP-synthase (FabH) 
FabH is an enzyme involved in fatty acid biosynthesis. It catalyses the addition of 2 carbons onto 
malonyl-ACP to form 3-oxobutanoyl-ACP, using acetyl-coenzyme A as a carbon donor, as shown on 
Figure 2.5957. 
 
Figure 2.59: FabH reaction scheme. 
 
 E. coli FabH is made of 317 residues and has a molecular weight of 33.5 kDa, which compares with 
EcBioH, 29.5kDa. While the covalent inhibition of FabH by antimicrobial agent 4,5-dichloro-1,2-dithiol-
3-one was studied in the Campopiano lab57, the structure of E. coli FabH dimer was determined in 





Figure 2.61: Crystal structure of E. coli FabH (PDB ID: 3IL9). 
 
2.8.6.4 D-phenylglycine aminotransferase (D-PhgAT) 
The last enzyme which was investigated was D-PhgAT from P.stutzeri. This PLP-dependent enzyme 
catalyses the amino group transfer from L-glutamic acid to benzoylformate to form D-phenylglycine 
and ketoglutarate as shown on Figure 2.6259.  
 
Figure 2.62: D-PhgAT reaction scheme 
 
This enzyme is much larger than EcBioH, with a molecular weight of 49kDa34. D-PhgAT was 
extensively studied in the group and, while the first apo crystal structure of this enzyme was deposited 
in the PDB in 200659, the first pyridoxal-5’-phosphate internal aldimine-bound structure was added to 





Figure 2.63: Crystal structure of a P.stutzeri D-PhgAT dimer (PLP shown in green) (PDB ID: 6G1F). 
 
2.8.6.5 Assaying these enzymes  
Hence, to further investigate the involvement of the hexahistidine tag, the tagged enzymes 
presented in parts 2.8.6.1-4 were transferred into the reaction buffer by discontinuous diafiltration 
and were assayed along active EcBioH-C and thermally denatured EcBioH-C (heated at 95oC for one 
hour). The HPLC-measured conversion is shown in Table 2.15. 
Protein Conversion after 96 hours (%) 
EcBioH-C 55 ± 2 
Denatured EcBioH-C 53 ± 2 
ACP 63 ± 4 
BioF 44 ± 7 
FabH 57 ± 2 
D-PhgAT 42 ± 5 
Table 2.15: MBH conversion for various hexahistidine-tagged proteins. 
Conditions: 4-NBA concentration: 8 mM; MVK: 64 mM; EcBioH-C loading: 4 mg/mL; Temperature: 







Interestingly, all the hexahistidine tagged proteins show significant and comparable activities for 
the MBH reaction. Even acyl carrier protein, a peptide carrier protein which does not display any 
enzymatic capability in the literature, presents a similar activity to EcBioH-C. Besides, denaturation 
does not affect EcBioH-C’s catalytic activity for the MBH reaction as they both have similar activities.  
These results further provide strong evidence both that the fold of the enzyme does not have any 
positive effect on the EcBioH catalytic efficiency and that any hexahistidine-tagged proteins would 
display significant MBH catalytic activity. 
2.9 A general residue catalysis? 
It was proven that the hexahistidine tag provides a significant improvement over the untagged 
protein, as, for EcBioH-x, the conversion after 24 hours was 7% for the untagged protein, 15% for the 
hexahistidine tagged protein and 34% for the double hexahistidine-tagged protein. However, some 
activity is still observed for the untagged protein. This activity might be due to unspecific residue 
catalysis from the protein, including by the histidine residues contained in the sequence. To prove this, 
EcBioH-x was assayed alongside denatured EcBioH-x and untagged bovine serum albumin (BSA). BSA 
being a serum albumin protein, it does not have any enzymatic activity. The results of this assay are 
shown in Table 2.16: 
Protein Conversion after 96 hours (%) 
EcBioH-x 26 ± 1 
Denatured EcBioH-x 25 ± 3 
BSA 34 ± 4 
Table 2.16: MBH conversion for various untagged proteins. 
 
Hence, similarly to the previous results for hexahistidine tagged enzymes, denatured EcBioH-x and 
non-enzymatic proteins show similar activities to folded EcBioH-x. This is a strong evidence that 
significant activity results from unspecific residue catalysis. 
2.10 Conclusion 
This study aimed at gaining mechanistic insights into the biocatalysed MBH reaction. After 
choosing a suitable platform for that study in EcBioH and determining optimised conditions for the 
reaction, the origin of the EcBioH catalysis was investigated. It was found that part of the activity is 




hexahistidine tag is present. It is postulated that this increase in activity is explained by a synergistic 
relationship between the oxyanionic intermediates of the MBH reaction and the hexahistidine tag. 
Indeed, the oxyanionic intermediates could be stabilised by H-bond with a neighbouring histidine, 
which, in return, will gain electron density and will be able to undergo Micheal addition on the 




Figure 2.64: Proposed hexahistidine-tag catalysed MBH reaction: the oxyanionic intermediates 
could be stabilised by H-bond interaction with a neighbouring histidine, which, in return, could gain 
electron density and allowing it to undergo Micheal addition on the electrophilic alkene.  
 
Further study is needed to provide support to this mechanism, possibly by molecular dynamics 
simulations, yet this work provides solid data that supports the high impact of the hexahistidine tag 
on the biocatalysed MBH reaction. It is interesting to note that some of the biocatalysts investigated 
in the previous literature contain a hexahistidine tag24 and some do not26. In some other reported 
cases, the presence or not of a hexahistidine tag is not specified25. In this project, it was observed that 
a hexahistidine tag increases the MBH conversion 2-fold after 24 hours. With this in mind, it becomes 
hard to compare the previously published biocatalysts. 
Hence, this work provides strong evidence against some previously hypothesised mechanisms and 
most notably against the involvement of a catalytic triad or of a cysteine residue in the biocatalysed 
reaction. This study has also shed light on the significant impact of the hexahistidine tag in MBH 
biocatalysis and shows that general residue catalysis is observed as any protein, folded or denatured, 





1 K. Morita, Z. Suzuki et al., 1968, Bull. Chem. Soc. Jpn., 41, p 2815 
2 M. Shi, F. Wang et al., 2011, The Chemistry of the Morita-Baylis-Hillman reaction, RSC Publishing, 
Cambridge, UK 
3 V.K. Aggerwal, S.Y. Fulford and G.C. Lloyd-Jones, 2005, Angew.Chem.Intl.Ed., 44 pp 1706-1708 
4 S.E. Drewes, G.H.P. Roos, 1988, Tetrahedron, 44 pp 4653-4670 
5 A. Gilbert, T.W. Heritage, N.S. Isaacs, 1991, Tetrahedron: Asymmetry, 2 pp 969-972  
6 L.J. Brzezinski, S. Rafael, J.W. Leahy, 1997, J.Am.Chem.Soc., 119 pp 4317-4318  
7 T. Hayase, T. Shibata et al., 1998, Chem. Comm., pp 1271-1273 
8 Y. Iwabuchi, M. Nakatani et al., 1999, J.Am.Chem.Soc, 121 pp 10219-10220 
9 Y. Sohtome, N. Takemura et al., 2008, Tetrahedron, 64 pp 9423-9429 
10 N. McDougal, S.E. Schaus, 2003, J.Am.Chem.Soc., 125 pp 12094-12095 
11 M.M. Vasbinder, J.E. Imbriglio, S.J. Miller, 2006, Tetrahedron, 62 pp 11450-11459 
12 Q. He, G. Zhan et al., 2016, Beilstein J.Org.Chem, 12 pp 309-313  
13 H. Yoshimura, K. Takahashi et al., 2015, Chem.Comm., 51 pp 17004-17007 
14 Z. Duan, Z. Zhang et al., 2013, RSCAdv., 3 pp 10127-10130 
15 C. Wang, L. Wang, et al., 2013, Phosphorus, Sulfur, Silicon,Relat.Elem., 188 pp 1548-1554 
16 M. Reetz, R. Mondière et al., 2007, Tetrahedron Lett., 48 pp 1679-1681  
17 S. Bjelic, L.G Nivon et al., 2013, ACS Chem.Bio., 8, pp 749-757 
18 P.N. Joshi, L.Purushottam et al., 2016, RSC Adv., 6, pp 208-212 
19 L. Jiang, H.W. Yu, 2013, Biotechnol.Lett, 36 pp 99-103 
20 L. Jiang, H.W. Yu, 2014, Chem.Res.Chin.Univ., 30 pp 289-292 
21 J.T. Mindrebo, C.N. Nartey et al., 2016, Curr.Op.Structur.Biol., 41 pp 233-246  
22 N.H. Tomczyk, J.E. Nettleship et al., 2002, FEBS Lett., 513 pp 299-304 
23 J.E. Cronan, 2001, J.Biol.Chem, 276 pp 37355-37364 
24 S. Lin, J.E. Cronan, 2012, J.Biol.Chem., 287 pp 37010-37020 
25 S. Lin, R.E. Hanson, J.E. Cronan, 2010, Nature Chem.Bio., 6 pp 682-688 
26 W.R. Streit, P. Entcheva, 2002, Appl.Microbiol.Biotechnol., 61 pp 21-31 
27 W. Wei, H. Guan et al., 2019, iScience, 19, pp 796-808  
28 Q. Zeng, Q. Yang et al., 2020, Front.Microbiol., 11, 148 
29 W. Salaemae, A. Azhar et al., 2011, Prot. Cell., 2 pp 691-695 




31 V. Agarwal, S. Lin, et al., 2012, Proc.Natl.Acad.Sci.USA, 109 pp 17406-17411 
32 J.L. Arpigny, K.E. Jager, 1999, Biochem.J., 343 pp 177-183 
33 L. Wang, Y. Chen et al., 2019, Biochem.Biophys.Res.Commun., 520, pp 538-543 
34 J. Shi, X.Cao et al., 2016, Biochem., 55 pp 6705-6717 
35 S.R. Harrowing, J.B. Chaudhuri, 2003, J.Biochem.Biophys.Met. 56, pp 177-188 
36 J. Clayden, N. Greeves et al., 2000, Organic Chemistry, 1st Edition, Oxford University Press, 
Oxford, UK 
37 M. Lopez-Iglesias, E. Busto, et al., 2011, Adv.Synth.&Catal. 353, pp 2345-2350 
38 H. Liu, J.H. Naismith, 2008, BMC Biotechnol., 8 doi:10.1186/1472-6750-8-91 
39 S.R. Trevino, J.M. Scholtz, C.N. Pace, 2007, J.Mol.Biol., 366, pp 449-460 
40 I. Hunt, Table of pKa and pI values, accessed from 
http://www.chem.ucalgary.ca/courses/351/Carey5th/Ch27/ch27-1-4-2.html on 18/09/19 
41 A. Domsalla, M.F. Melzig et al. 2008, Planta Med., 74, pp 699-711 
42 G. Ferrer-Sueta, B. Manta, 2011, Chem.Res.Toxicol., 24, pp 434-450 
43 S.M. Marino, V.N. Gladyshev, 2010, J.Mol.Biol., 404, pp 902-916 
44 A. Narayanan, L.H. Jones, 2015, Chem.Sci., 6, pp 2650-2659 
45 K. Chibale, 2002, Arch.Org.Chem, 9, pp 93-98 
46 X. Zhang, H. Du et al., 2006, J.Org.Chem., 71, pp 2862-2869 
47 L.R. Domingo, J. Andres, 2003, J.Org.Chem., 68, pp 8662-8668 
48 P.M. Pihko, 2004, Angew.Chem.Intl.Ed., 43 pp 2062-2064 
49  S. Luo, B. Zhang et al., 2002, Tetrahedron Lett., 43, pp 7369-7371 
50 M. Baidya, F. Brotzel et al., 2010, Org.Biomol.Chem., 8, pp 1929-1935 
51 S. Luo, P.G. Wang, et al., 2004, J.Org.Chem., 69, pp 555-558 
52 M.P. Pereira, R. de Souza Martins et al., 2018, RSC Adv., 8, pp 23903-23913 
53 L. Raich, H. Santos et al., 2018, ACS Catal., 8, pp 1703-1714 
54 A. Roujeinikova, C. Baldock et al., 2002, Structure, 10 pp 825-835 
55 M. Manandhar, J.E. Cronan, 2017, App.Environ.Microbiol., 84, e02084-17 
56  D. Alexeev, M. Alexeeva et al., 1998, J.Mol.Biol., 284, pp 401-419 
57 A.G. Ekstrom, V. Kelly et al., 2017, Org.Biomol.Chem., 30, pp 6310-6313 
58 K.S. Gajiwala, S. Margosiak et al., 2009, FEBS Lett., 583, pp 2939-2946 
59 C.J.W. Walton, F. Thiebaut et al., 2018, Biochem., 57, pp 5437-5446 








Chapter 3 Overcoming evolution to expand the 
synthetic scope of a nitrile synthetase 
3.1 Introduction 
3.1.1 Nitrile synthetase, an interesting family of enzymes  
The nitrile synthetase (NS) family of enzymes is a small group of enzymes catalysing the conversion 
of 7-carboxydeazaguanine (CDG) into 7-cyanodeazaguanine (PreQ0) in the biosynthetic pathways of 
queuosine and toyocamycin1. The family is magnesium adenosine triphosphate (MgATP)-dependent 
and was shown to proceed via the formation of the corresponding amide intermediate, 7-
amidodeazaguanine (ADG)1. Interestingly, these enzymes bind a Zn2+ cation; however, this zinc is 
thought to be “structural” and not involved in activity1. The scheme of the reaction catalysed by NS is 
shown in Figure 3.1. 
 
Figure 3.1: NS reaction scheme. CDG is first transformed into ADG, using one equivalent of 
MgATP and then into PreQ0 using a second equivalent of MgATP. 
 
The reaction has been proposed to proceed via the formation of two adenylate intermediates to 











Figure 3.2: NS proposed reaction mechanism. Both transformations are thought to involve the 







Thus, the conversion of acid to nitrile uses 2 equivalents of ATP. In the first step of the reaction, 
the ATP α-phosphate is attacked by CDG carboxyl. This will form a reactive adenylate intermediate 
that will be broken down by the amine. This is the typical mechanism of the class of amide synthetase, 
the amide bond synthetases (ABS) the NS belong to. What makes the NS enzymes much less common 
is the second step: the transformation of the primary amide into the corresponding nitrile. This 
transformation is thought to proceed via a similar mechanism. While no mechanistic insights are 
currently available, it could be postulated that the amide attacks in a similar way the ATP α-phosphate. 
Amides being way less reactive than carboxylic acids, it is possible that one or both hydrogens bound 
to the amide nitrogen engage in H-bonds with enzyme residues and/or with the carboxyl that is part 
of ADG deazaguanine ring. These H-bond interactions might be able to increase enough the electron 
density of the amide so that it is capable of attacking the ATP α-phosphate to initiate the reaction. 
Attempts at separating the two parts of the reaction or at isolating the amide intermediate have not 
been successful so far. The structure of the active site of the enzyme is also unknown. In fact, it is 
unknown whether these enzymes have one active site where both the amide coupling and the 
dehydration of the amide take place or two active sites, each specific for one part of the reaction. 
Winkler and co-workers postulated that an aromatic residue such as a tyrosine may be involved in 
binding CDG through π-stacking interactions while an aspartic acid residue could direct the substrate 
through binding the primary and secondary amines of the substrate pyrimidine ring1. However, as no 
experimental or computational validation was reported, more data is required to reach any conclusion 
with regards to this hypothesis. As such, little is known about this class of enzymes, yet they can have 
interesting biocatalytic applications for the syntheses of commercially-relevant amide- or nitrile-
containing compounds.  
3.1.2 NS in natural products biosynthesis 
NS enzymes are involved in the biosyntheses of queuosine and toyocamycin, shown on Figure 3.3. 
 





Queuosine is a modified nucleoside found in tRNAs coding for asparagine, aspartic acid, histidine 
and tyrosine in bacteria, such as E. coli or B. subtilis and eukaryotes2. Queuosine plays a role in 
maintaining translational efficacy and improving codon recognition3. Low levels of queuosine-tRNAs 
were found to be associated with cell proliferation and cancer3. In contrast, toyocamycin is an 
antibiotic and antifungal agent produced by many Streptomyces bacteria, such as S. rimosus4, S. 
toyocaensis5 or S. diastatochromogenes6. Toyocamycin went through phase I trials for its antibiotic 
properties but did not display significant clinical response and was also found to be a candidate for 
multiple myeloma, as this compound was found to inhibit endoplasmic reticulum stress-induced 
mRNA splicing. However, no clinical investigation have been undertaken to develop this indication7. 
Both queuosine and toyocamycin possess a similar pyrrolopyrimidine core with different 
substituents. Both are biosynthesized from guanosine triphosphate (GTP), and the first four steps of 
their biosynthetic pathways, to PreQ0, are analogous, and then diverge. The first step of this pathway 
is the conversion of guanosine triphosphate (GTP) into dihydroneopterin triphosphate (H2NTP) 
catalysed by GTP cyclohydrolase I (GCH I)8. This enzyme, a member of the cyclohydrolase family, 
catalyses the hydrolytic ring-opening of the imidazole part of GTP and the elimination of one carbon 
as formic acid9. The following enzymes in these pathways, QueD/ToyB, are lyases that generate 6-
carboxy-5,6,7,8-tetrahydropterin (CPH4)10. 7-carboxy-7-deazaguanine synthase (QueE/ToyC) then 
catalyses a key S-adenosyl methionine (SAM)- and magnesium-dependent ring contraction step, which 
is initiated by the reductive cleavage of SAM, generating a reactive 5’-deoxyadenosyl radical. This step 
generates CDG, which is then converted into the nitrile PreQ0 by QueC/ToyM. Thereafter, the two 
pathways diverge, and two enzymes, specific to the queousine biosynthetic pathway will afford 






Figure 3.4: Queuosine biosynthetic pathway. Enzymes involved in queuosine biosynthesis are 
shown in blue and enzymes participating in toyocamycin biosynthesis are shown in red. Both 
queuosine and toyocamycin biosyntheses use GTP as a starting material. In addition, the first four 
steps of both pathways are analogous and are catalysed by GTP cyclohydrolase I (GCH I); a lyase 
(QueD/ToyB); a 7-carboxy-7-deazaguanine synthase (QueE/ToyC) and a NS (QueC/ToyM). Then 







Interestingly toyocamycin can go through another transformation in some Streptomyces species 
including S. rimosus and be transformed in sangivamycin, a potent protein kinase C inhibitor with Ki 
values in the low micromolar region11. Nitrile hydratase ToyJ was found to catalyse the hydration of 
toyocamycin nitrile into a primary amide to form sangivamycin following the scheme shown in Figure 
3.5. 
 
Figure 3.5: ToyJ reaction scheme. This enzyme catalyses a nitrile hydration reaction. 
 
ToyJ is a cobalt-dependent metalloenzyme. It was proposed that ToyJ displays a typical nitrile 
hydratase mechanism, where the substrate and cysteine sulfenic acid both coordinate to the cobalt 
for activity following the mechanism shown in Figure 3.612. 
 
 
Figure 3.6: ToyJ reaction mechanism. ToyJ is a cobalt-dependent metalloenzyme. Both the 
substate and a reactive cysteine sulfenic acid coordinate to the catalytic cobalt. The sulfenic acid 
will be protonated by a water molecule, allowing the hydroxyl to undertake nucleophilic attack on 





It is interesting to note that, similarly to ToyM, ToyJ makes a primary amide. However, in ToyM 
case, the primary amide is only an intermediate for the synthesis of the nitrile (PreQ0) and cannot be 
isolated. Hence, Nelp and Bandarian were able to report the enzyme-catalysed synthesis of ADG 
through converting CDG into PreQ0 with ToyM and then using ToyJ to hydrate the nitrile to generate 
ADG, as shown in Figure 3.813. 
 
Figure 3.8: ADG biocatalytic route by Nelp and Bandarian13: ToyM was first used to convert CDG 
into PreQ0. While the primary amide was formed in this reaction, the team was not able to isolate 
it. The nitrile was then converted into the primary amide, using nitrile hydratase ToyJ. 
 
3.1.3 Overview of QueC and ToyM 
As previously mentioned, neither QueC nor ToyM mechanism and location of the active site(s) are 
known. McCarty and co-workers were the first to assay QueC and could observe the production of 
PreQ014. Winkler and colleagues then found that QueC was extremely specific for its natural substrate, 
CDG1. They have screened a panel of benzoic/indolic acid derivatives for activity with B. subtilis, E. coli, 
Archaeoglobus sulficallidus, Pectobacterium atrosepticum and Geobacillus kaustophilus QueC and 
found that CDG is the only substrate for which any of these enzymes was active1. The range of 






Figure 3.9: QueC substrate screen; Green: Enzyme activity observed, Red: No enzyme activity. 
Adapted from Winkler et al. 1.  
 
This team was also the first to gain some mechanistic insights on B. subtilis QueC (BsQueC) by 
monitoring the reaction with 31P NMR. Over the time-course, they were able to observe a spectral 
change that could be consistent with the conversion of MgATP into MgAMP and pyrophosphate1. This 
suggested the formation of an adenylate intermediate. 
A sequence alignment of some NS, including those studied by Winkler and colleagues, was also 





Figure 3.10: Sequence alignment the NSs from B. subtilis (BsQueC) (Uniprot code: O31675), E. 
coli (Uniprot code: E2QH39), Archeoglobi sulfaticallidus (N0BDM1), Pectobactum atrosepticum 
(Q6D820), Geobacillus kaustrophilus (Uniprot code:GK1520), B. clausii (Q5WG41), S. rimosus 
(SrToyM) (Uniprot code: B6CWJ6) and S. diastatochromogenes (A0A1L7B5M4). 
 
Hence, as shown in Figure 3.10, NSs have relatively low sequence identity (20 to 35% to BsQueC). 
However, this sequence alignment shows that two distinctive features of NS are retained along all 
species: the proposed Mg2+ binding site which corresponds to the well-conserved regions in residues 
10-20 and the Zn2+ binding site, corresponding to the four conserved cysteines in residues 186-201. 
Both the known crystal structure, described below, and this sequence alignment will be useful for the 
protein engineering that will be undergone in this study. 
An important milestone in this area was the BsQueC crystal structure, solved in 2008 at a 
resolution of 2.9 Å, before the protein was first assayed (PDB ID: 3BL5)15. Pectobactum atrosepticum 
QueC was also deposited in the PBD in 2007 (PDB ID: 2PG3), without an associated paper, at a 
resolution of 2.4 Å. While BsQueC was found to form a tetramer in solution, the structure of a BsQueC 
monomer is shown in Figure 3.11. This structure was determined with both magnesium, phosphate 








Figure 3.11: A) Structure of the BsQueC tetramer (PDB ID: 3BL515).   
 B) Structure of a BsQueC monomer Zn2+ is shown as a blue sphere and Mg2+is shown 
as a pink sphere. The phosphate ion is shown in sticks. 
 
Hence, two different parts can be observed in this structure:  
• First an N-terminal Rossmann fold composed of five β-sheets flanked by six α-helices. This fold 
also contains a phosphate-binding loop which is in close proximity to the Mg2+ ion and which will 
help direct the ATP for enzymatic activity. The Rossmann fold is a motif often observed in 
nucleotide-binding proteins such as BsQueC, as it binds MgATP.   
• A C-terminal zinc-binding motif composed of three additional helices which form a Zn-S cluster 
with four cysteine residues found on one of the helices and on the flexible connecting loops. This 
Zn-S cluster is shown in close detail in Figure 3.12. However, as mentioned earlier, this zinc is not 
believed to play a catalytic role in the reaction. 
The structure of BsQueC showing the two parts of the structure is shown in Figure 3.13. 










Figure 3.12: Structure of the Zn-Cys complex located on the BsQueC Zn binding site. 
 
 
Figure 3.13: BsQueC structure displaying the Rossmann fold in green and the zinc-binding site in 
yellow. The phosphate ion is shown in sticks. 
 
3.1.4 Chemical approaches to amide synthesis from carboxylic acid 
As presented earlier, the NS enzymes are able to generate an amide from a carboxylic acid and 
also to convert that amide into the corresponding nitrile. The generation of an amide from carboxylic 
acid is the most important reaction in medicinal chemistry by many metrics: in an analysis of 125 
manuscripts published in the Journal of Medicinal Chemistry in 2014, Brown and Boström have found 
that 30% of these manuscripts describe at least one acid/amine coupling, making it the most common 
reaction by far, before Suzuki-Miyaura couplings (20%), aromatic nucleophilic substitutions (14%) or 









contain at least one amide group16. While the simple coupling of a carboxylic acid and an amine is 
possible on paper as this reaction is, in general, thermodynamically favorable, a high activation energy 
is required, hence requiring high temperatures17. In addition, the amine will deprotonate the 
carboxylic acid, hence reducing its reactivity. As such, a great amount of research is dedicated to 
finding synthetic strategies and reagents to efficiently produce this bond17. More specifically, it is 
about increasing the reactivity of the carboxylic acid through generating a better leaving group than 
the hydroxyl group on the carboxylic acid. Two of the most common strategies, the use of coupling 
reagents and the formation of the acyl chloride will be discussed. 
3.1.4.1 Coupling reagents 
While a large amount of research was dedicated in the development of efficient amide coupling 
reagents, not a single one of them will be efficient on all substrates. Hence, the choice of coupling 
reagent can sometimes be a challenge by itself. The role of these reagents is to activate the carboxylic 
acid and to generate a reactive intermediate with a leaving group good enough for the nucleophilic 
amine to attack. There are three main types of “go-to” commercial coupling reagents: the 
carbodiimides, the phosphonium reagents and the aminium/uronium reagents. General structures 








































Figure 3.14: General structure and examples of amide coupling reagents. 
 
The reaction mechanism for the amide coupling, using 1-[Bis(dimethylamino)methylene]-1H-




     
Figure 3.15: Amide coupling mechanism upon using a coupling reagent such as HATU. 
 
Hence, as shown in Figure 3.15, the carboxylic acid derivative first attacks the coupling reagent, 
to form an unstable O-acyl(tetramethyl)isouronium salt, liberating a very nucleophilic anionic 
triazolopyrimidium N-oxide. This anion will be much more nucleophilic than the amine and, therefore, 
it will attack the isoronium salt preferentially, forming a triazolopyrimidium ester and liberating a 
stoichiometric amount of tetramethylurea. Then the amine will finally be able to attack the 
triazolopyrimidium ester to form the amide and, there again, release a stoichiometric amount of 
hydroxytriazolopyrimidium.  
While HATU is one example of a coupling reagent, all coupling reagents work following relatively 
similar mechanisms, and all share the same downside - their atom inefficiency. A stoichiometric 
amount of these coupling reagents is required for the reaction to proceed. In addition, stoichiometric 
amounts of organic by-products are formed, which may complicate downstream purification. 
Developing amide coupling reagent recycling systems for liquid- or solid-phase peptide synthesis, to 
lower the amount of coupling reagent needed, is a growing area of research18. However, no widely 
used viable systems are currently available, and this represents a critical unmet need according to the 
Americal Chemical Society (ACS) Green Chemistry Institute Pharmaceutical Roundtable held in 201619. 
3.1.4.2 Making amides via the acyl chloride 
Acyl chloride is a very reactive functionality and can be used to produce a wide range of 
functionalities as shown on Figure 3.16. Acyl chlorides by reacting the corresponding carboxylic acid 
with one equivalent of thionyl chloride following the mechanism shown in Figure 3.17. Other 
chlorinating reagents such as phosphorus pentachloride or oxalyl chloride + catalytic amount of 













Figure 3.17: Generation of acyl chloride using thionyl chloride. 
 
Hence, producing acyl chloride strongly increases the reactivity of the carboxylic acid. Indeed, 
chlorine being an excellent leaving group, any nucleophile will be able to undergo nucleophilic 
substitution. As such, making an acyl chloride is another way to activate the carboxylic acid and 
generate a better leaving group. Generation of the amide from the acyl chloride, however, is facile 
and only requires one equivalent of the corresponding amine moiety. As such, being very reactive, the 
acyl chloride is generally not isolated, and the amine is simply added to the reaction mix after a few 
minutes to form the amide.  However, this strategy comes with similar downsides to using coupling 
reagents: as one equivalent of thionyl chloride is required, this reaction is not atom economical and 
no recycling system currently exists. In addition, while thionyl chloride is less expensive than most 
coupling reagents, it is also less safe to handle, being both very toxic, corrosive and violently reactive 
with water. For these reasons, biocatalytic alternatives are investigated, leading to new industrially 




3.1.5 Amide bond formation using biocatalysis 
3.1.5.1 ATP-dependent amide synthetases 
The vast majority of amide synthetases (AmS) are ATP dependent. Exceptions include the GSK-
developed amoxicillin synthase (discussed in section 3.1.5.2) and also include CapW, an ester-amide 
exchange enzyme involved in the biosynthesis of A-5003083s, a capuramycin-type antibiotic20. CapW 
requires first the activation of the carboxylic acid precursor by methylation, performed by CapS, a 
SAM-dependent methyltransferase.  Then CapW forms the corresponding amide, as shown in Figure 
3.18.  
 
Figure 3.18: Schemes of the amide coupling reactions catalysed by adenylating enzymes, ATP-
grasp enzymes and an ATP-independent system. Multiple types of AmS mechanisms exist: the 
adenylating enzymes, the ATP-grasp enzymes and the ATP-independent systems 
 
The ATP-dependent enzymes can be further split into two sub-families: the adenylating enzymes 
and the ATP-grasp enzymes. In the ATP-grasp enzymes, an acylphosphate intermediate is formed, and 
ADP is released21. On the other hand, for the adenylating enzymes, including NS, the generation of a 
reactive acyl-adenylate intermediate is observed and AMP is released. The mechanism of adenylating 
enzymes can also differ slightly as the amine can directly attack the adenylate intermediate to make 
the amide (ABS), or could also proceed via the formation of an acyl-CoA thioester (acyl-CoA synthetase 
(ACS2)), a carrier protein (CP) thioester (non-ribosomal peptide synthase complexes (NRPS)) or a tRNA 
ester (aminoacyl-tRNA synthetase (aaRS) as shown on Figure 3.1821. In addition, adenylating enzymes 
also display structural diversity, and can be divided into four classes: 
• Class I includes NRPSs, ABSs, acyl- or aryl-CoA synthetases and oxidoreductases and have 
a large N-terminal domain with a smaller C-terminal moiety connected via a flexible loop. 




An example of a Class I AmS is carbapenam synthetase, an ABS that catalyses the 
formation of the β-lactam ring of carbapenam-3-carboxylic acid, in the biosynthesis of 
clavulanic acid23. Its structure is shown in Figure 3.19.    
• Class II includes aaRS enzymes and includes two domains: an anticodon-binding domain, 
for the binding of the tRNA and a central catalytic domain22. However, some class II 
enzymes have an additional amino acid-specific proofreading domain that is important for 
enzyme fidelity22. The structure of Asp-tRNA-bound yeast aspartyl-tRNA synthetase is 
shown in Figure 3.19. 
• Class III enzymes comprise NRPS-independent siderophores and contain three domains, 
an N-terminal domain, a central catalytic domain as well as a C-terminal domain24. 
Examples of Class III adenylating enzymes include AcsD from Pectobacterium 
chrysanthemi, whose structure is shown in Figure 3.1925. 
• The fourth class of adenylating enzymes was a recently discovered family of enzymes: the 
pimeloyl-CoA synthetase (PCAS)26. They are composed of a small N-terminal domain and 
a larger C-terminal domain composed of a central antiparallel seven-stranded β-sheets 
surrounded by two α-helices on each sides26. B. subtilis BioW structure was determined 
by this group in 2017 and is shown in Figure 3.1926. 
While adenylating enzymes and ATP grasp enzymes are very important for the biosynthesis of 
proteins (aaRS) and natural products (other AmS), their use in biocatalysis has also been explored. 
While some examples will be briefly presented, a more comprehensive review, presenting further 
examples of AmS biocatalytic applications was published by the Campopiano group recently21. 
Examples of adenylating enzymes used in biocatalysis include McbA from Marinactinospora 
thermotolerans. This ABS enzyme was found to have a broad aryl acid specificity as it accepted a 
wide range of benzoic, naphthoic, indoles, quinolones and benzofurans carboxylic acids27. In 
addition, TamA from Pseudoalteromonas tunicata, an NRPS from the tambjamine YP1 
biosynthetic pathway, was found in this group to be a broad substrate scope. This enzyme contains 
both an adenylation domain and an ACP domain, and it was found that the adenylation domain 
alone can be used as a versatile catalyst to generate a wide range of fatty N-acyl amides as well as 
a class of N-acyl histidine amide natural products from Legionella pneumophilia28. In addition, ATP-
grasp enzymes have also been explored for uses in biocatalysis. For example, it was found that 
BacD, an L-aminoacid ligase found in the bacilysin, a dipeptide antibiotic synthetic pathway could 





Figure 3.19: Structures of one example of each class of adenylating enzymes. Class I example is 
P. caratovorum carbapenem synthetase (PDB 1Q1523). Class II example is yeast Asp-tRNA 
synthetase in complex with Asp tRNA (shown in light blue and light red) (PDB 1ASY24). Class III 
example is Dickeya chrysanthemi achromobactin synthetase (PDB 3FFE25). Class IV example is 
B. subtilis pimeloyl-CoA ligase (PDB 5FLG26) 
 
3.1.5.2 The biocatalytic approach in action: examples of industrial uses  
As discussed earlier, about 25% of small molecule drugs contain an amide function. As such, the 
biocatalytic route has been widely explored for the industrial-scale synthesis of commercial drugs. For 
example, GlaxoSmithKline (GSK) produces the β-lactam 3rd generation broad-spectrum antibiotic 
amoxicillin using an engineered penicillin G acylase from E. coli30. This drug is one of GSK’s blockbusters 
and is produced at a scale of 1.1 tonnes per year31, generating $4.9 billion revenue every year, with a 
CAGR of 2% until 202632. The chemical and biocatalytic routes are shown in Figure 3.20. Some 






Figure 3.20: Chemical and biocatalytic syntheses of amoxicillin. The chemical route requires three 
steps, the use of a protecting group, extremely low temperature and the use of acid, bases and 
organic solvents. In contrast, the biocatalytic route only necessitates one step, mild temperature 








Parameter Chemical synthesis Biocatalytic synthesis 
Number of steps 3 1 
Protecting group required Yes No 
Acids/Bases used KOH, Pyridine, 2-ethylhexanoic 
acid, HCl, all in reaction 
HCl and KOH used to maintain pH 
Solvents used KOH, Dimethyl acetamide, 
dichloromethane, HCl 
Water 
Temperature range -75oC to RT 37oC 
Carbon dioxide emissions X X – 36000 tonnes 
Organic waste X X – 3000 tonnes 
Table 3.1: Comparison of various parameters for the chemical and biocatalytic industrial syntheses 
of amoxicillin. X denotes an unknown number.  
 
In addition, GSK has also been granted a patent in key territories for the lipase-catalysed synthesis 
of (4-isopropylpiperazin-1yl)(oxazol-5-yl)methanone, a potential phosphatidylinositol-3-OH kinase 
(PI3Kδ) inhibitor, a kinase involved in various immunodeficiency syndromes33. The chemical and 
biocatalytic routes to generate this compound are shown in Figure 3.21. 
 
Figure 3.21: Chemical and biocatalytic syntheses of (4-isopropylpiperazin-1yl)(oxazol-5-
yl)methanone. The chemical route requires the synthesis of an acyl chloride, unlike the biocatalytic 
route which only necissitates one step 
 
 Hence, the first example shows an example where an enzyme replaced a coupling reagent 
while the second one shows a case where a biocatalyst-driven strategy substituted a synthetic route 




already discussed, this shows that enzymes can also provide an efficient alternative for the industrial 
production of amides.  
In addition, as developed earlier, most amide-producing enzymes are ATP-dependent. These, 
however, have a major downside for their industrial use as they require one equivalent of ATP. As 
such, similarly to chemical approaches, these enzymes would require a stoichiometric amount of ATP, 
which would, just like a coupling reagent, be used to activate the carboxylic acid. However, this 
consideration is alleviated by the fact that, unlike for coupling reagents, ATP recycling systems have 
been developed. An example of such recycling systems is the use of polyphosphate, 
phosphotransferase (PPT) and adenylate kinase (AdK)34. Upon consumption of the ATP by the AmS, 
generating adenosine monophosphate (AMP) or adenosine diphosphate (ADP), AdK will be able to 
transfer phosphate groups from one or two molecules of ADP35. The phosphate donor, transformed 
into AMP, will be regenerated into ADP by PPT, which will use cheap polyphosphates such as 
polyphosphoric acid as a phosphate source34. Examples of the successful use of this recycling system 
include the regeneration of ATP in the carboxylic acid reductases-catalysed transformation of acids 
into ketones36 by the group of Nicholas Turner or the enzymatic generation of glutathione by GSH 
synthase37. The scheme of this ATP recycling system is shown in Figure 3.22.  
 
 
Figure 3.22: Phosphotransferase/Adenylate kinase recycling system scheme: The ADP or AMP 
generated from the transformation of the carboxylic acid to the amide is recycled by the PPT/AdK 
system, using a polyphosphate as the phosphate donor. 
 
3.1.6 Making nitriles from carboxylic acids. 
3.1.6.1 The direct route 
In 1872, Edmund Letts published a method for the synthesis of aromatic nitriles directly from the 
corresponding carboxylic acids using an excess of potassium thiocyanate and heat with yields of up to 




deprotonate the acid. Then, the benzoic acid derivative will undergo thermal decomposition while 
heated and release carbon dioxide and a benzene anion39. The benzene anion will then undergo 
nucleophilic substitution on potassium thiocyanate, forming benzonitrile and potassium 
hydrosulfide38. The reaction scheme and mechanism are shown in Figure 3.23 
 
 
Figure 3.23: The Letts reaction scheme and proposed mechanism: potassium thiocyanate 
deprotonates benzoic acid, which will release carbon dioxide through decomposition, generating 
a benzene anion. The anion will undergo nucleophilic substitution, generating benzonitrile and 
potassium hydrosulfate. 
 
This reaction, however, is not very efficient with only a 50% yield. In addition, as the protocol 
involves hard heating of benzoic acid and potassium thiocyanate (both solid at room temperature), 
above their melting points in neat conditions. Upon melting, the reagents will form a liquid bilayer for 
the reaction to occur. In addition, this reaction leads to the evolution of potassium hydrosulfide, a 
toxic gas. This reaction was trialled in the laboratory. However, instead of heating the solids, the 
reaction was refluxed at 200°C in anhydrous toluene. However, no benzonitrile was formed.  
Other direct transformations from carboxylic acid to nitrile were found to be difficult and require 
high temperatures (ammonia and silica at 500°C40, ammonium hydroxide at 600°C41 or ammonia in 
continuous flow at 360°C42), although microwave irradiation could provide a promising alternative as 
Juncai and colleagues were able to convert dodecanoic acid into the corresponding nitrile with a 79% 
yield through microwave irradiation, using aluminium oxide, aminosulfonic acid and urea43. 
3.1.6.2 The amide route 
A more convenient route to generate a nitrile from a carboxylic acid is to first generate the amide 
and then dehydrate it. The amide can be generated as described in Section 3.1.5. Various conditions 
exist for the amide dehydration, amongst which the use of thionyl chloride44, palladium chloride44, 
phosphorus pentoxide44 or conditions close to those of the Appel reaction (oxalyl chloride, 




for thionyl chloride is shown in Figure 3.24. It involves the attack of the amide on thionyl chloride. 
After rearrangement, the amide is deprotonated, and the leaving group is removed. 
 
 
Figure 3.24: Mechanism of nitrile synthesis from a primary amide using thionyl chloride: the amide 
attacks thionyl chloride, inducing a rearrangement which leads to the liberation of a chloride anion. 
This anion will deprotonate the amide and induce the removal of the leaving group to afford the 
nitrile. 
 
Interestingly, except for the NS, no enzyme was shown to catalyse amide dehydration, 
emphasizing the unusual nature of NS enzymes which will be presented in this project. 
3.1.7 Aims 
The aims of this project are: 
• To express, purify and characterise NS enzymes 
• To design an assay to monitor efficiently and precisely the NS reaction 
• To optimise the NS reaction 
• To carry out a structural study of the NSs and, more specifically, to obtain a ligand-bound 
structure of one of the NS enzymes 
• To use this ligand-bound structure to carry out rational engineering of the enzyme in order to 
generate a novel amide synthetase (BsQueC eAmS K163A, R204A). 
• To characterise the kinetics of the BsQueC eAmS K163A, R204A and use this to prepare ADG 
from CDG on a synthetic scale.  
3.2 Generation of the biocatalysts 
To commence this study, two recombinant NSs were prepared: B. subtilis QueC (BsQueC; Uniprot: 
O31675) and S. rimosus ToyM (SrToyM; Uniprot: B6CWJ6). Both enzymes were cloned in pET28a, a 
plasmid previously introduced in Chapter 3, so the recombinant form of the enzymes will contain an 
N-terminal hexahistidine tag. Both enzymes were expressed in E. coli and purified by IMAC and SEC. 
Plasmid maps are available in the Appendix. 
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3.2.1 Generation of BsQueC 
The BsQueC (Mwt: 26535 Da) cloning and expression optimisation were carried out by Mari 
Nelson, a previous student in the Campopiano group. The expression tests SDS-PAGE gel is shown in 
Figure 3.25. 
 
Figure 3.25: 12% SDS-PAGE gel for BsQueC expression tests. M: low molecular weight ladder; 1: 
Pre-IPTG; 2: 0.1 mM IPTG, 30°C, 3h; 3:  0.1 mM IPTG, 30°C, 5h; 4: 0.1 mM IPTG, 18°C, 18h; 5: 
0.5 mM IPTG, 30°C, 3h; 6: 0.5 mM IPTG, 30°C, 5h; 7: 0.5 mM IPTG, 18°C, 18h. 0.1 mM ZnSO4 
was also added in all tested conditions. Only soluble fractions are shown. A large band at 26 kDa, 
thought to correspond to BsQueC was observed in conditions 3, 4, 6 and 7. Conditions 6 were 
concluded to be the best. Figure generated by Mari Nelson. 
 
Hence, the optimised expression protocol involves expressing the B. subtilis QueC gene in E. coli 
BL21 (DE3) strain for 5 hours at 30°C after induction with 0.5 mM IPTG and in the presence of 0.1 mM 
ZnSO4, as a zinc source. The enzyme was then purified by nickel affinity chromatography using a 40-
500 mM imidazole gradient. The enzyme eluted at 220 mM imidazole and SDS-PAGE analysis showed 
traces of a few higher molecular weight proteins. The protein was then purified by SEC using a 
Superdex S200 HR column. The protein eluted at 66 mL, suggesting, using the column calibration curve 
shown in the Appendix, that BsQueC eluted as a hexamer (Determined Mwt of the complex from S200 
calibration curve: 164 kDa; Mwt of BsQueC hexamer: 159 kDa). This oligomeric state was expected as 





Figure 3.26: Superdex S200 size-exclusion chromatogram of BsQueC. A single peak 
corresponding to BsQueC is observed at an elution volume of 66 mL. From the column calibration 
curve, this corresponds to a Mwt of 158 kDa, suggesting that BsQueC eluted as an hexamer (Mwt 
159kDa) 
 
The BsQueC SDS-PAGE analysis of a typical purification is shown in Figure 3.27. The purified 
enzyme was also characterised by ESI-MS, following SEC. The ESI-MS spectrum is shown in Figure 3.28. 
 
 
Figure 3.27: 12 % SDS-PAGE gel of a hexahistidine tagged BsQueC purification steps. 
L: Low molecular weight ladder, P: Cell pellets, Ni: Sample after immobilised nickel affinity 








































Figure 3.28: BsQueC ESI-MS spectrum. The BsQueC experimental mass was found to be 
26535.89 ± 0.73 Da and in agreement with its theoretical mass (ExPasy): 26535.31 Da. 
 
Hence, as shown in Figure 3.3, while immobilized nickel affinity chromatography recovered the 
protein with an estimated purity of 80%, the purity after SEC was increased to >95%.  The 
experimentally-determined mass was 26535.89 ± 0.73 Da, in good agreement with the predicted mass 
(26535.31 Da). Yields of 20-25 mg of pure protein/L of culture (LB) were routinely obtained.  
3.2.2 Generation of SrToyM 
The S. rimosus toyM codon-optimised gene was bought from GenScript and shipped in a pUC57 
plasmid. The gene was then cloned into a pET28a plasmid, so the recombinant protein will feature a 



























Figure 3.29: Expression tests for SrToyM. In all the experiments, the cells were induced with 0.1 
M IPTG and 0.1 M ZnSO4. P: insoluble fraction, S: soluble fraction, C: Control (uninduced). 
Overnight expression at 18°C was found to be the best conditions.   
 
As a band of good intensity was observed near the predicted 30 kDa region on the gel shown on 
Figure 3.5, it was concluded that best expression was obtained after expressing the toyM gene in E. 
coli BL21 (DE3) strain for 18 hours at 18°C after induction with 0.1 mM IPTG and in the presence of 0.1 
mM ZnSO4, as a zinc source. SrToyM large scale expression (5 L) was carried out. As for BsQueC, 
SrToyM was purified by nickel affinity chromatography using a 40-500 mM imidazole gradient. The 
enzyme eluted at 300 mM imidazole and SDS-PAGE analysis showed traces of a few higher molecular 
weight proteins. The protein was then purified by SEC using a Superdex S200 column. The protein 
eluted at 61 mL, suggesting that SrToyM also eluted as an octamer (Determined Mwt of the complex 
from S200 calibration curve: 224 kDa; Mwt of SrToyM octamer: 220 kDa). The SEC chromatogram is 



























Figure 3.30: A): Superdex S200 size-exclusion chromatogram of SrToyM A single peak 
corresponding to the enzyme is observed at an elution volume of 61 mL. 
B): 12% SDS-PAGE gel of a hexahistidine tagged SrToyM purification steps. S: Cell-free lysate; 
P: Cell pellets (insoluble). 
 
As shown on the SDS-PAGE analysis, enzyme purity superior to 95% was achieved after the SEC. 
Yields of 10-15 mg of pure protein/L of culture (LB) were routinely obtained. As for the other proteins 






















Figure 3.31: SrToyM ESI-MS spectrum. The SrToyM theoretical mass (ExPasy) is 27497.71 Da. 
SrToyM actual mass was 27498.34 ± 1.12 Da. The two sets of peaks correspond to apo-ToyM and 
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The experimentally-determined mass was 27498.34 ± 1.12 Da, in good agreement with the 
predicted mass (27497.11 Da). A second peak was observed at 27676 Da. This peak corresponds to 
the glycophosphorylated form, typically observed with recombinant proteins expressed in E. coli. 
3.3 Generation of the substrates and products 
3.3.1 Syntheses of CDG and PreQ0 
CDG and PreQ0 were synthetised from commercially-available products following a route adapted 
from Nelp et al. work13 shown in Figure 3.32. 
 
Figure 3.32: A) CDG and B) PreQ0 synthetic schemes. 
 
Hence, the first step of these syntheses is the Claisen condensation of methyl formate (I) with 
chloroacetonitrile or methyl chloroacetate (II) to form a chloroaldehyde (III) which will be able to 
undergo a Knorr reaction with 2,4-diamino-6-pyrimidinone (IV) to generate the pyrrole moiety of the 
deazaguanine ring (V). The Knorr reaction is commonly used to generate substituted pyrroles. It starts 
with the nucleophilic attack of one of the pyrimidinone free amines on the carbonyl. After the 
elimination of water, a double bond will be formed. Through rearrangement, the π-electrons of one 
of the pyrimidinone moiety will undergo nucleophilic substitution, eliminating Cl- and closing the 
pyrrole ring, forming the deazaguanine core. The proposed mechanism of this reaction is shown in 
Figure 3.33. 








Figure 3.33: Knorr pyrrole synthesis mechanism. 
 
After carrying out these two steps, that can be done in one pot, without isolating the 
chloroaldehyde, both PreQ0 and CDG-methyl ester was isolated with yields in the region of 70-75% 
and purities of >95% (by HPLC and NMR). CDG was then generated through the hydrolysis of CDG 
methyl ester. Some optimisation, in both basic, acidic and biocatalytic conditions was carried as shown 
in Table 3.2. 
 




hours       
(%) 





NaOH (3 M) H2O 130 100 Not isolated Mixture of 
by-products   
NaOH (3 M) H2O/DMSO 
(1:1) 
RT 0 Not isolated  
NaOH (1 M) H2O 130 57 Not isolated Mixture of 
by-products      
Biocatalysis BioH (0.12 
mM) 
GFC buffer 37 0 Not isolated  
Acidic 
conditions 
HCl (1 M) H2O 130 13 Not isolated  
HCl (6 M) H2O/DMSO 
(1:1) 
RT 0 Not isolated  
HCl (6 M) H2O/THF 
(1:1) 
130 100 264 Formation of 
4-
chlorobutanol 
HCl (6 M) H2O/Dioxane 
(1:1) 
130 100 76 Purity: 95+% 
Table 3.2: Optimisation of the CDG-methyl ester hydrolysis reactions. Best conditions are acidic 
hydrolysis with HCl (6 M) in H2O/dioxane (1:1) at 130°C.  
 
It was found that basic hydrolysis was not a suitable method to generate CDG as the methyl 
ester was fully converted into a mixture of by-products upon carrying the reaction with concentrated 




reaction was observed. It was also observed that lowering the concentration of sodium hydroxide did 
not provide any improvement as, in this case, conversion of the starting material was incomplete, and 
the desired product was not observed. Acidic hydrolysis was found to be much more efficient: full 
conversion of the methyl ester to the acid was observed when using 6M HCl in reflux conditions. While 
this was first tested in water and THF, it was observed that THF was undergoing a ring-opening 
reaction with HCl to form 4-chlorobutanol. This compound was very hard to remove from the mix, but 
this problem was fixed by using 1,4-dioxane instead, which does not undergo any ring-opening 
reaction. Hence, CDG was isolated with a 76% yield and 95+% purity. Moreover, E. coli BioH (EcBioH), 
being a methyl esterase (see Chapter 3), was also tested but did not exhibit any activity for the 
substrate. As robust conditions were found for this reaction, the biocatalytic route was not further 
explored. 
3.3.2 Synthesis of ADG 
Surprisingly, the corresponding primary amide was much more challenging to obtain. Through 
searching on the Reaxys database, four synthetic routes were available. Two of which were described 
in the Nelp et al. paper13, and involve the use of enzymes (ToyJ nitrile hydratase from PreQ0 and 
SrToyM from CDG, although ADG was not isolated in the SrToyM route as it was readily converted into 
PreQ0). This synthetic route is shown in Figure 3.8. The two other routes used either PreQ046 or CDG-




after 24 h    
(%) 
Remarks 
2 PreQ0 Sodium percarbonate (1.5 eq), 




Ammonia (excess), methanol (solvent), 
120°C 
24 CDG observed 
Table 3.3: Trial of literature conditions to generate ADG. 
 
As no satisfactory results were obtained through reproducing literature conditions, four 
different approaches were explored for generating ADG: peptide coupling and acyl chloride formation 
on CDG, hydrolysis of PreQ0 nitrile and the direct conversion of CDG-methyl ester into ADG. Findings 







Approach Reagent Temp 
(°C) 
Conversion 
(%) (time in 
brackets) 




reagent           
 
SM: CDG 
HATU (1.5 eq) + ammonia 
(2.5 eq) 
RT 0 (24 hours) Not 
isolated 
 
HATU (5 eq) + ammonia (2.5 
eq) 
130 0 (24 hours) Not 
isolated 
 
DCC (1.5 eq) + ammonia 
(2.5 eq) 
RT 0 (24 hours) Not 
isolated 
 
DCC (5 eq) + ammonia (2.5 
eq) 
130 0 (24 hours) Not 
isolated 
 
TOTT (1.5 eq) + ammonia 
(2.5 eq) 
RT 0 (24 hours) Not 
isolated 
 
TOTT (5 eq) + ammonia (2.5 
eq) 




of the acyl 
chloride   
 
SM: CDG 
1) Thionyl chloride (1.5 eq)              
2) ammonia (excess)1 
RT 0 (48 hours) Not 
isolated 
 
1) Thionyl chloride (excess)              
2) ammonia (excess)2 
RT 0 (48 hours) Not 
isolated 
 
1) Oxalyl chloride (5 eq)                     
+ DMF (cat. amount)                            
2) ammonia (excess)1 
RT 0 (48 hours) Not 
isolated 
 
1) Thionyl chloride (1.5 eq)              
2) ammonia (excess)1 







SM: PreQ0  
Sodium percarbonate (1.5 
eq), potassium hydroxide (1 
M) 
RT 8 (24 hours) Not 
isolated 
 
Sodium percarbonate (1.5 
eq), potassium hydroxide (1 
M) 
130 72 (24 
hours) 
41 Purity (NMR) = 58%, 
traces of unreacted 










Magnesium nitride (5 eq) in a 
sealed tube 
80 20 (24 
hours) 
7 Purity (NMR) = 27%. 
Mix of CDG Me-ester, 
CDG and PreQ0 
Magnesium nitride (15 eq) in 
a sealed tube 





Table 3.4: Conditions screen for the generation of ADG. Best conditions are the hydrolysis of PreQ0 
nitrile using sodium percarbonate (1.5 eq), potassium hydroxide (1 M) at 130°C. 
SM: starting material; DCC: dicyclohexyl carbodiimide; TOTT: 2-(1-Oxy-pyridin-2-yl)-1,1,3,3-
tetramethylisothiouronium tetrafluoroborate. 
1: 10 mL of ammonia (13.4 M) solution were added after 5 hours of reaction with thionyl/oxalyl 
chloride. 
2: 5 mL thionyl chloride was added (neat). After 5 hours of reaction, 15 mL ammonia (13.4 M) 
solution were added. 
 
The best found conditions still resulted in low yields. As ADG (as well as CDG and PreQ0) is insoluble 
in organic solvents and only soluble in DMSO and highly concentrated strong bases (500 mM KOH), no 




hence the low achieved purity. While this could still be used to determine the ADG HPLC retention 
time for assay development, it was also concluded that biocatalysis should be a better route for the 
high yield and purity generation of ADG.  
3.4 Towards a nitrile synthetase assay 
3.4.1 Development of an HPLC assay 
The first assay developed for this study was an HPLC assay, separating all the reagents and 
products (CDG, ADG, PreQ0, MgATP, and MgAMP). As such, all the reagents and products were tested 
through running each compound on a 0-95% acetonitrile gradient at 254 nm on a Phenomenex Luna 
5u C18 reverse phase HPLC column to assess at which acetonitrile concentration each compound 
elutes. It was found that all MgATP and MgAMP eluted at 0% acetonitrile while CDG, ADG and PreQ0 
eluted at 15-20%. This separation was further optimised, through modifying the acetonitrile gradient 
and, in the finalised protocol, two region could be observed in the chromatogram, one containing the 
MgATP and MgAMP peaks (3-5 min) and one containing CDG, ADG and PreQ0 peaks (18-21 min). A 
chromatogram featuring all the compounds observed in the assay is shown in Figure 3.34.  
  
Figure 3.34: HPLC chromatogram of MgATP, MgAMP, ADG, PreQ0 and CDG. Mobile phase: 0-
20% acetonitrile + 0.1% TFA in water + 0.1% TFA 
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Figure 3.35: HPLC chromatogram of ADG, PreQ0 and CDG. Mobile phase: 15-20% acetonitrile + 
0.1% TFA in water + 0.1% TFA. 
 
Hence, as efficient separation of the CDG starting material and the two products was achieved, 
calibration curves (shown in appendix) were obtained for CDG and PreQ0 to determine their extinction 
coefficients at 254 nm. A summary of the HPLC retention times of each compound is shown in Table 
3.5. This method being only 27 mins long, it represents an improvement to Nelp et al. HPLC protocol, 
which was 40 mins long13. 
Compound Retention time                       
(min) 
Extinction coefficient       
(L/mol/cm) (254 nm) 
MgATP 2.7 NC 
MgADP 2.8 NC 
MgAMP 4.0 NC 
ADG 18.1 NC 
PreQ0 19.3 487430 
CDG 20.4 207780 
 
Table 3.5: HPLC retention times of each reagent and products of the NS reaction. 
 
 
3.4.2 Can an efficient HT coupled assay be found ? 
The first potential HT assay which was considered was to couple an NS with the next enzyme in 
the queuosine biosynthetic pathway, QueF from B. subtilis (BsQueF). BsQueF is an NADPH-dependent 



























compound (340 nm) is converted into NADP+, which does not absorb UV, NADPH disappearance can 
be easily monitored at 340 nm. Two equivalents of NADPH are required for this reaction. This 
reduction is thought to involve the nucleophilic attack of a cysteine residue in QueF catalytic triad on 
PreQ0 nitrile to form a covalent thioimide intermediate. Then, one equivalent of NADPH will deliver a 
hydride to form a thiohemiaminal intermediate which will be broken down into an imine by the 
hydride delivered by the second NADPH equivalent49. The scheme of this assay and the mechanism of 
BsQueF reduction are shown in Figure 3.36. 
 
 
Figure 3.36: Coupled NS-QueF assay scheme and mechanism of the QueF-catalysed reduction 
of PreQ0. 
 
BsQueF (Uniprot: O31678) was expressed, purified (IMAC and Superdex S200 SEC) and 
characterised following the same procedure described for SrToyM with the exception that no zinc 




in Figure 3.37. It was found that the mass observed by ESI-MS (20440.08 ± 0.35 Da) is in agreement 



















Figure 3.37: A): BsQueF S200 chromatogram; B): BsQueF ESI-MS spectrum. Theoretical mass 
(ExPasy): 20440.30 Da; Actual mass: 20440.08 ± 0.35 Da. 
 
First, BsQueF was assayed with PreQ0 as substrate, and two equivalents of NADPH and its kinetic 
parameters were determined. The Michaelis-Menten plot is shown in Figure 3.38, and the determined 
kinetic parameters are shown in Table 3.6. 
 
Figure 3.38: BsQueF Michaelis-Menton plot for PreQ0 
 
 




























A)                                             B)  




Michaelis constant KM 78.9 ± 9.1 μM 
Turnover number kcat 0.0093 ± 0.0038 s-1  
Specificity constant kcat/KM 1.2E-4 ± 1.4E-5 μM-1.s-1 
Table 3.6: BsQueF kinetic parameters for PreQ0 reduction. 
 
This enzyme catalyses the reaction at a low rate as it displays a kcat of 0.0093 s-1 or 0.558 min-1. 
This is consistent with literature results as a kcat of 0.66 min-1 was previously reported50. However, 
while coupling NSs with BsQueF could be a good assay to detect PreQ0, ADG cannot be detected with 
this method. As the aim of this study is to split the CDG to ADG and the ADG to PreQ0 reactions in 
order to engineer an AmS from an NS, a robust assay for this project would be an assay where both 
products could be detected. In addition, while some phosphate detection assays such as the 
methylthioguanosine assay51 or the malachite green assay52 were also investigated, these assays were 
not optimised either because these would not be able to differentiate the formation of ADG and PreQ0 
from CDG. As such, these high throughput assays are not optimal for this study. It was therefore 
concluded that the HPLC assay would be the best assay to quantify directly the relative and absolute 
amounts of CDG, ADG and PreQ0. A summary of these assays is shown in Table 3.7. 




Compound(s) detected CDG, ADG and PreQ0 PreQ0 Phosphate 
Throughput Low-medium High High 
Ability to detect both 
ADG and PreQ0 
Yes No (ADG not detected) Yes 
Ability to distinguish 
ADG and PreQ0  
Yes Yes No 
Table 3.7: Summary of the properties of the investigated assays. 
 
3.5 Assaying NSs 
3.5.1 Optimisation of reaction conditions 
Several conditions (the enzyme and CDG loadings and the number of equivalents of MgATP) were 
screened using BsQueC in order to identify efficient reaction conditions for the NS-catalysed 
biotransformation. The best conditions obtained after this screen were also used for SrToyM to allow 




3.5.1.1 Enzyme loading 
First, BsQueC loading was investigated for the transformation of CDG to ADG and PreQ0. The 
conversion of CDG was assessed after 5 hours, as shown in Table 3.8. 
 
  
Enzyme loading                                        
(mg/mL) 
CDG                                           
(%) 
ADG                                                   
(%) 
PreQ0                                                
(%) 
2 4 34 62 
1 5 60 35 
0.25 7 89 4 
0 100 0 0 
Table 3.8: Condition screen – Enzyme loading. Conditions taken forward are shown in yellow. 
Conditions: 2 mM CDG, 4 mM ATP, 50 mM magnesium chloride, 50 mM ammonium sulfate in 100 
mM TRIS (pH 7.0), 1 mM DTT at 37°C. All reactions were run in duplicates. The conversion was 
measured by HPLC after 5 hours.  
 
It was found that 2 mg/mL of BsQueC provides the best conversion to PreQ0. Even at this 
concentration, the conversion to PreQ0 was not total, although complete consumption of the starting 
material was observed. In addition, while even small enzyme concentrations lead to significant 
formation of the amide, ADG dehydration is more challenging, and ADG is, in all cases, the major 





3.5.1.2 MgATP equivalents 
The second parameter which was investigated was the number of equivalents of MgATP. The 
conversion was measured by HPLC after 5 hours, as shown in Table 3.9. HPLC chromatograms after 5 







CDG                                      
(%) 
ADG                                            
(%) 
PreQ0                               
(%) 
2 4 0 58 42 
1.5 3 4 71 24 
1 2 9 79 12 
0.5 1 46 54 0 
0 0 100 0 0 
Table 3.9: Condition screen – MgATP equivalents. Conditions taken forward are shown in yellow. 
Conditions: 2 mg/mL BsQueC, 2 mM CDG, 50 mM magnesium chloride, 50 mM ammonium sulfate 
in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. All reactions were run in duplicates. The conversion 
was measured by HPLC after 5 hours.  
 
Winkler and co-workers suggested an adenylating mechanism where one equivalent of 
MgATP is required for the transformation of CDG to ADG and another MgATP equivalent to proceed 
























































Figure 3.39: Reaction chromatograms after 5 hours for the NS reaction with multiple concentrations of ATP. 
Conditions: 2 mg/mL BsQueC, 2 mM CDG, 50 mM magnesium chloride, 50 mM ammonium sulfate in 100 
mM TRIS (pH 7.0), 1 mM DTT at 37°C. 






As such, the results obtained seem fairly consistent with the mechanism postulated by Winkler et 
al., where two equivalents of MgATP are needed to convert CDG into PreQ0.  
3.5.1.3 CDG loading 
The substrate loading was the final parameter to be investigated. Different concentrations of CDG 
were investigated. Two equivalents of MgATP were added in each case. CDG conversion was assessed 
after 5 hours, as shown in Table 3.10. 
CDG 





CDG                                      
(%) 
ADG                                            
(%) 
PreQ0                               
(%) 
10* 20* 100 0 0 
5* 10* 100 0 0 
2* 4* 0 58 42 
1 2 0 19 81 
0.5 1 0 0 100 
Table 3.10: Condition screen – CDG loading. Conditions taken forward are shown in yellow. 
* Precipitation was observed upon MgATP addition. 
Conditions: 2 mg/mL BsQueC, 50 mM magnesium chloride, 50 mM ammonium sulfate in 100 mM 
TRIS (pH 7.0), 1 mM DTT at 37°C. All reactions were run in duplicates. The conversion was 
measured by HPLC after 5 hours.  
 
Hence, the optimal CDG loading was found to be 0.5 mM. While at 4 mM MgATP, partial 
precipitation of the enzyme has been likely to affect the reaction, at higher concentrations of MgATP, 
full enzyme precipitation was observed. For this reason, no conversion of CDG was observed. A time-
dependent study of the conversion of CDG to ADG and PreQ0 using these optimised conditions is 









Figure 3.40: Time-dependant study of the NS-catalysed reaction.  
Conditions: Conditions: 2 mg/mL BsQueC, 0.5 mM CDG, 1 mM ATP, 50 mM magnesium chloride, 50 






















































Figure 3.41: Evolution of the relative percentage of CDG, ADG and PreQ0.  
Conditions: Conditions: 2 mg/mL BsQueC, 0.5 mM CDG, 1 mM ATP, 50 mM magnesium chloride, 
50 mM amine in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. 
 
As shown on Figures 3.40 and 3.41, the conversion of CDG to ADG is very quick, and the half-life 
of CDG was found to be 1.47 min and the full conversion of CDG to ADG is observed after 30 mins. In 
contrast, the conversion of ADG to PreQ0 is much slower. This means that there is a very fast buildup 
of ADG that is converted into PreQ0 over the full course of the reaction. The full disappearance of the 
ADG peak, that will be fully converted into PreQ0 is observed after 300 mins.  
SrToyM was also assayed using these optimised conditions. In this case, incomplete conversion of 
CDG was observed (97% conversion). ADG was the major product (63%) and PreQ0 was minor (34%) 













































Figure 3.42: HPLC chromatogram of the SrToyM-catalysed synthesis of ADG and PreQ0 from CDG 
after 5 hours. Conditions: 2 mg/mL SrToyM, 0.5 mM CDG, 1 mM ATP, 50 mM magnesium chloride, 
50 mM ammonium sulfate in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. 
 
3.6 Substrate screens 
3.6.1 Carboxylic acid substrate screen  
Winkler and colleagues have published a small screen of 11 carboxylic acids1. They had screened 
a few benzoic and heterocyclic acids to assess its scope which was discussed earlier in part 3.1.3. They 
concluded that BsQueC displays catalytic activity for no substrate other than CDG. No substrate scope 
studies have been carried out for SrToyM. A screen of other relevant carboxylic acid substrates with 
BsQueC and SrToyM is presented on Figure 3.43, and the results for compounds who displayed activity 
are shown on Table 3.11 (compounds that did not display activity are not shown on Table 3.11). HPLC 




























Figure 3.43: Carboxylic acid substrate scope studies of BsQueC and SrToyM.  
Conditions: 2 mg/mL BsQueC, 0.5 mM acid, 1 mM ATP, 50 mM magnesium chloride, 50 mM 
ammonium sulfate in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. All reactions were run in 
duplicates. The conversion was measured by HPLC after 24 hours. 
 
 
 BsQueC conversion                     
(%) 
SrToyM conversion                         
(%) 
CDG (positive control) 100 100 
5-benzimidazole carboxylic acid 94 8 
7-azaindole-3-carboxylic acid 11 8 
Table 3.11: Results for the compounds which displayed activity for the NSs tested. Compounds 













































































Figure 3.44: HPLC chromatogram for the NS-catalysed reactions of A) 7-azaindole-3-carboxylic acid and 
B) 5-benzimidazole carboxylic acid .  
Conditions: Conditions: 2 mg/mL NS, 0.5 mM acid, 1 mM ATP, 50 mM magnesium chloride, 50 mM 
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Hence, this screen confirmed that the NSs carboxylic acid substrate scope is very restricted as 
all benzoic acids and most heterocyclic acids screened were not converted by either of the NSs. The 
only two compounds which were accepted by the NSs were 5-benzimidazole carboxylic acid and 7-
azaindole-3-carboxylic acid. In common with CDG, both have an H-bond donor (N-H) at close proximity 
(2 bonds away) of an H-bond acceptor (N). As such, this might be a feature required for NS activity. 
This suggestion is strengthened by the fact that, in their substrate screen, Winkler showed that 
BsQueC does not exhibit any activity for 2-methyl-4-oxo-4,5,6,7-tetrahydroindole-3-carboxylic acid, 
shown on Figure 3.9, which is similar to CDG but does have one H-bond donor at close proximity of an 
H-bond acceptor1. The explanation of this pattern should be that these H-bonds donor and acceptor 
should be involved in critical interactions with the enzyme that potentially “lock” the compound in the 
active site to initiate the NS reaction. However, 6-aminopyridine-3-carboxylic acid, which was not 
converted by any NSs, also has a hydrogen bond donor (primary amine -NH2) two bonds away from a 
hydrogen bond acceptor (N). Hence, suggesting that other features on the substrate are required for 
activity. More insights on the structure-activity relationship would be gained from a ligand-bound 
crystal structure as it would allow to precisely locate the residues interacting with the ligands. 
 
3.6.2 Amine screen 
It was shown in this work and also in the literature1 that using ammonium sulfate in the NS-
catalysed transformation of CDG generates ADG, which is readily converted by the NSs into the 
corresponding nitrile as ADG is a primary amide. However, using more complex amines would 
generate secondary or tertiary amides in lieu of ADG, which could not be transformed into the 
corresponding nitrile. In this part, some primary and secondary amines were screened to investigate 
the range of secondary and tertiary amides that could be generated using NS enzymes. This screen is 
presented in Figure 3.45, and the results for compounds who displayed activity are shown in Table 
3.12 (compounds that did not display activity are not shown). The HPLC chromatograms of the 







                       
 
Figure 3.45:  Amine scope studies of BsQueC and SrToyM.  
Conditions: 2 mg/mL BsQueC, 0.5 mM CDG, 1 mM ATP, 50 mM magnesium chloride, 50 mM 
amine in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. All reactions were run in duplicates. The 
conversion was measured by HPLC after 24 hours. 
 
 BsQueC conversion                     
(%) 
SrToyM conversion                         
(%) 
Ammonium sulfate (positive 
control) 
100 100 
Methylamine 81 68 
Propylamine 79 85 
Dimethylamine 70 72 
Glycine 35 35 
Table 3.12: Results for the compounds which displayed activity for the NSs tested. Compounds 


















Figure 3.46: HPLC chromatogram for the SrToyM-catalysed reactions of CDG with various amines 
Conditions: Conditions: 2 mg/mL SrToyM, 0.5 mM CDG, 1 mM ATP, 50 mM magnesium chloride, 50 mM 











































Hence, it was observed that a small range of simple secondary and tertiary CDG-amides could be 
made using NSs enzymes as methylamine, dimethylamine, glycine and propylamine are accepted by 
NSs enzymes with conversions between 35-85%. However, none of the tested NSs exhibits activity 
towards bulkier amines, suggesting that the active site can only accommodate small amines. More 
insights on the structure-activity relationship would be gained from a ligand-bound crystal structure. 
3.7 Structural studies 
3.7.1 BsQueC 
Structural studies of the NS enzymes were carried out to gain better mechanistic insights on this 
enzyme family. As discussed, two crystal structures of NS enzymes exist in the PDB, including one of 
BsQueC, determined by Cicmil and Huang15. However, on this structure, shown in Figure 3.47, zinc, 
magnesium and phosphate ions are bound to the enzyme, and neither CDG nor ATP is present.  
  
Figure 3.47: A) Structure of the BsQueC tetramer (PDB ID: 3BL515).   
 B) Structure of a BsQueC monomer Zn2+ is shown as a blue sphere and Mg2+is shown 
as a pink sphere. The phosphate ion is shown in sticks. 
 
 The aim was to obtain a structure of a NS with ligands to locate the active site. 
3.7.1.1 HT conditions screens on the unbound enzyme 
After unsuccessful replication of the conditions optimised by Cicmil et al., HTP conditions screens 
were carried out to find suitable conditions to prepare diffraction-quality crystals. These screens were 
undergone using a Gryphon robot on a 96 wells plate with three different screens: 
• Molecular Dimensions JCSG+: a broadly used screen for initial screening experiments as 
it contains a wide range of PEGs, salts, organic precipitants and neutralised carboxylic 




• Molecular Dimensions Structures 1+2: a screen developed by Jancarik and Kim where the 
composition of each crystallisation solutions was empirically derived from common 
previously published conditions53.  
• Hampton Research PEG/Ion: a screen where each crystallisation solution is composed of 
polyethylene glycol (PEG) 3350 and salts representing a complete range of anions and 
cations commonly used for the crystallisation of proteins. 
Crystals were generated by vapour diffusion via the sitting drop method. Initial screens, with an 
enzyme concentration of 15 mg/mL, were unsuccessful as the formation of protein aggregates was 
observed. However, at an enzyme concentration of 7.5 mg/mL, one encouraging hit, from the 
Molecular Dimensions JCSG+ screen was observed, as shown in Figure 3.48. 
 
Figure 3.48: HT condition screens hit for BsQueC. 
Conditions: BsQueC: 7.5 mg/mL; 0.2 M magnesium chloride hexahydrate, 0.1 M Tris (pH 7), 10% 
w/v PEG 8000. 
 
3.7.1.2 Optimisation 
These hit conditions were then optimised both for ligand-free BsQueC, (BsQueC + MgADP), 
(BsQueC + MgATP), (BsQueC + CDG) and (BsQueC + CDG + MgATP). The crystals were generated by 
vapour diffusion via the hanging drop method and grown at 23°C. Optimisation conditions are shown 
on Figure 3.49 and crystals obtained after 7 days growth are shown in Table 3.13. 
 




Experiment Additives No Conditions Size Crystal morphology Outcome 
BsQueC 
ligand-free 
None 1 A1 <40 Å 
 
Too small 
2 A4 40-60 Å 
 
Diffraction    
to >4 Å 
3 B5 40-60 Å 
 
Diffraction    
to >4 Å 
BsQueC + 
MgADP 
2.5 mM ADP 
12.5 mM 
MgCl2 
4 A3 80-100 
Å 
 
Diffraction    
to 2.1 Å 
5 A4 60-80 Å 
 
Diffraction    
to >4 Å 
 








Experiment Additives No Conditions Size Crystal morphology Outcome 
BsQueC + 
MgATP 
2.5 mM ATP 
12.5 mM 
MgCl2 
7 C3 20-40 Å 
 
Too small 








9 N/A N/A N/A No crystals 
formed 
0.5 mM CDG 
(in DMSO) 
10 N/A N/A N/A No crystals 
formed 
0.5 mM CDG 
(in 500 mM 
KOH) 











DMSO)          
2.5 mM ATP 
12.5 mM 
MgCl2 
13 N/A N/A N/A No crystals 
formed 
0.5 mM CDG 
(in DMSO)   
2.5 mM ATP 
12.5 mM 
MgCl2 
14 N/A N/A N/A No crystals 
formed 
Table 3.13: Results of BsQueC crystallisation optimisation. 
 
Hence, crystals of ligand-free BsQueC, BsQueC + MgADP and BsQueC + MgATP were obtained. 
Most crystals were of rhombohedron shape with also some tetrahedron- or scalenohedron-shaped 
crystals. However, no crystals were obtained when CDG was present. Lowering CDG loading, changing 
CDG stock solvent to a strong base (500 mM KOH), where CDG is also soluble, or adding CDG powder 
to the drop was also unsuccessful.  In addition, further HTP screens with BsQueC + 0.5 mM CDG in 





The crystals obtained were fished, prepared and diffracted in collaboration with Dr Jon Marles-
Wright (Newcastle University). While most crystals did not exhibit any diffraction or showed poor 
resolution (> 4 Å), the crystals from Entry 4 displayed an adequate resolution of 2.1 Å and were used 
to solve the structure of BsQueC + MgADP.  
3.7.1.3 BsQueC + ADP structure 
Solving of the BsQueC + ADP structure was performed by Dr Jon Marles-Wright (Newcastle 
University) by molecular replacement using the BsQueC structure with PDB code 3BL5, shown in Figure 
3.44. The structure reported in 3BL5 has a resolution slightly better than the one obtained in this study 
(2.95 Å for 3BL5 vs 2.1 Å here). There are six protein molecules in one asymmetric unit, four of which 
forming a tetramer while the two remaining form a tetramer with two other protein molecules from 
a neighbouring asymmetric unit. A monomer is shown in Figure 3.47. As expected, similarly to 3BL5 
structure, a Rossmann fold composed of 5 β-sheets flanked by five α-helices can be observed between 
residues 3 and 155 as well as a phosphate-binding loop, between residues 9 and 14. In addition, a C-
terminal zinc-binding motif is also featured with a cluster of 4 cysteine residues which should complex 
a Zn2+ ion. Interestingly, a disulphide bond between Cys186 and Cys195 was rendered. However, the 
electron density corresponding to that bond could also be the Zn2+ ion. Both ADP and a Zn2+ ion are 
thought to be bound to this structure as areas of electron density are observed both at the proximity 
of the phosphate-binding loop and the cysteine cluster as shown on Figure 3.50. Similarly to the 3BL5, 
structure determination was incomplete as the loop between residues 76-91 was not rendered, 
suggesting that this loop is very flexible. In addition, residues 123-128 were also part of a loop that 













Figure 3.50: A) Structure of a unit cell in the final refinement of BsQueC structure. Six BsQueC molecules 
are part of each unit cells: four of them (blue) form a tetramer while the two other (red) form a tetramer with 
two BsQueC molecules (light pink) that are part of another unit cell 
B) Structure of a BsQueC tetramer 
C) Structure of a BsQueC monomer (blue) superposed with a BsQueC monomer from PDB structure 3BL5 
(green) 
D) Structure of a BsQueC monomer displaying the Rossmann fold (blue) and the Zn2+ binding site (yellow) 
E) Area of electron density (green) thought to be MgADP bound to the phosphate-binding loop (light green) 
F) Area of electron density (green) thought to be a Zn2+ ion in close proximity of the cysteine residues cluster   


















Coot, one of the programmes of the Collaborative Computational Project No. 4 (CCP4) suite was 
then used to fit an ADP ligand onto the electron density area shown in Figure 3.50-E.  The ADP 3D 
structure was taken from the PDB database. Because of the fairly low resolution (3.1 Å), it is not fully 
certain that this electron density area corresponds to a ligand, as it could also correspond to another 
conformation of the phosphate-binding loop. However, it was found that ADP could fit the electron 
density area fairly well, as shown in Figure 3.51. 
 
Figure 3.51: Structure of the ADP pose that is most closely matching the electron density area 
(cyan). The phosphate-binding loop residues (Val9-Gln14) are shown in green sticks.  
 
Hence, as expected, ADP phosphate moiety faces the phosphate-binding loop (Val9-Gln14) shown 
in green sticks in Figure 3.51). These interactions are shown in Figure 3.52.  
 
Figure 3.52: Interactions between ADP and BsQueC. The ADP molecule is shown in cyan sticks. 
The residues of the phosphate-binding loop (green) and also T185 (light blue) are also shown in 
sticks. The intermolecular distance in angstroms between H atoms of H-bond donors and the H-





Specifically, numerous H-bound interactions can be observed as the oxygen atoms which are part 
of the terminal phosphate group are involved in possible H-bond interactions with the Ser11 side chain 
hydroxyl group, Gly13 backbone NH proton as well as the Thr185 side chain hydroxyl, which is not part 
of the phosphate-binding loop. The Thr185 hydroxyl could also interact with the ADP α-phosphate 
group. Finally, the primary amine of the adenine moiety could also interact with the carboxyl oxygen 
atom of Val9, in the phosphate-binding loop.  
The structure of the BsQueC:ADP-bound complex was compared with the BsQueC:phosphate 
complex previously determined by Cicmil et al. (PDB: 3BL5, Figure 3.47). Both the phosphate and the 
ADP are in close proximity to the phosphate-binding loop. In addition, it was found that the phosphate 
ion from the BsQueC:phosphate complex overlaps with the α-phosphate of ADP from the structure of 
the BsQueC;ADP complex. This is supporting evidence that the electron density that was used to fit 
the ligand corresponds to an ADP molecule. 
 
 
Figure 3.53: A) Structure of the BsQueC:ADP complex (determined in this work). B) Structure of 
the BsQueC:phosphate complex (PDB: 3BL5; determined by Cicmil et al.). C) Overlay of the two 
complexes using the Align feature of Pymol. The BsQueC has been removed leaving the 
phosphate ligand. The phosphate-binding loop is composed of residues Val9-Gln14 (green). Both 
the phosphate from 3BL5 structure and the ADP phosphate groups are in close proximity to the 
phosphate binding loop and the phosphate from 3BL5 overlaps closely with ADP α-phosphate 
group. 
 
Looking back at the whole protein-ligand complex, the coulombic electrostatic surface map, 
shown on Figure 3.54 displays BsQueC binding pocket. The large active site cavity is fit to 
accommodate both MgATP, the substrate and the amine and a predominance of positively-charged 
residues is observed around the ADP molecule. This is not surprising as these positively-charged 





Figure 3.54:BsQueC surface coloured by electrostatic potential showing a large binding pocket 
which accommodates the ADP molecule.  
 
3.7.2 SrToyM 
3.7.2.1 HT conditions screens on the ligand-free enzyme 
Unlike BsQueC, the crystallographic structure of SrToyM has not been determined. As such, high-
throughput condition screens were carried out. The same screens than for BsQueC (Molecular 
Dimensions JSCG+ and Structures 1+2 and Hampton Research PEG/Ion) were chosen. These screens 






Figure 3.55: HT condition screens hits for SrToyM (10 mg/mL). 
Conditions A: 1.26 M Ammonium sulfate, 0.2 M lithium sulfate, 0.1 M Tris pH 8.5 
Conditions B: 1.6 M Ammonium sulfate, 10% w/v dioxane, 0.1 M 2-(N-morpholino)ethanesulfonic 
acid (MES) pH 6.5 
Conditions C: 20% w/v PEG 3350, 0.2 M sodium malonate pH 5 





3.7.2.2 Generation of Selenomethionine-enriched SrToyM 
As, unlike for BsQueC, no structure of SrToyM is available, solving the SrToyM structure might be 
challenging because of the phase problem. The data generated by an X-ray diffractometer is a 
diffraction pattern, which will show how the protein crystal diffracted the incident light beam54. In 
order to reconstruct the structure, the amplitude and the phases of the diffracted light waves need to 
be determined. However, only the amplitude of the light waves can be recovered from the measured 
intensity of the spots. For proteins that have high identity to previously solved proteins, molecular 
replacement (MR) allows easier determination of the phases through “using” the phases of the solved 
structure. Sequence analysis of BsQueC and SrToyM showed they display 30.7% identity, which should 
be high enough to carry MR to solve SrToyM structure, as MR can be successful with proteins that 
have an identity as low as 20%54. However, selenomethionine-enriched ToyM (SeMet-SrToyM) crystals 
were also generated. The incorporation of heavy atoms such as selenium allows solving the phase 
problem when MR is not possible. The diffraction maps originating from the WT and SeMet enriched 
proteins will be compared as all the differences between these two datasets will be caused by the 
heavy atoms. Their position in the protein will be determined and will be used as a starting point to 
determine the protein phase angles. As such, SeMet-SrToyM was expressed in B834(DE3) cells, a 
parental strain for BL21(DE3) which is methionine auxotroph and selenomethionine was added to the 





Figure 3.56: A) SDS-PAGE (P: pellet, S: soluble) 
        B) ESI-MS spectrum of SeMet-SrToyM. Experimental mass: 27801.10 ± 6.1Da 
 
This ESI-MS analysis was useful to verify that SeMet residues had been fully incorporated in lieu 






















± 1.12 Da and the molecular weight of the SeMet-SrToyM was found to be 27801.10 ± 6.19 Da. The 
molecular weight difference between SrToyM and SeMet-ToyM is 302.76 Da. This mass difference is 
due solely to the substitution of the sulfur atoms of methionine by selenium atoms in 
selenomethionine. With the atomic mass difference between selenium and sulfur being 46.9 Da, the 
number of incorporated selenomethionines was found to be 6. As there are five methionines in 
SrToyM sequence as well as one methionine in the part of the pET28a vector that is expressed, it was 
concluded that SeMet had been successfully incorporated at all the Met positions.  
3.7.2.3 Optimisation of Conditions A 
As for BsQueC, the hits that resulted from the HT screen were optimised. As conditions A gave the 
most symmetrical and largest crystals, these conditions were explored first and in most details for 
ligand-free SrToyM, ligand-free SeMet-SrToyM, (SrToyM + MgADP), (SrToyM + MgATP), (SrToyM + 
CDG) and (SrToyM + CDG + MgATP). ). The crystals were generated by vapour diffusion via the hanging 
drop method and grown at 23C. The conditions are shown in Figure 3.57, and the crystals obtained 






Figure 3.57: Optimisation conditions for Conditions A. 
Experiment Additives No Conditions Size Picture Outcome 
SrToyM 
ligand-free 






200 Å  
 
Diffraction 















None 4 A1 200+ Å 
 
No diffraction 





























Experiment Additives No Conditions Size Picture Outcome 
SrToyM + 
MgATP 























0.5 mM CDG 
(in DMSO) 





0.5 mM CDG 
(in DMSO)   
2.5 mM ATP 
12.5 mM 
MgCl2 
15 N/A N/A N/A No crystals 
formed 
Table 3.14: Results of SrToyM and SeMet-SrToyM crystallisation optimisation with Conditions A. 
 
The crystals formed with these conditions have a prismoid shape. In the ligand-free enzyme trials 
(both SrToyM and SeMet-SrToyM) the crystals appear to be irregular at both ends. However, this was 
not observed upon addition of MgADP or MgATP. Interestingly, some SrToyM-MgATP co-crystals 
(conditions A1 and C2) were much thinner than the other crystals, adopting a needle-shape. This could 




not be verified because none of the crystals tested diffracted to an adequate resolution. As for BsQueC, 
no crystals were obtained for when CDG was added. Other conditions found in the HTP condition 
screen described in Part 3.7.2.1 were then optimised. 
3.7.2.4 Optimisation of Conditions B  
Conditions B were also optimised, as shown in Figure 3.58.  
 
Figure 3.58: Optimisation conditions for Conditions B. 
 
These conditions were tried both to obtain crystals of ligand-free SrToyM and co-crystals of 
SrToyM + MgADP and SrToyM + MgADP. However, after seven days of growth at 23°C, no crystals 
were observed in any of the conditions. 
3.7.2.5 Optimisation of Conditions C 
Finally, Conditions C obtained from the condition screen were optimised for ligand-free SrToyM, 
(SrToyM + MgATP) and (SrToyM + CDG + MgATP) as on Figure 3.59. Results are shown in Table 3.15. 
 




Experiment Additives No Conditions Size Picture Outcome 
SrToyM 
ligand-free 





























0.5 mM CDG 
(in DMSO) 





0.5 mM CDG 
(in DMSO)   
2.5 mM ATP 
12.5 mM 
MgCl2 
7 N/A N/A N/A No crystals 
formed 




It was noted that, while very large needle-shaped crystals were obtained for both unbound 
SrToyM and SrToyM + MgATP, none of the obtained crystals diffracted. In addition, as before, no 
SrToyM co-crystals were obtained upon adding CDG. 
3.7.2.6 SrToyM + CDG co-crystals 
Obtaining SrToyM + CDG co-crystals was unsuccessful so far. For this reason, HT conditions screens 
were done for SrToyM + 1 mM CDG + 2 mM MgATP + 10 mM magnesium chloride. The same screens 
than the ones described in 3.5.1.1 were used (Molecular Dimensions JSCG+ and Structures 1+2 and 
Hampton Research PEG/Ion). One hit was obtained, as shown in Figure 3.60. 
 
Figure 3.60: HT condition screens hit for SrToyM + CDG + MgATP + MgCl2. 
Conditions: SrToyM: 10 mg/mL., 1 mM CDG, 2 mM MgATP, 10 mM magnesium chloride; 
Precipitant: 0.1 M bicine (pH 9), 20% w/v PEG 6000. 
 
These initial hit conditions were optimised, as shown in Figure 3.61: 
 
Figure 3.61: Optimisation conditions for the hit obtained after HT conditions screening for ToyM + 





Optimisation of these conditions failed to yield crystals. Other attempts through reducing CDG 
concentration to 0.1 mM, changing CDG stock solvent to 500 mM KOH or not adding ATP and MgCl2 
were also unsuccessful. This suggests that the crystals obtained in the HT screen might have been 
precipitant salts. 
3.7.2.7 Structure of SrToyM 
Because none of the crystals obtained diffracted to a good resolution, the structure of SrToyM 
was predicted using RaptorX, using the BsQueC structure published in the PDB (3BL5) as template15. 
This program predicts secondary and tertiary structures of proteins from a previously-determined 






Figure 3.62: A) RaptorX-predicted structure of SrToyM 
B) RaptorX-predicted structure of SrToyM (magenta) superposed with BsQueC structure (blue) 
 
Hence, as shown in Figure 3.62 B), the predicted structure of SrToyM is very similar to the one of 
BsQueC. SrToyM is predicted to also feature a Rossmann fold as well as a Zn binding domain. The loop 
that was rendered neither on 3BL5 nor on the BsQueC structure presented in this work was predicted 
here (residues 86 to 98 of SrToyM) and can be seen on the top right of Figure 3.62. 
3.8 Engineering an amide synthetase  
So far, the exact location of the active site for the NS-catalysed reactions is unknown, and no 
mechanistic studies of the reactions have identified catalytically essential residues. As such, locating 
the active site is key for NS biocatalytic engineering. The location of the MgATP binding site could be 
inferred from the published structure as both magnesium and phosphate are bound to it and was then 
further confirmed in this project as the first ADP-bound structure of BsQueC was solved as shown on 
Figures 3.50-3.52. In order to choose the target residues for enzyme engineering, residues that fulfil 
the following three conditions were searched on BsQueC: 




• Residues with hydrophilic side chains, well conserved across all species 
• Not involved in the binding of MgATP or Zn2+ 
• Close in space to the ADP pyrophosphate moiety binding site 
3.8.1 Identifying conserved residues 
To identify residues potentially involved in substrate binding and catalysis, sequence homology 
was performed to highlight conserved residues. This search was done as residues that are involved in 
substrate binding, and catalysis should be well conserved. Besides, considering CDG and ADG high 
number of H-bond donors and acceptors, it was postulated that hydrophilic residues should strongly 
favour substrate binding. As such, the sequence alignment of some NSs, showing all well conserved 
hydrophilic residues is shown in Figure 3.63. 
 
Figure 3.63: Sequence alignment the NSs from B. subtilis (BsQueC) (Uniprot code: O31675), E. 
coli (Uniprot code: E2QH39), Archeoglobi sulfaticallidus (N0BDM1), Pectobactum atrosepticum 
(Q6D820), Geobacillus kaustrophilus (Uniprot code:GK1520), B.clausii (Q5WG41), S. rimosus 
(SrToyM) (Uniprot code: B6CWJ6) and S. diastatochromogenes (A0A1L7B5M4).Conserved 
hydrophilic residues are shown in yellow. 
 
Twenty-five hydrophilic residues were found to be conserved across species. Some of these 





3.8.2 Finding conserved residues that are not involved in MgATP or Zn2+ binding 
A second sequence analysis sought to identify motifs within the NS family. Such motifs should be 
well-conserved residues and involved in the binding of MgATP and Zn2+. It is known already that 
MgATP binds through a phosphate-binding loop present in residues 9-14. Besides, the Zn2+ binding 
site is known to be composed of 4 cysteines (Cys186, Cys195, Cys198 and Cys201). These residues, 
while well conserved, should not be involved in the binding of CDG/ADG. To ensure that no other 
motifs are present on NSs sequences, a motif search was done on the Pfam database using MOTIF. It 
was found, on all the NSs tested that the residues corresponding to residues 1 to 61 on BsQueC 
sequence are part of a PF01171 motif, involved in the binding of ATP. For this reason, both residues 1 
to 61 and the four cysteines involved in zinc binding are thought not to be involved in CDG/ADG 
binding. This leaves 12 residues possibly involved in CDG/ADG binding, as shown in Figure 3.64.  
 
Figure 3.64: Sequence alignment the NSs from B. subtilis (BsQueC) (Uniprot code: O31675), E. 
coli (Uniprot code: E2QH39), Archeoglobi sulfaticallidus (N0BDM1), Pectobactum atrosepticum 
(Q6D820), Geobacillus kaustrophilus (Uniprot code:GK1520), B.clausii (Q5WG41), S. rimosus 
(SrToyM) (Uniprot code: B6CWJ6) and S. diastatochromogenes (A0A1L7B5M4). The region 
involved in ATP binding is shown in green, and cysteine residues involved in zinc binding are 








3.8.3 Finding conserved residues in the vicinity of the ADP 
The number of residues likely to be involved in CDG/ADG binding was reduced to 12. This number 
can be further reduced as it is postulated that the mechanism of the NS-catalysed reactions involves 
the formation of an adenylate intermediate (as shown previously on Figure 3.2). For this reason, it can 
be postulated that the reaction will take place close to the phosphate moiety of the MgATP molecule. 
The ADP-bound structure of BsQueC that was resolved previously in Part 3.5.1.3 can, therefore, be 
used to locate the residues possibly involved in CDG/ADG binding that are close to the phosphate 
moiety of the ADP. The structure of BsQueC showing 11 of the 12 potential residues potentially 
involved in CDG/ADG binding is shown on Figure 3.65 (one residue (D125 was part of a loop that was 
not rendered)). 
 
Figure 3.65: Structure of BsQueC showing 11 of the 12 residues (yellow) potentially involved in 
CDG/ADG binding. ADP is shown in cyan. 
 
From Figure 3.65, three residues, Lys163, Tyr187 and Arg204, that are shown on Figure 3.66 are 
both close to the phosphate moiety of ADP, well conserved across all NS enzymes and also not part of 





Figure 3.66: A) Structure of BsQueC highlighting the three residues (magenta) which are both 
conserved across all NSs, not part of any other motifs and close to ADP’s phosphate moiety. ADP 
is shown in cyan.   
 
As shown on Figure 3.66, intermolecular distances between the ADP molecule and the residues is 
slightly above the threshold for hydrogen-bonding in the current situation. However, as, in this work, 
ADP was co-crystallised with the enzyme, it is possible that ATP, the actual cofactor used in the NS 
reaction, adopts a slightly different conformation where the α-phosphate is closer to the three 
residues thought to be involved in the NS reaction. In addition,  upon binding CDG, the conformation 
of the enzyme-ATP complex might also be disrupted, bringing the ATP α-phosphate within H-bond 
distance to these residues. Both of these hypotheses are possible considering that only a 1.5-2 Å 
displacement of the ATP molecule would bring it close enough to interact with the three residues. The 
best possible way to confirm that would be to successfully co-crystallise the enzyme with CDG and 
ATP. However, as discussed previously, this was attempted with no success. 
3.8.4 Generation and assay of the BsQueC mutants  
To assess their involvement in NS activity, these three residues were modified by site-directed 
mutagenesis. As such, the BsQueC K163A, Y187A and R204A one-point mutants were generated 
following the overlapping primers method explained in Chapter 2. These mutants were expressed and 
purified following the same procedure than WT BsQueC and were characterised by ESI-MS. Yields of 
20-25 mg of pure enzymes per litres of culture were obtained. The ESI-MS analyses of these mutants 
are shown in Figure 3.67, and their theoretical (calculated with ExPaSy) and determined masses are 
shown in Table 3.16. The three BsQueC mutants were then assayed for the NS reaction to assess their 














C)       BsQueC R204A 
 Theoretical mw 
(Da) 
Determined mw    
(Da) 
BsQueC K163A 26476.14 26475.16 ± 1.88 
BsQueC Y187A 26441.13 26441.38 ± 1.16 



















































Figure 3.67: A) ESI-MS spectrum of BsQueC K163A. 
        B) ESI-MS spectrum of BsQueC Y187A. 
        C) ESI-MS spectrum of BsQueC R204A. 
Table 3.16: Theoretical and experimental molecular 
weight for various BsQueC point mutants. 
26+ : m/z=1018 
26+ : m/z=1019 




















































Figure 3.68: HPLC chromatograms of the NS reaction for BsQueC WT and various BsQueC point mutants 
after 5 hours.  
Conditions: 2 mg/mL BsQueC, 0.5 mM CDG, 1 mM ATP, 50 mM magnesium chloride, 50 mM ammonium 
sulfate in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. 





 CDG                                    
(%) 
ADG                                    
(%) 
PreQ0                                   
(%) 
No enzyme 100 0 0 
BsQueC WT 0 0 100 
BsQueC Y187A 5 3 92 
BsQueC R204A 1 52 47 
BsQueC K163A 1 75 24 
Table 3.17: NS conversion for BsQueC WT and various BsQueC single mutants. 
Conditions: 2 mg/mL BsQueC, 0.5 mM CDG, 1 mM ATP, 50 mM magnesium chloride, 50 mM 
ammonium sulfate in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. All reactions were run in 
duplicates. The conversion was measured by HPLC after 5 hours.  
 
Hence, after 5 hours, 95 to 99% conversion from CDG to ADG was observed for all the BsQueC 
mutants. As developed earlier, for BsQueC WT, 91% conversion of ADG to PreQ0 is observed. A similar 
conversion is observed for BsQueC Y187A, suggesting that Tyr187 is not involved in NS catalysis. 
However, both K163A and R204A mutations lead to significant decreases in the conversion of CDG to 
PreQ0 in identical conditions, suggesting that both residues are involved in ADG to PreQ0 conversion 
and are therefore involved in NS activity. 
Both lysine and arginine have in common that they are positively-charged. Positively-charged 
residues are crucial in adenylating enzymes mechanism as they will stabilise the negatively-charged 
adenylate intermediate. Indeed, Schmelz and Naismith have shown that, in many but all classes 
adenylating enzymes, the ATP α-phosphate is surrounded by positively-charged residues (Lys and/or 
Arg and/or His) (Figure 3.69)22. This ATP α-phosphate can be considered as the focal point of the 





Figure 3.69: Overlay of the coordination of the ATP α-phosphate by positively-charged residues in 
different classes of adenylating enzymes.In all cases at least one positively-charged residue is 
present. Acetyl-CoA synthetase (2P2F) and Japanese firefly luciferase (2D1Q) are class I; human 
Trp-tRNA synthetase (2QUI) and Lys-tRNA synthetase (1E24) are class II; AcsD (2WO2) and AlcC 
(ALCC) are class III adenylating enzymes. Figure taken from 22. 
 
 As both Lys163 and Arg204 are positively-charged residue, this decrease of activity was expected 
and provides further proof of the importance of positively-charge residues in adenylate-forming 
enzymes. Deactivating these two positively-charged residues would disfavour the formation of the 
negatively-charged intermediates in the reaction. Significant effects resulting from the deactivation of 
a positively-charged residue in an adenylating enzyme were already observed in the research group. 
It was found by Tron and colleagues that the mutation of an arginine residue to glycine (R40G) in biotin 
protein ligase, an enzyme which catalyses the formation of biotinyl-5’-AMP from biotin and ATP, led 
to promisciuous biotinylation56. This is because the biotin adenylate is no longer “trapped” in the 
active site by the positively-charged arginine and can therefore escape amd react with free amines56. 
3.8.5 Generation of the double-mutant 
As previous results suggest that both Lys163 and Arg204 are involved in the ADG to PreQ0 
conversion, the K163A R204A double mutant was generated by site-directed mutagenesis. This 
mutant was expressed and purified following the same procedure than WT BsQueC and was 
characterised by ESI-MS and SDS-PAGE. Yields of 25 mg/L of culture were obtained. The SDS-PAGE 













Figure 3.70: A) 12% SDS-PAGE gel for a BsQueC K163A R204A purification. L: low molecular 
weight ladder, P: pellets, Ni: After IMAC, SEC: after SEC. 
                    B) BsQueC K163A R204A ESI-MS spectrum. Theoretical mass (ExPasy): 26391.03 
Da; Actual mass: 26389.15 ± 2.07 Da. 
 
. 
The double mutant was assayed alongside the BsQueC WT for the NS reaction to assess its activity, 
as shown in Figure 3.71 and Table 3.18: 
  
A)            B) 






































 CDG                                    
(%) 
ADG                                    
(%) 
PreQ0                                   
(%) 
No enzyme 100 0 0 
BsQueC WT 0 0 100 
BsQueC K163A R204A 0 100 0 
Table 3.18: NS conversion for BsQueC WT and BsQueC K163A R204A. 
Conditions: 2 mg/mL BsQueC, 0.5 mM CDG, 1 mM ATP, 50 mM magnesium chloride, 50 mM 
ammonium sulfate in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. All reactions were run in 
































Figure 3.71: HPLC chromatograms of the NS reaction for BsQueC WT and BsQueC K163A R204A. 
Conditions: 2 mg/mL BsQueC, 0.5 mM CDG, 1 mM ATP, 50 mM magnesium chloride, 50 mM 















Hence, it was found that this double mutant NS, while retaining its amide synthetase activity, does 
not possess any amide dehydratase activity. It was therefore possible to separate NS two activities. 
This should represent the first successful engineering of an NS enzyme. This engineered amide 
synthetase, named BsQueC-eAmS, will be further studied and characterised below (section 3.10). 
3.9 Engineering an amide synthetase from SrToyM 
With the successful engineering of BsQueC accomplished, it was attempted to produce a similar 
AmS from SrToyM by mutating the equivalent residues on SrToyM, K176 and R213 to alanine. Hence 
the SrToyM K176A and R213A single-point mutants and the double-mutant were generated following 
the overlapping primers method explained in Chapter 2. These mutants were expressed and purified 
following the same procedure than for SrToyM WT. However, both SrToyM R213A and SrToyM double 







Figure 3.72: 12% SDS-PAGE gel of the cell pellets (I) and supernatant (S) of SrToyM WT, K176A-
R204A (x2 Mutant), R213A and K176A. This shows that the enzyme is only soluble in the case of 
SrToyM WT and SrToyM K176A. 
L: low molecular weight ladder 
 
This suggests that R213 has an important role in ToyM and may be involved in a key solvent 
interaction that is not permitted upon its deactivation by mutagenesis. Only the SrToyM K176A single 
mutant could be purified with a yield of 19 mg/L of culture and characterised by ESI-MS, as shown in 
Figure 3.73. This mutant was also assayed, and full conversion of CDG was observed to ADG (88%) and 
PreQ0 (12%). 
                   WT      x2 Mutant    R213A       K176A 





Figure 3.73: ESI-MS spectrum of ToyM K176A. Theoretical mass is 27571.80 Da. Experimental 
mass is 27572.92 ± 1.88 Da. 
 
 Small scale expression of the SrToyM K176A R213A with additives thought to enhance protein 
solubility were carried out.  Leibly and coworkers published a method paper where they screened a 
wide range of salts, detergents, PEGs or sugars to solubilise some insoluble proteins57. Some of the 
additives which were the most successful in facilitating protein solubility were trialled. These included 
700 mM trehalose, 500 mM mannitol and 400 mM L-arginine. The solubility of the protein expressed 








































Figure 3.74: 12% SDS-PAGE gel of the cell pellets (I) and supernatant (S) of the expression of 
SrToyM K176A R213A with various additives. This shows that the enzyme is insoluble in all cases.  
L: low molecular weight ladder 
1: no additive 
2: 700 mM trehalose 
3: 500 mM mannitol 
4: 400 mM L-arginine 
5: 700 mM trehalose, 500 mM mannitol and 400 mM L-arginine 
 
Hence, while no conditions in which SrToyM K176A R213A was soluble were found, this 
experiment highlighted the importance of the arginine residue in NSs behaviour. The focus was then 
placed on the further characterisation of BsQueC engineered amide synthetase (BsQueC-eAmS). 
3.10 Characterisation of BsQueC-eAmS 
3.10.1 BsQueC-eAmS kinetic studies 
First, a kinetic study of the BsQueC-eAmS was carried out for the transformation of CDG to ADG 
by monitor production by HPLC (see Fig. 3.68). The scheme, kinetics curve and Michaelis-Menten 
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Figure 3.75: A) BsQueC-eAmS-catalysed formation of ADG monitored over time (HPLC). 
        B) BsQueC-eAmS-catalysed formation of ADG monitored over time (first 30 min). 
      C) Michaelis-Menten curve for the formation of ADG. 
Conditions: 1 mg/mL BsQueC-eAmS, 0-1 mM CDG, 0-2 mM ATP, 50 mM magnesium chloride, 50 
mM ammonium sulfate in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. 
C) 




Parameter  Determined values 
Michaelis constant KM 125 ± 6.8 µM 
Turnover number kcat 1.27 ± 0.21 min-1  
Specificity constant kcat/KM 1.01E-2 ± 2.70E-4 µM-1.s-1 
Table 3.19: Kinetic parameters for BsQueC-eAmS-catalysed amide coupling between CDG and 
ammonium sulfate. 
 
Hence, BsQueC-eAmS was found to have a KM in the micromolar range and a fairly small turnover, 
with slightly more than one catalytic cycle per minute. This is the first time that the kinetic parameters 
of a NS enzyme have been determined and also, the first time a KM for CDG was found. Interestingly, 
the initial rates of the 250 µM, 500 µM and 1000 µM were found to follow a negative trend, suggesting 
a slight product inhibition at higher concentrations. This kinetic study was also used to compare the 




Figure 3.76: Evolution of the relative percentages of CDG, ADG and PreQ0. Results for BsQueC-
eAmS are shown as a bold line. Results for BsQueC WT are shown as a dashed lane. 
Conditions: Conditions: 2 mg/mL BsQueC-eAmS, 0.5 mM CDG, 1 mM ATP, 50 mM magnesium 
chloride, 50 mM amine in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. 
 
Hence, while it has already been determined that the conversion from ADG to PreQ0 is completely 
knocked out for BsQueC-eAmS, it is interesting to note that for BsQueC-eAmS, the conversion from 












































BsQueC WT t1/2(CDG) = 1.47 min 





after 30 minutes, the full conversion of CDG only occurs after 5 hours for BsQueC-eAmS. In addition, 
the half-life of CDG in BsQueC WT reaction is 1.47 min, while this half-life is 6.16 min when reacted 
with BsQueC-eAmS. This strongly suggests that the two residues that were mutated to generate 
BsQueC-eAmS might have a certain degree of involvement in the generation of the amide from CDG. 
Additionally, this also suggests that both the conversion from CDG to ADG and the hydration of ADG 
into PreQ0 occur in a single active site. Therefore, this sheds light on the fact that the NS active site is 
fit to catalyse two reactions. 
3.10.2 BsQueC-eAmS structural study 
Structural studies were carried for the BsQueC-eAmS. The unbound structure of the BsQueC-eAmS 
was to be generated in order to compare the fold of BsQueC-eAmS with BsQueC WT ligand-free 
structure determined by Cicmil and coworkers10. Besides, the ligand-bound (CDG and MgATP) 
structure of BsQueC-eAmS was also aimed. The conditions used to obtain the ATP-bound BsQueC 
structure were trialled but did not yield any crystals. Consequently, HT screens were carried out for 
both the unbound BsQueC-eAmS (in Newcastle, in collaboration with Dr Jon Marles-Wright and 
Edinburgh), ATP-bound BsQueC-eAmS and CDG-bound BsQueC-eAmS (both in Edinburgh). Only one 
condition yielded crystals which could be further optimised, from the screens done in Newcastle with 
the unbound BsQueC-eAmS, as shown in Figure 3.77. 
 
Figure 3.77: HT condition screens hit for BsQueC-eAmS. 
Conditions: BsQueC-eAmS: 7.5 mg/mL; 0.2 M calcium acetate hydrate, 0.1 M sodium cacodylate 
pH = 6.5, 18% w/v PEG 8000. 
 
 However, optimisation of these conditions did not yield any diffraction-quality crystals. This 
suggests that the mutations might either impact the stability of the protein or lie at key crystal 
interfaces (for example interaction with a key water molecule). In addition, this could also be due to 
an increased flexibility of the double-mutant due to the loss of a key interaction in the active site. In 




3.10.3 ADG synthesis using the BsQueC-eAmS biocatalyst 
It was found, in Part 3.3.2, that ADG was hard to synthesize chemically. For this reason, this novel 
BsQueC-eAmS was used to synthesize this molecule at preparative scale (200 mg of starting material, 
split in three (66.7 mg per reaction)). To minimise the amount of enzyme required, the CDG 
concentration and BsQueC-eAmS loading were optimised, as shown in Table 3.20 and 3.21. HPLC 
chromatograms of the optimisation of the enzyme loading are shown on Figure 3.78. 
CDG concentration                                                            
(mM) 
ATP concentration                
(mM) 
Conversion to ADG                                                                  
(%) 
0.5 1 100 
1 2 100 
3 6 74 





BsQueC-eAmS concentration                                       
(mg/mL) 









Table 3.20: Condition screen – CDG concentration. Conditions taken forward are shown in yellow. 
*Precipitation of the mix was observed upon adding ATP 
Conditions: BsQueC-eAmS loading: 2 mg/mL, 50 mM magnesium chloride, 50 mM ammonium 
sulfate in 100 mM TRIS (pH 7.0), 1 mM DTT at 37°C. All reactions were run in duplicates. The 
conversion was measured by HPLC after 5 hours. 
Table 3.21: Condition screen – BsQueC-eAmS loading. Conditions taken forward are shown in 
yellow. 
Conditions: CDG: 1 mM, ATP: 2 mM, 50 mM magnesium chloride, 50 mM ammonium sulfate in 100 
mM TRIS (pH 7.0), 1 mM DTT at 37°C. All reactions were run in duplicates. The conversion was 








Figure 3.78: Reaction chromatograms after 5 hours for the BsQueC-eAmS reaction with multiple 
concentrations of enzyme. 
Conditions: 2 mg/mL BsQueC, 2 mM CDG, 50 mM magnesium chloride, 50 mM ammonium sulfate in 100 




























































Consequently, from requiring 2 mg/mL enzyme to convert 0.5 mM CDG, only 0.25 mg/mL BsQueC-
eAmS are required to convert 1 mM CDG after this optimisation. Therefore, to carry out the 
biotransformation planned of 200 mg CDG, the amount of enzyme required previously was 4120 mg. 
Based on protein yields of 25 mg of pure enzyme per litre of culture routinely obtained, 166 litres of 
culture would have been required to make sufficient amounts of BsQueC-eAmS to carry out this 
transformation. This would have been very hardly feasible in the laboratory. After optimisation, the 
amount of BsQueC-AmS required to carry out the same biotransformation is reduced to 258 mg. 
Hence, only 10.3 litres of culture was needed to produce this amount of enzyme. The reaction was 
carried out in three 1L conical flasks and monitored by HPLC. Interestingly, after 2 hours, full 
conversion of CDG was observed on all three replicates. Purification of only one of the replicates was 
carried (67 mg of starting material). The product was filtered and recovered alongside some 
precipitated BsQueC-eAmS. The product was then redissolved in 20 mL DMSO, diafiltered using a 
10000 Da cut-off membrane to ensure that no precipitated enzyme was present. DMSO was then 
removed under high vacuum for five days. The product was finally washed with THF and recovered by 
filtration. 9 mg of ADG were recovered and found to be 95+% pure by HPLC and NMR. This represents 
the first successful direct biosynthesis of ADG from CDG, with an isolated yield of 14%. Interestingly, 
on the 1H NMR, it was noted that the two protons of the primary amide have different chemical shifts, 
with a difference of about 2 ppm between the two shifts. This strongly suggests that one of the two 
protons of the primary amide undergoes intramolecular H-bonding interaction with the deazaguanine 
carboxyl, as shown in Figure 3.79. This gives extra credit on the hypothesis that the amide is able to 
attack the ATP α-phosphate because at least one of the amide protons acts as a hydrogen-bond donor, 
and therefore receive electron density, hence activating the amide for attack.  The HPLC and NMRs 
(1H and 13C) of the product are shown in Figure 3.80.  
 
 
Figure 3.79: Intramolecular H-bonding interaction between one of the primary amide hydrogen 
atoms and the deazaguanine carboxyl, explaining the 1H NMR shift difference between these two 
protons 
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Figure 3.80: A) HPLC chromatogram of the ADG produced by BsQueC-eAmS. 
One single peak (retention time: 18 min), corresponding to ADG, is observed. 
B) 1H NMR spectrum (600 MHz, DMSO) 





This work explored the structure, substrate specificity and mechanism of the NS biocatalysts. Two 
recombinant NSs, MgATP-dependent BsQueC and SrToyM were successfully expressed and purified in 
good yields and purities. A robust HPLC assay was then developed and used to assay these enzymes 
for their natural NS reaction: the transformation of CDG into the corresponding nitrile, PreQ0, via the 
primary amide ADG, as shown on Figure 3.81.  
 
Figure 3.81: NS reaction scheme. CDG is first transformed into ADG, using one equivalent of 
MgATP and then into PreQ0 using a second equivalent of MgATP. 
 
It was found that, while complete conversion of CDG into PreQ0 was observed for BsQueC, a 
mixture of ADG and PreQ0 was obtained with SrToyM. The substrate scope of both biocatalysts was 
then explored, and it was confirmed that both NSs have a very narrow acid substrate scope, only 
accepting their natural ligand and close derivatives. However, it was found that a fairly wide range of 
CDG-derived secondary and tertiary amides could be produced using both NS enzymes tested. A 
rigorous structural study of these NS enzymes was then carried out, leading to the resolution of the 
ADP-bound BsQueC structure with a resolution of 2.1 Å. This structure was the cornerstone of the 
rational engineering carried on BsQueC to engineer an amide synthetase from the NS (BsQueC-eAmS) 
and to separate the two activities. Three residues (K163, Y187 and R204) were identified and mutated 
to alanine, and it was observed that two of these mutations (K163A, R204A) were important as 
significant losses in amide dehydratase activity were observed. This suggests that these residues are 
not involved in the first step of the reaction, rather they play a role in the second amide to nitrile 
conversion. Generating a double mutant, which combined both mutations, finally led to the complete 
disappearance of the amide dehydratase activity, allowing this engineered enzyme to join the amide 
synthetase family. However, as an impact on the speed of the conversion from CDG to ADG was 
observed, these observations weaken the hypothesis that the two reaction steps proceed in two 
different active sites. This novel amide synthetase was further characterised through kinetic and 
structural studies. For the first time, the kinetic parameters for CDG were determined. In addition, this 




Further development of this project would be to engineer this novel amide synthetase to expand 
its substrate scope and allow it to produce industrially-relevant primary amides. Examples could 
include Levetiracetam, an anticonvulsant drug used to treat epilepsy and the 60th top-selling small 
molecule in 201858, or Favipiravir, an antiviral drug which was the first molecule approved in China to 
treat the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)59. Their structures are 
shown in Figure 3.82. 
 
Figure 3.82: Structures of Levetiracetam and Favipiravir 
 
In addition, as the residues involved in the amide dehydratase activity of the enzyme have been 
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Chapter 4 Summary and outlook 
Before designing enhanced biocatalysts and carrying out directed evolution, it is important to get 
an understanding of the mechanism of action of the enzyme. Where and how to “hit”? The aim of this 
thesis was to understand the catalytic machinery involved in two biocatalysed reactions: the EcBioH-
catalysed MBH reaction and the NS-catalysed ATP-dependent conversion of carboxylic acids into the 
corresponding nitrile. 
As such, firstly, EcBioH was successfully cloned, expressed, purified and characterised. A robust 
HPLC assay was developed along with efficient reaction conditions for the MBH coupling of 4-NBA and 
MVK. It was also found that no enantioselectivity of the MBH product is obtained upon using EcBioH. 
A search of the residues involved in MBH catalytic activity was then performed. The catalytic triad (S82, 
D207, H235) involved in EcBioH esterase activity was first targeted. At first, these residues, along with 
the serine of another, cryptic, catalytic triad (S55) were deactivated by site-directed mutagenesis. No 
decrease in MBH activity was observed, suggesting that these triads are not involved in MBH catalysis. 
The involvement of a catalytic cysteine was also tested but it was also found that a catalytic cysteine 
is unlikely to be involved in MBH catalysis. The activity of EcBioH was then compared to one of another 
pimeloyl-ACP methyl ester esterase, HiBioG but no significant difference in MBH activity was found. 
Finally, the involvement of histidine was explored by expressing variants of EcBioH with different 
numbers of hexahistidine tags. It was found that the numbers of hexahistidine tags have a significant 
impact on MBH catalysis. With this result in hand, it was found that other hexahistidine tagged 
proteins, including denatured EcBioH and E. coli ACP also exhibit comparable MBH activities. It was 
therefore concluded that any protein that contains a hexahistidine tag could catalyse the MBH 
reaction. A mechanistic rationale, involving a synergic relationship between the histidine residues of 
the tag and the oxyanionic reactive intermediates, which could explain the increase in activity 
compared to imidazole, was postulated. 
With these data in hand, further work could be to construct a histidine-rich active site. While a 
hexahistidine tag is hard to engineer due to its flexibility, having multiple histidine residues in a more 
rigid active site shall permit easier engineering to build enantioselectivity and increase the activity of 
the biocatalyst.  
In a second project, NSs, a small enzyme family which converts a carboxylic acid first into the 
corresponding primary amide and then into the corresponding nitrile, were studied. The aim of this 
project was to separate these two reactions and to engineer a primary amide synthetase from NS 




found that, while they both have a very poor acid substrate scope, they are both accepting a small 
range of amines, which make both enzymes fit to produce secondary and tertiary amides. It was also 
aimed to obtain a ligand-bound structure of a NS enzyme which will be used for rational evolution of 
the enzyme. The structure of ADP-bound BsQueC was successfully determined and used to locate 
residues which may be involved in catalysis. Three residues (K163, Y187 and R204) were identified and 
deactivated by site-directed mutagenesis. The mutations of the two positively-charged residues 
(K163A and R204A) resulted in substantial reduction of the conversion from primary amide to nitrile. 
The double mutant, which contained both mutations was completely knockout for amide to nitrile 
conversion, making this mutant, de facto, an engineered amide synthetase. This novel primary amide 
synthetase was further characterised and used to produce 7-amidodeazaguanine (ADG) from 7-
carboxydeazaguanine (CDG) at laboratory scale. 
As strong evidence of the residues involved in NS amide hydration was obtained, further 
engineering could be carried with the aim of enhancing the substrate scope of the enzyme. Hence, 
site saturation mutagenesis could be carried on the two residues found to be involved in the reaction 
(Lys163 and Arg204). In this technique, the WT gene will amplified by site-directed mutagenesis PCR 
with a mixture of primers containing all the possible mutations into the other 19 amino acids. The 
mutants generated would then be assayed on other, industrially-relevant, substrates to assay their 
activities against non-natural ligands and all the hits, for which the mutants display some activity, will 
be sequenced. Further rounds of evolution, to mutate residues in the vicinity of Lys163 and Arg204 
are also possible. However, it is clear that a CDG + ATP bound structure of BsQueC, SrToyM or any 
other NS (such as E.coli QueC) would be very useful to get a clearer understanding of the binding mode 
of the ligands. If that is not feasible, the structure generated in this work could be used to carry 
molecular dynamics simulations of the conversion of CDG into ADG and PreQ0. It would be especially 
interesting to get a better understanding on how the substrate is “trapped” in the active site for both 
reactions. 
Through generating the first ligand-bound structure of BsQueC, targeted enzyme engineering 
could be carried, leading to the generation a double-mutant where the complete disappearance of 
the amide dehydration activity was observed. Through carrying a comparative assay of the NS reaction 
for the WT enzyme and the mutants, it was observed that the amide synthesis step of the NS reaction 
was also slowed by the mutations, strongly suggesting that one single active site is responsible for 
both reactions catalysed by NS enzymes. As a result, as well as being the first time that both reactions 
catalysed by NS enzymes were isolated by enzyme engineering, this work also provides strong 




suggests that engineering this active site could impact both reactions and, therefore, could be done 
to expand the substrate scope of NS enzymes for them to be fit to catalyse the syntheses of 




Chapter 5 Materials and Methods 
5.1 Materials 
All reagents, chemicals and media were purchased from Sigma-Aldrich, Thermo Fisher Scientific, 
Alfa Aesar, Fluorochem or Bio-Rad unless otherwise stated. All primers were purchased from Sigma-
Aldrich and competent cells, pET plasmids and restriction enzymes from New England Biolabs (NEB), 
Novagen, Promega and Life Technologies. Protein purification columns were purchased from GE 
Healthcare. HPLC columns were bought from Phenomex. The codon-optimised S. rimosus toyM gene 
was purchased from GenScript.  
5.1.1 Growth media 
All growth media were prepared by dissolving the components listed in Table 5.1 in deionised 




10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract  
LB Agar 10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract, 15 g/L agar 
Super optimal 
broth (SOC) 
10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract, 2.5 mM KCl, 10 mM MgCl2, 2% w/v 
glucose 
SelenoMet™ 
base Medium  
21.6 g/L Molecular Dimensions SelenoMet™ base medium powder  
SelenoMet™ 
Nutrient mix* 
102 g/L Molecular Dimensions SelenoMet™ nutrient mix powder 
Table 5.1: Components of the growth media used in this work 
*Sterilised by filtration (33 μm) instead of autoclaving 
 
Appropriate antibiotic was added to the cool growth media after sterilisation. Kanamycin and 
ampicillin stocks were made with concentrations of 30 mg/mL and 100 mg/mL respectively. The stocks 
were dissolved in water and were added to media in a ratio of 1:1000 for final concentrations of 30 
µg/mL or 100 µg/mL. 
5.1.2 Competent cell lines 
Various cell lines from E. coli were used to store and amplify plasmids for cloning and recombinant 






Cell line Supplier Application 
BL21 (DE3) New England Biolabs Protein expression 
C2987 New England Biolabs High transformation efficiency and amplification during cloning 
DH5α Life Technologies Plasmid storage and amplification 
B834 Novagen Expression of selenomethionine-enriched proteins 
Table 5.2: E. coli cell lines used in this work 
 
5.1.3 Plasmids 
Target genes were cloned into various plasmids to yield recombinant proteins with specific 
hexahistidine tags or for cloning as shown in Table 5.3  
Plasmid Resistance Applications 
pET22b Ampicillin Protein expression of proteins with a C-terminal hexahistidine tag or no 
tag  
pET28a Kanamycin Protein expression of proteins with a N-terminal hexahistidine tag or N- 
and C-terminal hexahistidine tags 
pGEM T-Easy Ampicillin Cloning/blue-white screen 
Table 5.3: Plasmids used in this work 
 
5.1.4 Buffers 
Buffers were prepared by dissolving components in deionised water and adjusting to desired pH 
using hydrochloric acid (HCl, 33% w/v) and sodium hydroxide (NaOH, 5 M). These were filtered 












A 50 mM Tris, pH = 7.5 
B 50 mM Tris 1 M NaCl, pH = 7.5 
C 20 mM tris(hydroxymethyl)aminomethane (Tris), 500 mM NaCl, 10% Glycerol 30 mM imidazole,   
pH = 8.0 
D 20 mM tris(hydroxymethyl)aminomethane (Tris), 500 mM NaCl, 10% Glycerol 250 mM imidazole, 
pH = 8.0 
E 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 500 mM NaCl, 10% Glycerol 
pH = 7.5 
F 500 mM KCl, 40 mM imidazole, pH = 7.5 
G 500 mM KCl, 500 mM imidazole, pH = 7.5 
H 100 mM Tris, 1 mM 1,4-Dithiothreitol (DTT), pH = 7.0 
Table 5.4: Buffers used in this work 
 
5.2 Molecular cloning  
5.2.1 Overview 
EcBioH-N was cloned at the beginning of this study following the procedure highlighted in Section 
5.2.3. EcBioH-C and EcBioH-x have been previously cloned by Dr Menglu Wang. The EcBioH-NC clone 
was sub-cloned by cutting the C-terminal hexahistidine tagged EcBioH gene from a pET22a plasmid 
(Nde1/Xho1) and transferring it to a Nde1/Xho1 digested pET28a plasmid. BsQueC and BsQueF were 
previously cloned by Mari Nelson. The full length, codon optimised toyM (S. rimosus, Uniprot code: 
B6CWJ6) was purchased from GenScript. After cutting with Nde1/Xho1, the toyM gene was sub-cloned 
into Nde1/Xho1 digested pET28a plasmid to give a recombinant SrToyM plasmid which could be used 
to express SrToyM with a non-cleavable N-terminal hexahistidine tag. 
5.2.2 General procedures 
5.2.2.1 Gel electrophoresis and extraction 
DNA gels were prepared by putting agarose (1 g) in TAE buffer containing 40 mM Tris, 20 mM 
acetic acid and 1 mM EDTA (100 mL). The mixture was microwaved until complete dissolution of the 
agarose and  cooled to 60°C before adding GelRed (10 µL). The solution was stirred, poured into a 
casting mold and set at 4°C. PCR products and other DNA samples were mixed with 6x Purple DNA 
loading dye (NEB) and loaded onto the gel. A DNA ladder (Hyperladder I, Bioline) was also loaded. Gels 
were run at a constant voltage of 100 V for around 30 min. DNA bands were visualised using UV light 




weighed and the DNA was extracted using a ThermoScientific gel extraction kit according to the 
manufacturer’s instructions. 
5.2.2.2 Restriction digest 
The PCR product or plasmid to be digested (30 µL) was mixed with 5* CutSmart buffer (6 µL), and 
the restriction enzymes (Nde1 and Xho1 2x 1.5 µL). Deionised water was added to a final volume of 
50 µL . The reaction was incubated at 37°C overnight. The product was then purified by gel 
electrophoresis and extracted as per procedure 5.2.1.1. 
5.2.2.3 Analytical digest 
The plasmid to be digested (6 µL) was mixed with CutSmart buffer (2 µL), and the restriction 
enzymes (Nde1 and Xho1 2x 1 µL). The reaction was incubated at 37°C overnight. The product was 
then analysed by gel electrophoresis. Positive clones have two bands, one with correct size for 
backbone, one for correct size for gene of interest. Positive clones were sequenced by Eurofins 
Genomics using their T7 and pET-RP primers to verify that the gene of interest was correctly 
incorporated. 
5.2.2.4 Ligation  
The plasmid backbone (70 ng) and insert containing the gene of interest (~250 ng, 1:10 molar ratio 
of backbone to insert) were mixed with T4 DNA ligase (1.5 µL) and 10x ligation buffer (1 µL) and made 
up to 10 µL with deionised water. The reaction was incubated at 37°C for 3 hours. 5 µL of the reaction 
were then used to transform C2987 cells which were grown on LB + appropriate antibiotic. 
5.2.2.5 Miniprep  
Single colonies were picked from agar plates and inoculated in 10 mL LB supplemented by the 
appropriate antibiotic. These cultures were shaken at 37°C for 16 hours. These cultures were then 
centrifuged at 3500 rpm in a Hearaeus Function Line centrifuge for 15 minutes. The supernatant was 
decontaminated with Virkon and discarded. The plasmid was extracted from the pellet using a Qiagen 
QIAprep miniprep kit according to the manufacturer instructions. Plasmid DNA was eluted in deionised 
water instead of elution buffer provided by the kit and stored at -20°C.  
5.2.2.6 Site-directed mutagenesis 
The sequence of the primers used for this work are shown in Table 5.5. The overlapping method 





Protein Primer Sequence (5’-3’) Melting 
temperature (Tm) 
(°C) 
EcBioH S53A For GGGCGTGCCCGGGGATTTGGTGC 68 
S53A Rev GGCTTCGGGCGTGCCCGGGGATTT 69 
S82A For GGCTGGGCTCTGGGCGGGCTGGTGGCAAGC 75 
S82A Rev GCCCAGAGCCCAGCCTAACCAAATGGCTTTATCAGGTGCC 72 
D207A For  TATCTCGCCGGTCTGGTGCCGCGCAAAGTG 70 
D207A Rev CCGTTTTTGCGATTGTATGGCTATCTCGCCGGTCTG 68 
H235A For GCGGCCGCTGCGCCATTTATTTCGCAT 68 
H235A Rev TGGCGCAGCGGCCGCTTTGGCGAAGATATATGA 71 
BsQueC K163A For CTCAATGCGGCAGAAACGTGGAAGCTT 64 
K163A Rev TTCTGCCGCATTGAGCCACATGAGAGG 65 
Y187A For ACATGTGCTAACGGCATCATCGCAGAC 64 
Y187A Rev GCCGTTAGCACATGTCAGCGTGTTGTT 64 
R204A For CACCTTGCCTCAAAAGGGTATGAAGAA 59 
R204A Rev TTTTGAGGCAAGGTGGCATGC 59 
SrToyM K176A For GGAGCGCGACGGACATCG 59 
K176A Rev GTCCGTCGCGCTCCAGTGGAT 58 
R213A For TACGAAGCCCGTGAGGCATTC 60 
R213A Rev CTCACGGGCTTCGTAACACGT 60 
Table 5.5: Sequences of the site-directed mutagenesis primers used in this work. Modified 
sequences are highlighted in bold 
 
PCR reactions were prepared on ice and consisted of: 150 ng template DNA, 10 µM forward primer 
(1.5 µL), 10 µM reverse primer (1.5 µL), 10 mM dNTP mix (1.0 µL), 5x Phusion HF reaction buffer (10 
µL), Pfu DNA polymerase enzyme (1.0 µL) and deionised water to a final volume of 50 µL. Primer 






Step Temperature (°C) Time (min) Number of Cycles 
Initial denaturation 98 2 1 
Denaturation 98 1  
30 
Annealing Tm - 5 0.5 
Extension 72 2 
Final Extension 72 5 1 
Table 5.6: PCR reactions conditions 
 
15 µL of the reaction was analysed by gel electrophoresis to check for correct amplification. 
Amplified PCR products were mixed with CutSmart buffer (4 µL) and Dpn1 enzyme (1.5 µL). The 
reaction was incubated at 37°C overnight. 5 µL of the mix were used to transform C2987 cells on LB 
Agar. 
5.2.3 EcBioH initial cloning 
5.2.3.1) Amplification and purification of ECBioH gene 
Gene amplification was done by polymerase chain reaction (PCR) using E.Coli genomic DNA as a 
template and a pair of forward and reverse primers. These primers contain restriction sites to allow 
ligation and digestion of the gene on the plasmid (Nde1 for the Forward, Xho1 for Reverse). Primer 
sequences showing the restriction sites and PCR conditions are showed on Table 5.7. 
Step Temperature (°C) Time (min) Number of Cycles 
Initial denaturation 98 2 1 
Denaturation 98 1  
30 
Annealing 55 0.5 
Extension 72 1 
Final Extension 72 5 1 
Forward Primer CGATCATATGAATAACATCTGGTGGCAGACCAAAGGT 
Reverse Primer CGATCTCGAGCTACACCCTCTGCTTCAACGCCAC 
Table 5.7: PCR reactions conditions and primers sequences. Restriction sites are showed in red. 
 
The amplified gene was then A-tailed to add a single deoxyadenosine to the 3’ end, in order to 




25 mins in presence of PureTaq beads, containing Taq DNA polymerase, nucleotides and stabilizers. 
The amplified and A-tailed gene was then purified on a 1% agarose gel containing 0.01% Gel Red, 
revealed by UV light and extracted from the gel using a ThermoScientific gel extraction kit. 
5.2.3.2) pGEM ligation and analysis 
To ease the analysis of the gene, it was first cloned onto a pGEM-T vector because it is an efficient 
way to check if the amplified gene was correctly ligated onto the vector, as this vector is compatible 
with blue-white screen using X-Gal. 
First, the gene was ligated in the pGEM-T vector. The ligation reaction consisted of 150 ng of the 
amplified gene, 1 µL pGEM-T vector, 1 µL pGEM-T reaction buffer and 1 µL T4 ligase. The reaction was 
incubated overnight at 4°C. 
The ligation mixture (4 µL) was then transformed into C2987 highly competent cells (25 µL) in LB 
Agar / X-Gal plates supplemented with Ampicillin (100 µg/mL). Such plates were used to do a blue-
white screening. White colonies should indeed contain the insert while blue colonies do not. Hence, 
five white colonies were picked on the following day and inoculated into five aliquots of LB broth (10 
mL) supplemented with Ampicillin (100 µg/mL). These aliquots were shaken for 16 hours at 37C and 
centrifuged at 3500 rpm for 10 mins separately. The supernatant was discarded, while the DNA of the 
cell pellets was extracted with a ThermoScientific GeneJET miniprep kit following the manufacturer 
procedure. The DNA of each colonies was eluted separately into 50 µL elution buffer. 
To further verify the presence of the insert, analytical digest of the five products was undergone. 
The analytical digest consisted of 1 µL DNA from the previous step, 1 µL of each restriction enzymes 
(Nde1 and Xho1), 1 µL CutSmart buffer and 6 µL water. This was let at 37°C for 3 hours and ran on an 
1% agarose gel supplemented with 0.01% GelRed and revealed under UV light. DNA products in which 
the insert was observed were then sequenced, others were discarded. 
5.2.3.3) Vector transfer of the insert: from pGEM-T vector to pET28a vector 
When the sequence was found to be the correct one, preparatory digest was done to cut off the 
insert from the pGEM-T vector as well as to open the circular pET28a vector in which the insert will 
subsequently be ligated. The preparatory digest reaction consisted of 50 µL DNA (insert + pGEM-T 
vector OR pET28a vector), 6 µL CutSmart buffer and 1 µL of each restriction enzymes (Nde1 and Xho1). 
The reaction was allowed to occur for 16 hours at 37°C. The opened pET28a vector could be used 
without any further purification but the insert had to be separated from the pGEM-T vector and was 




light, and extracted from the gel using a ThermoScientific gel extraction kit, following the 
manufacturer procedure. 
The insert was subsequently ligated into the pET28a vector. This ligation reaction was proceeded 
as previously described for the pGEM-T vector. The ligation mixture (4 µL) was then transformed into 
C2987 highly competent cells (25 µL) in LB Agar plates supplemented with Kanamycin (30 µg/mL). 
Twelve colonies were picked on the following day and inoculated into twelve aliquots of LB broth (10 
mL) supplemented with Kanamycin (30 µg/mL). These aliquots were shaken for 16 hours at 37C and 
centrifuged at 3500 rpm for 10 mins separately. The supernatant was discarded, while the DNA of the 
cell pellets was extracted with a ThermoScientific GeneJET miniprep kit following the manufacturer 
procedure. The DNA of each colonies was eluted separately into 50 µL elution buffer. 
To verify the presence of the insert, analytical digest of the products was undergone. The 
analytical digest consisted of 1 µL DNA from the previous step, 1 µL of each restriction enzymes (Nde1 
and Xho1), 1 µL CutSmart buffer and 6 µL water. This was let at 37°C for 3 hours and ran on an 1% 
agarose gel supplemented with 0.01% GelRed and revealed under UV light. DNA products in which the 
insert was observed were then used to express BioH, others were discarded. 
5.3 Protein production 
5.3.1 Transformation 
Plasmid DNA (2.5 µL) was added to an aliquot of competent E. coli cells (10 or 25 µL) and incubated 
on ice for 30 mins. The cells were subsequently heat shocked at 42°C for 45 seconds. SOC (120 µL) was 
added and the cells were incubated at 37°C with shaking (200 rpm) for 1 h. The mix was then 
transferred on an LB Agar plate supplemented with the appropriate antibiotic (ampicillin: 100 mg/L or 
kanamycin: 30 mg/L)  and the cells were grown for 16 hours at 37°C.  
5.3.2 Expression tests 
A single colony of BL21 (DE3) E. coli cells containing the expression plasmid was used to inoculate 
10 mL LB + appropriate antibiotic and shaken at 200 rpm for 16 hours at 37°C. The optical density at 
600 nm (OD600) was then recorded and the pre-culture was diluted in 10 mL fresh LB + appropriate 
antibiotic to an OD600 of 0.15. The new culture was allowed to grow to an OD600 of 0.6-0.9 at 37°C. IPTG 
was added to a final concentration of 0.1 mM and the cultures were incubated further at 16°C and 
30°C for 5 hours and overnight. The cell pellets were harvested by centrifugation (3500 rpm for 15 
mins) and resuspended in phosphate buffer saline (PBS) (1 mL). Protein expression was analysed after 




by centrifugation (13000 rpm for 10 mins) by denaturing 12% SDS-PAGE gel run at 200 V. Optimal 
conditions were use for large scale expression. 
5.3.3 Large scale expression 
A single colony of BL21 (DE3) E. coli cells containing the expression plasmid was used to inoculate 
250 mL LB + appropriate antibiotic and shaken at 200 rpm for 16 hours at 37°C. The optical density at 
600 nm (OD600) was then recorded, and the pre-culture was diluted in 1 L fresh LB + appropriate 
antibiotic to an OD600 of 0.15. The new culture was allowed to grow to an OD600 of 0.6-0.9 at 37°C. After 
which IPTG (to a final concentration of a mM) and ZnSO2 (to a final concentration of b mM) were 
added to induce protein expression. The cultures were shaken further for c hours at d°C. Bolded 













Parameter a b c D 
EcBioH WT and 
mutants, HiBioG 
WT 
0.5 0 18 18 
BsQueC WT and 
mutants 
0.1 0.1 5 30 
SrToyM WT and 
mutants, BsQueF 
WT 
0.1 0.1 18 16 
Table 5.9: Parameters used for large scale expression for each protein 
 
5.3.4 Expression of SeMet-SrToyM 
A single colony of B834 (DE3) E. coli cells containing the SrToyM expression plasmid was inoculated 
in 500 mL LB + kanamycin (30 mg/L) and shaken at 200 rpm for 16 hours at 37°C. The cells were then 
harvested by centrifugation (3000 rpm, 10 minutes). The supernatant was decontaminated with 
Virkon and discarded. The pellet was re-suspended in sterilised SelenoMet™ base medium (30 mL) 
and centrifuged (3000 rpm, 10 minutes). This was repeated three times to ensure no traces of LB 
medium remained. The supernatant was decontaminated with Virkon and discarded in each case. The 
pellet was resuspended in SelenoMet™ base medium (30 mL). On the other hand, 2 L sterilised 
SelenoMet™ base medium supplemented by SelenoMet™ nutrient mix (50 mL) and kanamycin (30 
mg/L) were prepared. To these cultures were added the cell suspension to a final OD600 of 0.05. These 
cultures were grown at 37°C with shaking (200 rpm) for 20 min. 10 mL of each culture were taken as 




(200 rpm) to an OD600 of 0.6.  Protein expression was then induced by addition of IPTG (to a final 
concentration of 0.1 mM) and ZnSO2 (to a final concentration of 0.1 mM). The cultures were shaken 
further for 18 hours at 16°C. 
5.3.5 Cell harvesting 
The bacterial cells were harvested by centrifugation in a ThermoScientific Multifuge centrifuge at 
7000 rpm for 7 min at 4°C. The supernatant was disinfected with Virkon and discarded, and the cell 
pellet was resuspended in a minimum amount of PBS and further centrifuged at 3500 rpm for 15 mins 
at 4°C. The supernatant was discarded, and the cell pellets, containing the protein of interest was 
stored at -20°C. 
5.4 Protein purification 
5.4.1 Cell lysis 
Cells were resuspended in buffer A/C/F and lysed by sonication for 15 cycles (30 seconds on, 30 
seconds off). DNase (0.2 mg) was added and the lysed cell suspension was centrifuged (12000 rpm, 45 
mins). The supernatant was filtered with a 0.45 μm filter. Protein was purified from the filtered cell-
free extract. 
5.4.2 IMAC purification 
All purification steps were carried out at 4°C or on ice. Histidine-tagged proteins were purified by 
Nickel immobilised metal affinity chromatography (IMAC) using 1 mL or 5 mL HisTrap HP columns 
attached to an AKTA Start. The column was washed with 10 column volumes (CVs) of Buffer a and the 
cell-free extract was loaded at x mL/min. The column was washed with Buffer a for 7 CVs and the 
protein of interest was eluted with a gradient between Buffer a and Buffer b for 10 CVs at a flow rate 
of x mL/min, monitoring at 280 nm. The fractions that contained the protein were then pooled and 
concentrated to 5 mL using a Vivaspin 20 (GE Healthcare, MW cut-off = 10 kDa) before SEC. Bolded 








 Wash buffer              
(from Table 5.4) 
Elution buffer 
(from Table 5.4) 
Flow rate  
(mL/min) 
Parameter a b x 
EcBioH WT and 
mutants, HiBioG WT 
C D  
BsQueC WT and 
mutants, BsQueF WT, 
SrToyM WT and 
mutants 
F G  
1 mL HisTrap HP 
column 
  1.0 
5 mL HisTrap HP 
column 
  5.0 
Table 5.10: Parameters used for the IMAC purification 
 
5.4.3 Anion exchange purification of untagged EcBioH 
Untagged EcBioH was purified by anion exchange chromatography using a HiPrep Q FF 16/10 
column attached to an AKTA Explorer. The column was washed with 5 CVs of Buffer C and the cell-free 
extract was loaded at 1.6 mL/min. The column was washed with Buffer C for 5 CVs and the protein of 
interest was eluted with a gradient between Buffer A and Buffer B for 10 CVs at a flow rate of 1.6 
mL/min, monitoring at 280 nm. The fractions that contained the protein were then pooled and 
concentrated to 5 mL using a Vivaspin 20 (GE Healthcare, MW cut-off = 10 kDa) before SEC. 
5.4.4 Size-exclusion chromatography 
The concentrated protein (5 mL) was then loaded onto a pre-equilibrated (1 CV, buffer a) HiPrep 
16/600 Superdex b. The recombinant enzyme was eluted at a flow rate of c mL/min, monitoring at 
280 nm. The purity of recombinant proteins was analysed by 12% SDS-PAGE. Fractions containing the 
protein were combined. If the protein was to be used for crystallography, it was concentrated to            
10 mg/mL using a Vivaspin 20 (GE Healthcare, MW cut-off = 10 kDa) and kept on ice at 4°C. Otherwise, 
the enzyme was concentrated/diluted to 4 mg/mL, flash-frozen in liquid nitrogen and stored at -80°C. 








 Buffer                      
(from Table 5.4) 
Column Flow rate  
(mL/min) 
Parameter a b c 
EcBioH WT and 
mutants, HiBioG WT 
E S-75 0.6 
BsQueC WT and 
mutants, BsQueF WT, 
SrToyM WT and 
mutants 
H S-200 1 
Table 5.10: Parameters used for the size-exclusion chromatography 
 
5.5 Protein characterisation 
5.5.1 Determination of enzyme concentration using Bradford assay 
In all cases, protein concentration in a sample was determined using the Bradford assay. Coomasie 
brilliant blue G-250 dye (shown in Figure 5.1) undergoes a colour change from brown to blue upon 
interacting with the basic residues side chains (Lys, Arg, His) contained in an enzyme. 
 
Figure 5.1: Structure of the Coomasie brilliant blue G-250 dye 
 
Five standard solutions of BSA (50 μL) at various concentrations (0 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 
1 mg/mL and 1.4 mg/mL) were prepared and mixed with Bradford reagent (1.5 mL). The absorbance 
of these solutions at 595 nm was recorded and used to plot a calibration curve. 50 μL of a solution 
containing the enzyme with unknown concentration was then diluted appropriately for its absorbance 
to fit within the calibration curve range, mixed with Bradford reagent (1.5 mL) and its absorbance at 







A routine gel consisted of a 15% acrylamide running gel topped by a 4% acrylamide stacking gel. 
The running gel was made by mixing deionised water (5.7 mL), 40% acrylamide (6 mL), 1.5 M Tris (pH 
= 8.8, 4 mL), 10 w/v SDS (150 μL), 50 mg/mL ammonium persulfate (APS) (350 μL) and 
tetramethylethylenediamine (TEMED) (20 μL). The running gel was made by mixing deionised water 
(2.9 mL), 40% acrylamide (750 μL), 0.5 M Tris (pH = 6.8, 1.25 mL), 10 w/v SDS (50 μL), 50 mg/mL APS 
(100 μL) and TEMED (5 μL). Protein samples (10 μL) were prepared by adding SDS loading buffer (5 μL) 
containing: 0.5 M Tris (pH = 6.8, 2.5 mL), glycerol (2 mL), 10 w/v SDS (4 mL), β-mercaptoethanol (1 mL) 
and 0.1% w/v bromophenol blue (500 μL). The samples were then boiled for 5 minutes and loaded 
onto gels alongside Low molecular weight marker (GE Healthcare) and were run for 50 minutes at a 
constant voltage of 200 V. Gels were revealed by immersion in Instant Blue Coomasie stain (Expedeon) 
for 30 minutes at room temperature (RT) with gentle shaking and then washed with water before 
revelation under light. 
5.5.3 Protein mass spectrometry 
The protein was diluted to a concentration of 10 μM using deionised water and centrifuged for 5 
minutes at 13000 rpm. The supernatant (5 μL) was injected on a Synapt G2-Si Q-TOF (Waters) 
instrument, that comprised a Phenomenex C4 2.6 μm liquid chromatography (LC) column coupled 
with an ESI source. The LC gradient ran from 5% to 95% acetonitrile in water in 12 minutes. Both 
solvents were supplemented by 0.1% formic acid. The MS source was set at 120°C  and the sampling 
cone voltage was 54 V. Protein spectra was smoothened, centered and subtracted using MassLynx 
V4.1. 
5.6 Organic synthesis 
5.6.1 Model MBH reaction 
 
To a stirred solution of 4-NBA (93 mg, 0.62 mmol, 1eq) in tetrahydrofuran (THF) (1 mL) were added 
successively DABCO (11 mg, 0.093 mmol, 0.15 eq) and MVK (130 mg, 1.85 mmol, 3eq). The reaction 
mixture was stirred for 20 hours at RT. The product was extracted with dichloromethane (DCM) (3*15 




the crude product. Flash column chromatography was then carried. Mobile phase was a gradient 0-
40% ethyl acetate (EtOAc) in Petroleum ether (30-40°C). The desired product was obtained (46 mg, 
0.21 mmol, 34%). Nuclear magnetic resonance (NMR) and ESI-MS analyses showed that the product 
has >95% purity. 
1H NMR (500 MHz, dCDCl3): δ = 8.21-8.23 (2H, d, CH-1,3), 7.59 (2H, d, CH-4,6), 6.28 (1H, s, CH-12), 
5.71 (1H, s, OH-10), 2.27 (1H, s, CH-8), 2.38 (3H, s, CH3-13). 
MS (ESI, [M - H+]): m/z = 220.0949 (Theoretical m/z (C11H11O3N) = 220.067) 
5.6.2 Organic synthesis of Chapter 4 compounds 
5.6.2.1. Synthetic route to CDG and PreQ0 
 
Figure 5.1: CDG and PreQ0 synthetic schemes. 
 
 
5.6.2.2 One-pot synthesis of CDG-methyl ester 
 
To methyl formate (3.20 g, 58 mmol, 5.8 eq.) in THF (25 mL) cooled to 0°C were subsequently 
added sodium methoxide (0.72 g, 13 mmol, 1.3 eq.) and methyl chloroacetate (1.09 g, 10 mmol, 1.0 
eq). The reaction was stirred overnight at RT. Deionised water (25 mL) was added to stop the reaction 
and quench excess sodium methoxide. Excess methyl formate and THF were removed under reduced 




and the mixture was refluxed for 1 hour. The product precipitated upon cooling and was recovered by 
filtration. After THF washings, the product was obtained (0.92 g, 3.7 mmol, 47% yield) with a purity 
exceeding 95% (1H NMR, 13NMR)  
1H NMR (600 Hz, dDMSO): δ = 11.63 (1H, s, NH-1), 10.35 (1H, br s, NH-7), 7.35  (1H, d, J = 3Hz, CH-8), 
6.49 (2H, br s, NH2-11), 2.80 (3H, s, CH3-15) 
13C NMR (600 Hz, dDMSO): δ = 163.80 (C-12), 160.30 (C-6), 153.66 (C-2), 153.34 (C-4), 125.40 (C-8), 
110.27 (C-9), 97.85 (C-5), 52.15 (C-15)  
5.6.2.3 One-pot synthesis of PreQ0 
 
To methyl formate (3.20 g, 58 mmol, 5.8 eq.) in THF (25 mL) cooled to 0°C were subsequently 
added sodium methoxide (0.72 g, 13 mmol, 1.3 eq.) and chloroacetonitrile (0.76 g, 10 mmol, 1.0 eq). 
The reaction was stirred overnight at RT. Deionised water (25 mL) was added to stop the reaction and 
quench excess sodium methoxide. Excess methyl formate and THF were removed under reduced 
pressure and 2,4-diamino-6-hydroxypyrimidine (1.20 g, 10 mmol, 1.0 eq.) was subsequently added 
and the mixture was refluxed for 1 hour. The product precipitated upon cooling and was recovered by 
filtration. After THF washings, the product was obtained (1.12 g, 6.4 mmol, 64% yield) with a purity 
exceeding 95% (1H NMR, 13NMR) (compared with literature data1). 
1H NMR (600 Hz, dDMSO): δ = 11.63 (1H, s, NH-1), 10.35 (1H, br s, NH-7), 7.35  (1H, d, J = 3Hz, CH-8), 
6.49 (2H, br s, NH2-11) 
13C NMR (600 Hz, dDMSO): δ = 158.09 (C-12), 154.26 (C-6), 152.16 (C-2), 128.40 (C-4), 116.37 (C-8), 
99.19 (C-9), 86.00 (C-5) 




5.6.2.4 Synthesis of CDG 
 
  To a suspension of CDG-methyl ester (0.92 g, 3.7 mmol, 1.0 eq.) in 1,4-dioxane (10 mL) was 
added HCl (37%, 10 mL, excess). The mixture was refluxed for 5 hours. The precipitate formed upon 
cooling was filtered, washed with copious amounts of THF and dried. The brown solid (0.67 g, 2.8 
mmol, 81%) was confirmed to be the product (1H NMR, 13C NMR and ESI-MS) at purity > 95% 
(compared with literature data1).   
1H NMR (600 Hz, dDMSO): δ = 11.96 (1H, s, NH-1), 11.63 (1H, br s, OH-14), 11.13 (1H, br s, NH-7), 7.43  
(1H, d, J = 3Hz, CH-8), 6.44 (2H, br s, NH2-11) 
13C NMR (600 Hz, dDMSO): δ = 163.48 (C-12), 161.86 (C-6), 153.55 (C-2), 152.74 (C-4), 126.30 (C-8), 
110.98 (C-9), 96.82 (C-5) 
MS (ESI, [M + H+]): m/z = 195.0509 (Theoretical m/z (C7H6O3N4) = 195.0518) 
5.7 Protein reactions for Chapter 3 
5.7.1 Biocatalysed MBH reaction optimised protocol  
To a solution of EcBioH (WT or mutant) in Buffer E (4 mg/mL) were subsequently added 4-NBA (8 
mM, from 50x stock in acetonitrile) and MVK (64 mM, from 50x stock in acetonitrile). The reaction 
mixture was shaken at 280 rpm at 30°C for 96h. 
5.7.2 Biocatalysed MBH reaction HPLC assay  
To a sample of the reaction mixture (15 µL) was added 100% trichloroacetic acid (TCA, 3 µL). The 
sample was centrifuged at 13000 rpm for 2 mins. To the supernatant was added 20% MeCN in water 
(100 µL). 10 µL of the sample was injected on a Phenomenex Luna 5u C18 HPLC column and eluted 
with 50% MeCN + 0.1% TFA in water + 0.1% TFA at a flow rate of 1 mL/min for 8 minutes. 4-NBA and 
the MBH product were detected by a UV detector at 254 nm, while MVK does not absorb at this 
wavelength. Concentrations of the analytes were determined by comparing the area under the curve 





5.7.3 Biocatalysed MBH reaction chiral HPLC assay  
A sample of the reaction mixture (200 µL) was extracted with ethyl acetate (EtOAc, 3*200 μL). The 
solvent was removed under reduced pressure and the solid was redissolved in isopropanol (100 μL). 
10 µL of the sample was injected on a HiChrom ChiralPak IC column and eluted with 8% isopropanol 
in hexane at a flow rate of 1 mL/min for 50 minutes. 4-NBA and the MBH product were detected by a 
UV detector at 254 nm, while MVK does not absorb at this wavelength. 
5.7.4 pNPA esterase assay 
The ECBioH and HiBioG esterase activity were assayed by monitoring the hydrolysis of pNPA        
(ξ410 = 18 L/mmol/cm). The final volume of the reactions was 250 μL and contained 0-4 mM pNPA from 
a 10 mM stock in isopropanol, 3.4 mg/mL Triton X-100 and 50 mM Tris (pH = 8.0). These reagents were 
preincubated and mixed at 37°C and the reaction was blanked. The reaction was initiated by the 
addition of the enzyme (67 μM). The increase of absorbance at 410 mM from the enzymatic 
conversion of pNPA into pNP was monitored over 1h on a BioTek Synergy HT plate reader with Costar 
96-well plate. The data was analysed using the Michaelis-Menten model and a nonlinear regression 
fit on OriginLab 2016 was used to find the values of KM and kcat.  
5.7.5 MS assay 
5.7.5.1 PMSF 
To EcBioH (1 mg/mL) was added PMSF (1 mM). The mixture was stirred for one hour at 37°C after 
which cyclohexenone (1 mM) was added. The mix was then stirred for 90 minutes and analysed by 
ESI-MS as developed in Part 5.5.3. Controls, where either PMSF or cyclohexenone was not added, 
were also prepared and assayed. 
5.7.5.2 IAA 
To EcBioH (1 mg/mL) was added IAA (final concentration: 1 mM). The mixture was stirred for one 
hour at 37°C in the dark after which cyclohexenone (1 mM) was added. The mix was then stirred for 
90 minutes and analysed by ESI-MS as developed in Part 5.5.3. Controls, where either IAA or 
cyclohexenone was not added, were also prepared and assayed. The IAA-only control was also assayed 
for MBH activity following the method described in section 5.7.1. 
5.7.6 Buffer exchange 
The enzymes and proteins used in Part 2.8.6 as well as BioH S82A D207A were buffered-




Vivaspin 20 (GE Healthcare, MW cut-off = 10 kDa) spin column. The sample was concentrated to a 
volume of 1 mL after which 15 mL of Buffer E were added. The sample was re-concentrated to a 
volume of 1 mL, and this operation was repeated twice. Finally, 10 mL of Buffer E were added and the 
sample was concentrated to an enzyme concentration of 4 mg/mL and assayed for the MBH reaction 
following the protocol described in section 5.7.1. 
5.8 Protein reactions for Chapter 4 
5.8.1 NS reaction optimised protocol 
To a solution of NS in Buffer H (2 mg/mL) were added magnesium chloride (50 mM, from 10x stock 
in deionised water), ammonium sulfate (50 mM, from 10x stock in deionised water), ATP (1 mM, from 
100x stock in deionised water) and CDG (0.5 mM, from 200x stock in DMSO). The mix was then stirred 
at 280 rpm for 5 hours at 37°C. 
5.8.2 Large scale biosynthesis of ADG using BsQueC-eAmS 
 
To a 350 mL solution of BsQueC-eAmS in Buffer H (0.25 mg/mL) were subsequently added 
magnesium chloride (50 mM, excess, from 10x stock in deionised water), ammonium sulfate (50 mM, 
excess, from 10x stock in deionised water), ATP (386 mg, 0.7 mmol, 2 mM, 2 eq., from 50x stock in 
water) and CDG (67 mg, 0.35 mmol, 1 mM, 1 eq., from 100x stock in DMSO). The reaction was shaken 
at 280 rpm for 2 hours at 37°C and filtered. The recovered solid was redissolved in DMSO (20 mL) and 
filtered on a centrifugal spin column (Vivaspin 20 (GE Healthcare, MW cut-off = 10 kDa). The filtrate 
was kept and the DMSO was removed under high vacuum (5 days). The product was finally washed 
with copious amounts of THF and recovered by filtration. The brown solid (9 mg, 0.05 mmol, 14%) was 
confirmed to be ADG (1H NMR, 13C NMR and ESI-MS) at purity > 95% (compared with literature data1).  
1H NMR (600 Hz, dDMSO): δ = 11.57 (1H, s, NH-1), 10.68 (1H, br s, NH-7), 9.55 (1H, s, NH-14), 7.21  
(1H, d, CH-8), 6.87 (1H, s, NH-14), 6.37 (2H, br s, NH2-11) 
13C NMR (600 Hz, dDMSO): δ = 164.75 (C-6), 160.76 (C-12), 153.20 (C-5), 153.06 (C-4), 123.43 (C-2), 




5.8.3 HPLC assay 
To samples of the reaction mixture (100 µL) was added 100% trichloroacetic acid (TCA, 5 µL). The 
samples were centrifuged at 13000 rpm for 2 mins. 10 µL of the supernatant was injected onto a 
Phenomenex Luna 5u C18 HPLC column. Samples were eluted with water + 0.1% TFA for 5 minutes 
followed by a 17 minutes gradient to 20% MeCN + 0.1% TFA. The column was then washed for 1 
minute with 50% MeCN + 0.1% TFA/50% water + 0.1% TFA before reequilibrating the column with 100% 
water + 0.1% for 5 minutes. The analytes were detected by a UV detector at 254 nm. 
5.8.4 BsQueF reductase assay 
BsQueF nitrile reductase activity was assayed by monitoring the hydrolysis of oxidation of NADPH 
into NADP+. The final volume of the reactions was 250 μL and contained NADPH (1 mM) and PreQ0 (0-
500μM). These reagents were preincubated and mixed at 37°C, and the reaction was blanked. The 
reaction was initiated by the addition of BsQueF (1 mg/mL). The decrease of absorbance at 340 mM 
from the enzymatic conversion of NADPH into NADP+ was monitored over 1h on a BioTek Synergy HT 
plate reader with Costar 96-well plate. The data was analysed using the Michaelis-Menten model, and 
a nonlinear regression fit on OriginLab 2016 was used to find the values of KM and kcat. 
5.8.5 BsQueC-eAmS kinetics study 
The activity of BsQueC-eAmS amide was measured by monitoring the conversion of CDG to ADG 
by reverse-phase HPLC. 1.2 mL reaction mixtures containing BsQueC-eAmS in Buffer H (1 mg/mL), 
magnesium chloride (50 mM, from 10x stock in deionised water), ammonium sulfate (50 mM, from 
10x stock in deionised water), ATP (0-2 mM, from 100 mM stock in deionised water) and CDG (0-1 
mM, from 100 mM stock in DMSO) were prepared. These mixtures were then shaken at 280 rpm at 
37°C. At various time points (0.5 min, 1 min, 2 min, 5 min, 15 min, 30 min, 60 min, 150 min, 300 min) 
samples (100 μL) of the reaction were taken, quenched with TCA (5 μL) and analysed by HPLC following 
the procedure presented in section 5.8.3. The concentration of formed ADG at each timepoint was 
found and the data was analysed using the Michaelis-Menten model. A nonlinear regression fit on 
OriginLab 2016 was used to find the values of KM and kcat. 
5.8.6 X-ray crystallography 
5.8.6.1 Robot screen 
After SEC, BsQueC and BsQueC-eAmS was concentrated to 7.5 mg/mL and SrToyM was 




10 kDa). Ligands were added at this stage as required and the protein sample was centrifuged for 10 
minutes at 14000 rpm to remove any aggregates. The supernatant was taken to set up high-
throughput screens using an ARI Robotics Gryphon robot and commercial screens (Hampton Research 
PEG ION, Molecular Dimensions JCSG+ and Molecular Dimensions Structures 1+2). Crystals were 
formed by vapour diffusion following the sitting-drop method. The screens were set up on a 96 wells 
MRC plate with 100 nl protein solution mixed with 100 nl mother liquor and equilibrated against 200 
nl mother liquor. Crystals were then allowed to grow for seven days at 23°C. Conditions yielding 
crystals were further optimised  
5.8.6.2 Optimisation protocol 
After SEC, the enzyme to crystallise was concentrated to the corresponding concentration (7.5 
mg/mL for BsQueC and BsQueC-eAmS; 10 mg/mL for SrToyM) using a centrifugal spin column 
(Vivaspin 20 (GE Healthcare, MW cut-off = 10 kDa). Ligands were then added as required and the 
protein sample was centrifuged for 10 minutes at 14000 rpm to remove any aggregates. Crystals were 
formed by vapour diffusion following the hanging-drop method. The optimisation was carried on a 24-
well plate. 1 mL of mother liquor was added to each well and each crystallisation drops was prepared 
by mixing various ratios (1:2, 1:1, 2:1) of protein solution and mother liquor. Crystals were grown for 
7 days at 23°C. Suitable crystals were cryoprotected using the same mother liquor supplemented by 
20% w/v glycerol and flash-frozen by immersion in liquid nitrogen. Datasets were collected on 
beamline I03 at the Diamond Light Source (Didcot, UK) at 100 K using a Pilatus 6 M detector, in 
collaboration with Dr Jon Marles-Wright (University of Newcastle). 
5.8.6.3 ADP-bound BsQueC structure 
BsQueC crystals trials were conducted in the presence of 2.5 mM ADP and 12.5 mM magnesium 
chloride. The crystals which were grown in 0.2 M magnesium chloride hexahydrate, 0.1 M Tris (pH 7), 
7% w/v PEG 8000, 2.5 mM ADP and 12.5 mM magnesium chloride has provided the best quality 
diffraction, to a resolution of 2.1 Å. The structure of BsQueC + ADP was determined by molecular 
replacement using BsQueC structure with PDB code 3BL5. Creation and refinement of the model were 
carried by Dr Jon Marles-Wright (University of Newcastle). ADP was fitted using Coot. Crystallographic 
figures were generated with PyMOL (Schrodinger LLC). Data collection and refinement statistics are 
shown in the Appendix. 
References: 





Appendix 1: EcBioH vector maps 





























Xho1 (158)  
Kan (4686-
5498) 
E. coli BioH 
NdeΙ (929)  





lac1 operon (1464-2583) 
Xho1 (158)  
Amp (4676-
5533) 
E. coli BioH 
NdeΙ (926)  
E. coli  BioH in pET22b 
C-terminal HisTagged 
6183 bp 
    
fddf66x6xHi


































Xho1 (158)  
Amp (4679-
5536) 
E. coli  BioH 
NdeΙ (929)  
E. coli  BioH in pET22b 
Untagged 
6186 bp 
    6xHisTag 
lac1 operon (1405-2484) 
Xho1 (158)  
Kan (4686-
5498) 
E. coli  BioH 
NdeΙ (929)  
E. coli  BioH in pET28b 
x2 HisTagged 
6059 bp 6xHisTag 
6xHisTag 














































































Appendix 9: Calibration curve of the Superdex HiLoad 16/60 S200 gel filtration column 
(taken from Dr Piera Marchetti PhD thesis) 
 
Estimation of the protein molecular weight could be determined as followed 
MW(Da) = 10a 
Where a =(Kav – 1.7958) / (-0.2853) 
Where Kav = (Ve – V0) / (Vt – V0) 
Where Ve = elution volume of the analysed protein 
Where V0 = void volume (41.9 mL) 





Appendix 10: Calibration curve of the Superdex HiLoad 16/60 S75 gel filtration column 
(taken from Dr Piera Marchetti PhD thesis) 
 
Estimation of the protein molecular weight could be determined as followed 
MW(Da) = 10a 
Where a =(Kav – 2.2851) / (-0.4621) 
Where Kav = (Ve – V0) / (Vt – V0) 
Where Ve = elution volume of the analysed protein 
Where V0 = void volume (41.9 mL) 





































































































































































B. subtilis QueC 
NdeΙ (818)  












E. coli BioH 
NdeΙ (653)  






























S. rimosus ToyM 
NdeΙ (875)  
S. rimosus ToyM in pET28b 
N-terminal HisTagged 
































































Appendix 21: 7-carboxydeazaguanine 1H NMR 
 





Appendix 23: 7-cyanodeazaguanine 1H NMR 
 





Appendix 25: BsQueC crystallography data refinement and refinement statistics 
Wavelength 0.9762 Ramachandran allowed (%) 7.78 
Resolution range 48.6  - 2.01 (3.118  - 
2.01) 
Ramachandran outliers (%) 1.41 
Space group C 1 2 1 Rotamer outliers (%) 0.20 
Unit cell 173.477 74.584 
135.076 90 93.211 90 
Clashscore 18.46 
Total reflections 127413 (12020) Average B-factor 154.95 
Unique reflections 34216 (3260)   macromolecules 154.95 
Multiplicity 3.7 (3.7) 
Completeness (%) 98.76 (94.98) 
Mean I/sigma(I) 8.15 (0.89) 
Wilson B-factor 93.53 
R-merge 0.09564 (1.467) 
R-meas 0.1117 (1.713) 
R-pim 0.05699 (0.8734) 
CC1/2 0.998 (0.514) 
CC* 1 (0.824) 
Reflections used in 
refinement 
34078 (3235) 
Reflections used for 
R-free 
1648 (204) 
R-work 0.2827 (0.5349) 
R-free 0.3612 (0.5986) 
CC(work) 0.914 (0.699) 
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